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1. INTRODUCTION 
 
 “Health is wealth” of all the wealth man can gain the most precious is being free 
from disease. 
 
 Health is defined by the world health organization as the “State of complete 
Physical, Mental and Social wall being and not merely the absence of disease and 
infirmity.  Medicine plays a major part in this process.  The world is endowed with many 
system of Medicines like Siddha, Ayurvedha, Unani, Allopathy, Homeopathy etc.,, 
  
The Siddha system is serving the mankind to all of its Physical and Mental, 
Social and Spiritual components of human being. The advantage and unique feature is 
the removal of root causes of the disease and perfect for body and mind. Siddha system 
of medicine was developed by 18Siddhars and hence the name Siddha Medicine. Siddha 
systemof medicine not only includes medicine, but also Astrology, Yoga, Pranayamam 
and Varmam in its treatment strategies. 
 
Fundamental principles of Siddha including theories of 
 Five Elements (Aimbootham) Ik;g+jk; 
 Three forces / Faults (Mukkuttram) Kf;Fw;wk; 
 Eight fold examination (Envagaithervugal) vz;tifNjh;Tfs; 
 
FIVE ELEMENTS (AIMBOOTHAM) Ik;g+jk; 
  
Njhy; MdJ Ik;g+jq;fspy; xd;whd cs;s Mfhaj;jpd; $whf cs;sJ.  
Mfha g+jkhdJ vy;yh caph;fSf;F mbg;gilahfpa czTk;> gytifg;gl;l 
kUe;JfSk;> kw;w g+jq;;fshd kz;> ePh;> jP> fhw;W Mfpa mstpw;flq;fhj vy;yhg; 
nghUs;fSfk; mlq;Ftjw;Fk; ,lk; jUk;. ,ijNghy; Njhy; vy;yh cWg;GfSk; 
jq;Ftjw;F ,lkspj;J mtw;iw ghJfhf;fpd;wJ. 
 
tsp =  tpz;  +  tsp = thjk; 
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Three Humors/ Faults (Mukkuttram)  Kf;Fw;wk; 
 
According to Siddhars the Physiological function of the human body is 
maintained by three vital humour called Vadham, Pitham and Kabham existing in the 
ratio 1:1/2:1/4 respectively. The equilibrium of this vital humour affected by any external 
(or) internal factors will result indisease. 
 
“kpfpDk ;FiwapDk; Neha;nra;Ak; E}Nyhh; 
 tspKjyh ntz;zpa %d;W” 
- jpUf;Fws; 941 
 
The learned books count three, with win as first; of these, As any one prevail, or 
fail; „twill cause disease.  
“thjky;yhJ Nkdp nflhJ” 
       - Njiuah; 
 
 As per the Siddha literature the body get affected mainly due to vitiation of 
Vadham (vali) humour including dermatological condition. 
 
The Eight Fold Examination (Envagaithervugal)  vz;tif Njh;Tfs; 
 
“ehb ];ghprk; ehepwk; nkhoptpop 
kyk; %j;jpu kpit kUj;JtuhAjk;” 
     – Njiuah; 
 
 Eight fold Examination is a tool in Siddha system of medicine used to determine 
Diagnosis, Etiology, Treatment and Prognosis of a disease. 
  
Skin is the largest organ in human body. Skin and its derivatives and appendages 
form the “Integumentary system”.  Skin derivatives include Nails, Hair and Several types 
of sweat and sebaceous glands. The skin forms protective covering of the body. The skin 
develops in the third week of fetal life. The skin at birth covered by vernix caseosa. The 
whitish greasy coats have bactericidal properties. There are so many skin disease like 
Vitiligo, Lichen Planus, Psoriasis, Scabies, Pityriasis alba affecting the children. Most 
common childhood skin disease is eczema. 
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 Eczema is a chronic inflammatory skin disease.  It is the most commonest disease 
affecting the school going children between the age of 3-7 year. It is a worst disease 
which affect all over the body and also cause mental worries in both children and their 
parents. The prevalence of eczema about 13% of world population in 2017.  In India it is 
ranged from 0.9% and 23.3%. Recent data shows that its prevalence is still increasing 
especially in low income countries. 
 In our classical Siddha literature there are 18 types of Eczema (Karappan) have 
been described.  Signs and symptoms of Eczema is nearly correlated to Bala Karappan 
mentioned in Siddha system to medicine (Balavagadam).  According to the Siddha texts 
it is characterized by skin Rashes, Papules, Vesicles, Pustules, Fissures, Oozing, 
Ulceration, Swelling, Itching, Hyperpigmentation lesion. 
 Siddha system plays a wide ranged role in the field of pediatrics.  It ensures the 
health of the children with its astonishing herbal formulations. Karappan Nei, a poly herb 
formulation described in the classical Siddha text book pillaipini Maruthuvam Part-2 
which is indicated for the treatment for Bala Karappan.  It is used both as in internal and 
External medicine. 
 Lot of research has been developed in the field of pediatric dermatology. Siddha 
medicines are more effective for skin disease that‟s why I have selected one of the skin 
disease Bala Karappan as my dissertation work. 
According to Siddha text skin disease occurs due to derangement of Vadham.  
Most of the ingredients present in karappan Nei having Kaippu (Bitter) and Kaarppu 
(Pungent) suvai which are the taste which can neutralize Vaatha humour.  Hence I have 
chosen this trial drug Karappan Nei for my dissertation.  All the ingredients of this drug 
are herbal only. Hence it will be good and safest drug for children. 
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2.  AIM AND OBJECTIVES 
 
Primary Objectives: 
 
 To evaluate the efficacy of Karappan Nei as Internal and External Medicine in 
the treatment of Bala Karappan (Eczema) in children. 
 
Secondary objectives: 
 
 To analyses the study drug Karappan Nei through Physicochemical analysis, 
Pharmacological activities, Acute toxicity studies, phytochemical analysis. 
 To collect and review the ideas mentioned in the ancient Siddha literature about 
the disease Bala Karappan. 
 To Explore the Definition, Etiology, Clinical features, Diagnosis, Investigations 
and treatment methods of Bala Karappan 
 To make a correlative study of the disease with Siddha and Modern concepts. 
 To have a clinical trial on the patients with the selected drugs along with proper 
diet regimen. 
 To use Modern diagnostic parameters for studying the progress of the patients. 
  
5 
 
3.  REVIEW OF LITERATURES 
3. a. SIDDHA ASPECTS 
 Bala Karappan is one of the eighteen types of Karappan which affects the 
children.  This skin disease was described by various Siddhars in detail about the general 
etiology signs and symptoms and prognosis. 
 
fug;ghd; 
,ay; (Definition) 
clypy; jpkpu;> jpdT> nrhwp> Gz;> jbg;G> ntbg;G> ePu; frpjy; Mfpa Fwp 
Fzq;fs; cz;lhf;fp clk;gpd; ,aw;if epwj;ij NtWgLj;Jk; Neha; fug;ghd; 
vdg;gLk;. 
 
Neha; tUk; gUtk; 
 jhy gUtk; Kjy; tUif gUtk; tiuAs;s ehd;F gUtq;fspYk; 
fug;ghd; Neha; Foe;ijfSf;F cz;lhff;$Lk;. 
 
Neha; tUk; top (Etiology) 
In Text book Balavagadam, it desccibed the etiology of Karappan as, 
 
ngUFQ; Nrhs kpWFk; ngUq;fk;G 
tuF fhUld; thioapd; fhnahL 
ciunfhs; ghfw; nfspw;W kPd; cz;bby; 
tpuptjha;f; fug;ghD kpFe;jNj. 
 
 In take of Fish, Mutton, rhizomes, Tubers of some plants and grains like, Kambu 
(Pennisetum typhoideum), Solam (Sorghum vulgarel, Varagu (Paspalum 
Scrobicculatum), Karrasi (Oryza Sativa), Vazhaikkai (Muza Paradisiac), Paakal 
(Momordica Charantica), Kelirrumean (Osteogeniosus militaris) taken by the mother (By 
breast feed) or child produces Karappan. 
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According to siddha literature yugi vaidhya chinthamani: 
  
According to Siddha text book Yugi Vaidhya Chinthamani etiology of Karappan 
described by eating meat, various types of millet and tubers can cause Karappan. 
 
Vohd fug;ghdpd; cw;gj;jpf; Nfsha; 
Vw;wkha; khkprq;fs; Grpf;ifahYk; 
$ohd fk;G jpid tuF rhikf; 
nfhbjhd fpoq;F tifaUe;j yhYk; 
- A+fp itj;jpa rpe;jhkzp 
 
According to siddha literature Pararasa Segaram:  
 
According to the Siddha literature Pararasa Segaram etiology of Karappan 
described as Air born infection, Excessive intake of Jaggery, Plantain, Brinjal, poisonous 
bites may cause the disease. 
 
Ntff; fhw;wjpdu; gid nty;yj;jhy; 
  ghfkpf;fyhd Nkjpg; ghntapyhy; 
  jhfkhdp tUf;f jprhu;jyhy; 
  Nkhf thio tOjiy Ks;spf;fha; 
 fhAk; gy;tplj; jhw;Ruj; jhw;fspy; 
 vAk; tz;nlyp ahy; tUNk Jntsp 
 Fb ey;ywpthd vUtpdhu; 
 ahdkhd fug;gd; tiffNs. 
- guuhr Nrfuk;. 
Classification of karappan: 
 As per the Siddha literature Bala vagadam, Karappan is classified into eighteen 
types as follows, 
“Kj;Njhl kupA+J #iy 
 Kd;Dntb kz;il nghuprl;il 
rw;NwL fUiknahL nrk;ik 
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jdpf;nfhs;sp NjhlnkhL thiy 
Kw;Nwhy;t ul;rpnahL tPq;fy; 
 %uptUk; gjpndl;L tifahk; 
nfhj;jhd fug;ghd;f nsd;W 
 $wpdhu; gz;ilNah uhkhy;” 
“nrq;fug;ghd; mdy;fug;gd; jhDk; kz;ilr; 
 rpuq;fpggz;Zk; mupfug;ghd; nghupf ug;ghd; 
mq;fkjp nyOfug;gd; jhD kpf;f 
 msuhk; cjp uf;fug;gd; fl;b NahL 
nghq;fkha; tPq;fp fug;ghd De;jhd; 
 Gfyupa rl;iljb ntbf ug;ghd; 
rpq;fKf vhpfug;gd; thj gpj;jr; 
 Nrj;Jkj;Njh Nlfug;gd; gjpndl; lnk 
vz;tiff; fug;gd; ,ire;jplf; NfS” 
 
Classification of karappan as per the text book of bala vagadam 
 
1. Vatha Karappan  (thj fug;ghd;) 
2. Pitha Karappan  (gpj;j fug;ghd;) 
3.  Sethuma Karappan  (Nrj;Jk fug;ghd;) 
4.  Ari Karappan   (mup fug;ghd;) 
5.  Oothu Karappan  (CJ fug;ghd;) 
6.  Soolai Karappan  (#iy fug;ghd;) 
7.  Vedi Karappan  (ntb fug;ghd;) 
8.  Mandai Karappan  (kz;il fug;ghd;) 
9.  Pori Karappan   (nghup fug;ghd;) 
10. Sattai Karappan  (rl;il fug;ghd;) 
11. Oodu Karappan  (XL fug;ghd;) 
12. Karung Karappan  (fuq;fug;ghd;) 
13. Seng Karappan  (nrq;fug;ghd;) 
14. Kolli Karappan  (nfhs;sp fug;ghd;) 
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15. Thoda Karappan  (Njhl fug;ghd;) 
16. Vaalai Karappan  (ghy fug;ghd;) 
17. Varal Karappan  (tus; fug;ghd;) 
18. Veengu Karappan  (tPq;F fug;ghd;) 
 
1. thj fug;ghd;: 
 
 njwpf;Fk; tPq;FKl nyq;F Nkjpkpu;f Lg;g jfpaOe; NjfNkw; 
 nghwpg; gwe;jnjd NtGz; zhfpajp Nyntbj; jjpf nghq;fkha; 
 KWf;fp NaRuk jhfp ehtJ twz;L NehaJ Kjpu;e;jpby; 
 ntwpf; fUq;Foyp khJ thjfug; ghnddg; Gfy;tu; NktpNl. 
     (ghy thflk; 4k; gjpg;G gf;f vz; 385) 
 Skin rashes or bumpy rashes
 Papules/ Vesicles/Pustules
 Oozing fromlesion
 Lymphadenopathy
 Itching
 Fever
 
2. mow;fug;ghd;: 
  
“nfhLikahd rpuNehapNdhL nrhwp $W Kl;bdKk; the;jpAk; 
 fLikahd Runka;rp te;jpLjy; fz;guj; Jnjhdp Ke;jpNa 
 jilfshfky ge;jkhfptpby; rhu;e;j gpj;jfug; ghndd;Nw 
 tplK NeuKj KQ;rkhdtpop ntz;z ifj;jpU kUe;jpNl” 
 Headache
 Itching
 Vomiting
 Fever
 Reddishness in affected skin
 Constipation 
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3. Iaf;fug;ghd;: 
 ,irA neQ;Rf silj;J Nstpuz khfpNajit typj;jpLk; 
 mirAk; thajdpy; nte;JNk jpul;rpafp NafL fLj;jpby; 
 tpirAQ; Nrj;Jk fug;ghndd rpfpr;irNkT nrt;tup gue;J epd; 
 tir nghUe;Jk; tpop fiyjpuz;lKf tdpijNa Tljq;fNs” 
 Ulcers in the mouth and trunk
 It changes to vesicles
 Chest pain
 Headache

4. mupfug;ghd;: 
 
 “,ilrp Wj;Jtd fdpG iuj;j nkhop apdpajhdtj uj;jpdha; 
 Jilap ilf;Fs;kpF tpuz khfpajpw; #or yq;ffSkp Fe;JNeha; 
 GilA ePs;jir fiue;J el;gltp Ue;J G+jTly; thbdhy; 
 milt Nrhup fug;g dhkpija wpe;J ed;kUe; jhw;wpNl” 
 Ulcers in the genital organs and both groins
 Itching and oozing in the inner aspect of the thigh
 Emaciation
 
5. CJ fug;ghd;: 
 
 Nfsha; Fspu;fha;r;ry; Nflhq; fUq;foiy 
 %shtp jhd; Nghy; Kad;Wepw;Fk; - ehs;NjhWk; 
 G+jk;Nghy; tPq;Ftpf;Fk; Gz;zhfp %f;fupf;Fk; 
 CJfug; ghe;Njhlk; cw;W.” 
 Fever with rigor
 Tumours in the body
 Generalised oedema and Itching
  
10 
 
6. #iyf; fug;ghd;: 
  
“gps;is Kfk;thbg; Ngjntb Nkdpnay;yhk; 
 rs;is nghUe;jpj; jtpf;FNk – nks;sf;Nfs; 
 ts;sy; Koq; fhy;if kUtpAz;zf; $lhJ 
 js;Snkd;Nw #iyaJ jhd;.” 
 Ulcers and pain in the body and general debility
 Difficulty in moving both knees and elbow joints

7. ntb fug;ghd;: 
 
 mupit NaAlyf nsq;Fk; tpq;Fkir fPypy; tPq;Fkjpy; Jz;lkha; 
tpupa tPq;fpajp nyntbj;jpL kpFe;j ntg;gJT khfNt 
jpupfp Najiy typj;J NkYk;ntF jpdT khfpaJ Nthbdhy; 
cupa jhFk;ntb fug;g dhnkd Tfe;J gz;bj Kzu;j;jpNl”. 
 Swelling in the body
 Pain and swelling all over the joints
 Itching, headache, and fever
 
8. kz;ilf; fug;ghd;: 
 
 “Xb kz;iljdp NyGz; zhfpAau; fhjpw; rPtope;jwpNa 
 ehb Najiyt ypj;J %f;fpdpy; eae;J epuJ g;upe;jpLk; 
 thb nka;aJk; ntg;gnkhL Fuy; tisap dpdwpdTkhfNt 
 $by; kz;ilf; fug;ghnd dg;gup fhu Nkypdpf; $Wthk;”. 
 Itching in the scalp
 Ear discharge, headache, and fever
 Loss of weight and pain in the throat
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9. nghupfug;ghd;: 
 
 “khW khnwd tbjj tnad Tlw;FNs jbg;ghfpNa 
 VW Nkrpte; NjhL Nafdj; njq;F Nky;ntbj; Js;SNk 
 ePW Nghydy; Fspu;r;rp ahfpAo dhT yu;e;Jnewp jho;j;jpby; 
 Mwp lhg;nghwp fug;g dhnkd twpe;J gz;bje; njhFj;jpNl”. 
 Papules in the body and altered sensorium
 Dryness of mouth
 
10. rl;ilf; fug;ghd;: 
 
 “kq;if fPypy;typ fs;spg; G+ntdk yu;e;J thupapL nka;apdpw; 
 nghq;F ePu;g; gdpfs; Nghy;tp Ke;Jlyk; ntg;g khfpkyQ; rpf;fpNa 
 Jq;f khdrpu NehT khfptsu; J}atd;dkJ JNtlkhk; 
 jq;F rl;il fug; ghNd zr;rpfpr;ir jhNd jw;Ftpupj; NjhJtha;”. 
 Pain in all the joints associated with fever
 Yellow colouration of the skin
 Itching and oozing in the lesion
 Loss of appetite
 
11. XL fug;ghd ;: 
 
 vz;Z fpd;wnjhU fPyp Nytypf Nsf khfpaJ fl;bNa 
 tz;z nka;euk; ngq;F NkaprpT Fj;j yhfpky ge;jkha; 
 ez;zp NajpdT kha;j;jbj; Jlyp db tPf;fK kpFe;jpbw; 
 fz;zp xLfug; ghd;, njd;wKiw fz;L nfhs;sb fUj;jpNy. 
 Pain and swelling in all the joints
 Difficul to flexion and extension of joints
 Allergic papules
 Itching
 Constipation
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12. fUq;fug;ghd;: 
  
mw;a Nfsa; fuq;fug;gd; monk Fotp cly;ntJk;Gk; 
 nrwpa KiyAk; cz;zhJ Njfepw;Fk; ntt;Ntwha;f; 
 fupa Nkdp gReuk;G fjpj;Nj fhl;Lk; guguj;J 
 KWf;fp kpfTe; Js;sp tpOk; KfKk; gjq;fs; CjpLNk”. 
 Fever
 Discolouration of the skin
 Oedema in the face and lower limbs
 
13. nrq;fug;ghd;: 
  
“fha;r;r NyhLfLg; gfp A+jply; fd;wp nkj;jT kod;WNgha; 
 Nka;r;r yhdjpd thfpnaq;fZ tpau;f;FUTfs; kpFe;Jjhd; 
 gha;r;r yhdKf Kq;fWj;Jly; gupe;J jhdJ rpte;jpby; 
 #l;r khfptsu; nrq;f ug;gnddj; Njhw;wp NaaT ljQ;nrNa”. 
 Low grade Fever
 Macules and papules are present
 Blackish discolouration in the face
 Erythematous lesion present in all over the body
 
14. nfhs;spf; fug;ghd;: 
 
 nfhj;Jf; nfhs;sp apd;fug;ghd; Fzj;ijf; Nfsha; NfhfpyNk 
 kw;Wk; tapW jhd;tPq;fp kyK kilf;Fk; ,isg;Gz;lhk; 
 fj;Jq; FuYk; miuAz;lhq; fdj;j tpf;fy; cz;lhdhy; 
 gj;Jk; gjpAk; xJtNjd; ghyd; gpiog;g jupjhNk”. 
 Abdomin swelling
 constipation
 Emaciation
 Hiccough
 Dyspnoea
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15. Njhlf; fug;ghd;: 
  
cs;S NkYespu; fha;r;r yhfpAlk; ngq;Fk; Gz;nzd tod;Wtha; 
 fs;S ehwpAly; jd;dp Nyfoiy fz;L G+jnkd tPq;fpNa 
 vs;spd; khkyiu nahf;F %f;fpd; epd;wOJ Nkq;fpdhy; 
 js;S khd;fspd; rha yha; nfhbaNjh lkhdfug; ghdpNj”. 
 Fever with rigor
 Papules and pustules in the body
 Foul smell in mouth
 Lymphnode enlargement
 Itching innose
 
16. thiy(ghy) fug;ghd;: 
  
fhyJ fLf;FQ; re;J fz;lKk; ntbj;Jg; Gz;zha; 
 VyNt fbtp lk;Nghy; ,Uj;Jgd; dPu;Ngy; gha;e;J 
 Nfhykha; tw;wp ehWk; FotpA nkhLq;F khfpy; 
 khyUq; Foyha; thy fug;ghd; nra; thW jhNd”. 
 Pain in the lower extremities
 Appearance of vesicles, oozing, bullae, papules
 Foul smelling discharge in the ulcers
 
17. tus; fug;ghd;: 
 
 cr;rpKj Ys;sq;fh Yw;wstp nyt;tplKk; 
 er;Rr; rpWrpuq;F ez;zpNa-epr;ry; 
 ntbj;J ePu; nkT eik nkth Jwf;fk; 
 fbe;jtul; rpf;fug;ghd; fhz;”. 
 Itching, Oozing, papules in the body
 Bullae present in the whole body
 Insomnia
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18. tPq;F fug;ghd;: 
  
Kd;dNu aq;fq;F %upf; fdKz;lha;g; 
 gpd;duit Gz;zha;g; ngU/jPaha;g-kd;dpnaupe; 
 jg;ghd Kj;jzpe;jtw;wp dPu; nrhupjy; 
 jg;ghtpq; Fq;fug;ghd; jhd;”. 
 Swelling in various parts of the body
 Burning sensation in the site of the lesion
 Oozing
 
Other Siddha Literatures describing the classificationof Karappan 
As per the another siddha text book Aathma rakshamirtham yennum vaithiya 
saarasankiram describes the classification of Karappan in eighteen types as follows 
 
a)  Mj;kh uj;rhkpu;j;nkd;Dk; itj;jpa rhurq;fpuk; 
 
 
 
1. thjf; fug;ghd; 
2. gpj;j fug;ghd; 
3. rpNyj;Jk fug;ghd; 
4. nrq;fug;ghd; 
5. fUq;fug;ghd; 
6. kz;il fug;ghd; 
7. mup fug;ghd; 
8. nghup fug;ghd; 
9. fpue;jpf; fug;ghd; 
10. #iyf; fug;ghd; 
11. thiyf; fug;ghd; 
12. CJ fug;ghd; 
13. nrt;thg;G fug;ghd; 
14. nfhs;sp fug;ghd; 
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15. fl;bnahLtpq;F fug;ghd; 
16. cjpuf; fug;ghd; 
17. rl;iljbntb fug;ghd; 
18. rpq;fKf vhp fug;ghd; 
b)  A+fp itj;jpa fhtpak; 
 As per thesiddhaliterature yugi vaithiya kaaviyam karappan is classified into 9 
types as follows 
1. thjf;fug;ghd; 
2. fz;lf;fug;ghd; 
3. twl;rpfug;ghd; 
4. gpj;jfug;ghd; 
5. gpj;jtwl;rpf;fug;ghd; 
6. fghy fug;ghd; 
7. thjtwl;rpf;fug;ghd; 
8. jpkpu;thjf;fug;ghd; 
9. nrq;fug;ghd; 
c)  rpfpr;rhuj;d jPg itj;jpa rpe;jhkzp 
As   per thesiddhaliterature Sigicha rathna theepam karappan is classified into 7 
types as follows 
1. thjf; fug;ghd; 
2. jpkpu; fug;ghd; 
3. fghy fug;ghd; 
4. fz;lf; fug;ghd; 
5. gpj;j fug;ghd; 
6. twl;rp fug;ghd; 
7. rpNyj;Jk; fug;ghd; 
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d) FUehb rh];jpuk; 
 Other Siddha Literature Guru naadi saasthiram Karappan is classified into eighty 
five a follows 
“gLtd; Kg;gj;jpuz;L gUntU ehw;gj;njhd;W 
 KUfpLk; tp\gkhW Kw;Wnkh\rp %d;Wu; 
 jpUfpLk; gPyp %d;W rpurpdpw; rpye;jp nrhy;ypy; 
 fLfpL iklk; gj;jhW fug;ghD nkd;gj;ije;J 
     (FUehb rh];jpuk;) 
e)  mfj;jpau; 2000 
 In Agathiyar 2000 classification of Karappan is sixty six in numbers 
 tpsk;gpL thjnehT vz;gj;J ehYkpf;f 
 cs;sq;fs; rd;dp Kg;gNjhq;Fly; thAnkl;L 
 foq;fK Kg;gj;njO fug;ghD kWg;gj;jhW 
 jdq;nfhs;spg; GUjp ehY rhw;Wis Fwit nal;Nl 
      (mfj;jpah; 2000) 
f)  mfj;jpau; ,uz E}y; ; 
 
Other siddha literature classification of Karappan is sixty six in numbers 
 vz;gJ fug;ghd; jd;ik apak;gpLkhW NfsPu; 
 ed;apLk; thjk; gpj;jk; eyq;nfl;Lj; jhsk;tpq;Fk; 
 Gz;gLq; fuq;fs; re;J Giye;jply; fUj;J NehFk; 
 td;ikAld; ntbj;Jr; #iy tUtJuig njd;nt 
      (mfj;jpau; ,uz E}y;) 
g)  A+fp itj;jpa rpe;jhkzp 
As per the Siddha literature Yogi Vaithiya Chinthamani Karappan is classified 
into seven types 
 Mnkd;w fug;ghd; jhd; VOtpj khFk; 
  mlq;fhj thjj;jpd; fug;ghNdhL 
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 fhnkd;w fz;lkhq; fug;ghdhFk; 
  fUjpa Njhu; twl;rpahq; fug;ghNdhL 
 Njnkd;w jpkpu;thjf; fug;ghd; whDk; 
  rpurpdpNy ngUf ghyf; fug;ghd; 
 Nghnkd;w gpj;jkhq; fug;ghNdhL 
  ngupa Nrl;Lkf; fug;ghd; ngau;jhNdNo”. 
     (A+fp itj;jpa rpe;jhkzp) 
1.  Vadha Karappan   (thj fug;ghd;) 
2.  Pitha Karappan   (gpj;j fug;ghd;)  
3.  Kabha Karappan   (fg fug;ghd;) 
4.  Kanda Karappan   (fz;l fug;ghd;) 
5. Varatchi Karappan   (twl;rp fug;ghd;) 
6.  Kabala Karappan   (fghy fug;ghd;) 
7.  Thimir Vatha Karappan  (jpkpu;thj fug;ghd;) 
 
Curable and incurable types of karappn as per siddha text book baavagadam 
1. nfhs;sp fug;ghd; - mrhj;jpak; (Incurable) 
2. kw;w 17 tiffs; - rhj;jpak ;(Curable) 
 
Kf;Fw;w NtWghLfs; (Pathogenesis) 
 
rpj;j kUj;Jtj;jpy; Kf;Fw;wq;fspd; mbg;gilapy; Neha;fs; 
tifg;gLj;jg;gl;Ls;sd. Kf;Fw;wwq;fshtJ thj> gpj;j> fgk; vd;W 
$wg;gl;Ls;sJ mit KiwNa 
 thjk;  - 10 
gpj;jk; - 5 
fgk; - 5 
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thjk; / tsp (Vatham) 
tbtj;jd;ik 
 Ez;ik (mZj;Jtk;) 
 neha;ik (fbdkpd;ik) 
 jz;ik (Fspu;r;rp) 
 ntk;ik (cl;bzk;) 
jz;ik> ntk;ik Mfpa ,t;tpuz;lhy; tUk; xg;Gutpd;ik (rUr;riu) 
vd;gdthk;. 
 
tsp thOkplk; (Location of Vatham in the body) 
 
 mghdk;> kyk;> ,lfiy> ce;jpapd; fPo; %yk;> fhkf;nfhb> ,Lg;G vYk;G> 
Njhy;> euk;Gf;$l;lk;> fPy;fy;> kapu;f;fhy;fs;> Cd; Mfpa ,lq;fspy; tho;tjhFk;. 
 
tiffs; gzpfs; 
1. gpuhzd; 
 %r;R thq;fy;> tpLjy; nra;Ak;. 
 Grpf;Fk; czTfisr; nrupf;fg; gz;Zk; 
2. mghdd; 
(fPo;Nehf;Ffhy;) 
 kyrj;ijj; js;Sk; 
 Mrdthiar; RUf;Fk; 
 md;drhuj;ijr; Nru Ntz;ba ,lq;fspy; 
Nru;g;gpf;Fk; 
3. tpahdd; 
 cWg;Gfis ePl;l klf;fr; nra;jy; 
 guprq;fisawpjy; 
 cz;Zk; cztpd; rhuj;ij mt;tt;tplq;fspy; 
      epug;gpj;J cliyf; fhf;Fk; 
4. cjhdd; (Nky; 
Nehf;Ff;fhy;) 
 cztpd; rhuj;ij mq;fq;Nf epWj;Jk;. 
     ntspg;gLj;jpAk;/fyf;fpAk; tUjy; nra;Ak; 
5. rkhdd; (eLf;fhy;) 
 thAf;fis kpQ;rnthl;lhky; klf;fpr; rupgLj;jp Nru 
gz;Zk;. 
 jz;zPu;> md;dk; Mfpatw;iw rkg;gLj;jp 
clypnyy;yhk; NrUk;gb nra;Ak ; 
6. ehfd; 
 mwpit vOg;gy;. 
ey;y gz;fisg; ghLtpf;Fk;. 
 fz;fis jpwf;f ,ikf;fr; nra;Ak; 
 kapu;fis rpypu;f;fg; gz;Zk; 
7. $u;kd;  ,iria nfhl;Ltpj;jy; 
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 nfhl;lhtp tplg;gz;zy; gyk; cz;L gz;zy; 
 fz;fis jpw;f;f/%l gz;zy;. 
 cyfg; nghUl;fs; ahtw;iwAk; fz;fSf;F 
fhz;gpf;Fk;. 
 fz;fspdpd;W ePiu tpog; gz;Zk; 
8. fpUfud; 
 ehtpw;frpT> ehrpapw; frpitAk; cz;lhf;fy;. 
 grpia cz;L gz;zy; 
 xd;iw epidj;jpUf;fr; nra;jy; 
 Nghjw; njhopiyr; nra;Ak; 
 Jk;kayak;> ,UkiyAk; cz;lhf;fy; 
9. Njtjj;jd; 
 rz;ilnfhs;sy; 
 ju;f;fk;Ngry;> kpf;f Nfhgk;. 
10. jdQ;nrad; 
 %f;fpypUe;j jbjJ clk;G KOikAk; tPq;fg; 
gz;Zk;. 
 fhjpy; fly; NghypiuAk;. 
 fhw;nwy;yhk; ntspg;gl;l gpd;du; 3tJ ehspy; jiy 
ntbj;j gpd; jhd; NghFk; 
 
ghyf; fug;ghdpy; mghdd;> cjhdd;> rkhdd;> fpUfud;> Njtjj;jd; 
,itfs; nghJthf ghjpg;G milAk;. 
 
gpj;jk;/moy; (Pitham) 
tbtj;jd;ik 
 ntg;gk; 
 nea;g;G 
 $u;ik 
 nefpo;r;rp 
 
gpj;jj;jpd; ,Ug;gpld;: 
 gpq;fiy> gpuhzthA> ePu;g;ig> %yhf;fpd;> ,Ujak;> jiy Mfpa 
,lq;fspy; tho;tjhFk;. 
 
tiffs; gzpfs; 
1. mdu;gpj;jk;  cz;l czit nrupf;Fk;gb nra;Ak; 
2. ,uQ;rfk; 
 nre;ePiu kpFjpgLj;Jk;. 
 cztpd; rhw;Wf;F nre;epwj;ijf; nfhLf;Fk; 
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3. rhjfg;gpj;jk; 
 epiwNtw;Wk; gz;GilaJ 
 kdk;> Gj;jp> gw;W ,tw;iwf; nfhz;L tpUg;gkhd 
njhopiyr; nra;J Kbf;Fk; 
4. MNyhrfg; gpj;jk; 
 fz;fSf;F nghUl;fisj; njuptpf;Fk; 
gz;GilaJ. 
5. gpuhrf gpj;jk;  NjhYf;F Xspiaf; nfhLj;J xspur; nra;Ak; 
 
ghyf; fug;gdpy; ,uQ;rfk;> gpuhrfk; ,itfs; nghJthf ghjpg;G milAk;. 
Iak;/fgk; (Kabham) 
tbtj;jd;ik 
 jd;ik  
 ke;jk; 
 nea;g;G 
 jpz;ik 
 tOtOg;G  
 nkd;ik 
 
Iak; thOkplk; 
 rkhdthA> RopKid> ntz;zPu (tpe;J)> jiy> ehf;F> cz;zhf;F> 
nfhOg;G> kr;ir> FUjp> %f;F> khu;G> euk;G> vYk;G> ngUq;Fly;> fz;> fPy;fs; 
Mfpa ,lq;fspy; tho;tjhFk;. 
 
tiffs; gzpfs; 
1. mtyk;gfk;  ehd;F Iaq;fl;F gw;Wf; NfhlhapUj;jy; 
2. fpNyjk; 
 czTg; nghUs;> ePu; ,itfis 
<ug;gLj;jpnkj;njdr; nra;Ak; njhopiyg; GupAk;. 
3. Nghjfk; 
 ehtpdpd;W cz;Zfpw Ritfis mwptpf;Fk; 
njhopiyg; GupAk; 
4. jw;gfk;  jiyapdpd;W fz;fSf;F Fspu;r;rpiaj; jUk;. 
5. re;jpfk; 
 G+l;Lfspy; epd;W ,aw;ifaha; vy;yh fPy;fisAk; 
xd;nwhnlhd;W nghUj;jp jsur; nra;J 
nfhz;bUf;Fk;. 
 
ghyf; fug;ghdpy; Iak; nghJthf ghjpg;G milahJ. 
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Diagnostic Methods (Piniyarimuraimai) 
 Piniyari Muraimai is the methods of determination of a disease.  It is bassed on 
the following principles 
1. Poriyalarithal (Inspection) 
2. Pulanal arithal (Palpation) 
3. Vinaathal (Interrogation)  
 
Poriyalarithal and pulanal arithal goes hand with the concept of Examining the 
patient‟s pori and pulan with that of physician‟s pori and pulan. 
 
Vinaathal is a method of interrogation about the details of that patients problem 
from his own words (or) from his parents or neighbours who are taking care of the 
patients, when the patient is not able to speak (or) patient may be child. 
 
rpj;j kUj;Jtj;jpd; Neha;fzpg;gpy; gpd;tUk; fhuzpfs; Kf;fpa gq;F 
tfpf;fpd;wd. 
Nehahspiar; rhh;e;Jj 
 
1. caph; jhJf;fs; (Kf;Fw;wk;) 
 
2. cly; jhJf;fs; (VO clw;fl;Lfs;) 
 
3. vz;tifj; Njh;T 
 
Nehahspiar; rhh;e;jJ 
4. nghOJ 
 rpWnghOJ   -  itfiw> tpbay;> vw;ghL> ez;gfy;>  
                         khiy> ahkk; 
 ngUk;nghOJ - fhh;> $jph;> Kd;gdp> gpd;gdp>   
                         ,sNtdpy;> KJNtdpy; 
5. Itif epyq;fs; -  FwpQ;rp> Ky;iy> kUjk;> nea;jy;>  
                      ghiy. 
 
Nkw;$wpa fhuzpfspd; khWghLfis xd;Wld; xd;W xg;gpl;L Neha; 
fzpf;fg;gLfpwJ. 
  
22 
 
Ennvagai thervugal (eight fold examination) 
 Envagai thervugal is a tool and it is described by Siddhar theraiyar as follows 
 
  ehbg; ghprk; eh epwk; nkhoptpop 
  kyk; %j;jpu kpitkUj;Jt uhAjk; 
- Njud; 
 The above concept also supported by another great Siddhar Agasthiyar in 
Vaidhya Chinthamani Venba – 4000 as follows 
 
“nka;Fwp epwk; njhdp tpop eh ,Ukyk; iff;Fwp” 
 
Another Siddha book describe Envagal thervugal as follows 
 
“Njba tpahjpf; nfy;yk; Njfj;jpy; ghpl;irAz;L 
$bNa epw;Fnkl;L ghpl;irahq; $wf;NfsPh; 
ehbNa njhl;lhw; Njfk; %j;jpuk; thh;j;ij fz;fs; ehf;F 
  ghbNa kyryq;fs; gy tz;zk; ghh;j;Jf; nfhs;Ns” 
- rpj;j kUj;Jtkzpfs; 
Nkw;$wpa ghlypd; %yk; ehb> ];ghprk;> eh> epwk;> nkhop>tpop> kyk;> 
%j;jpuk; Mfpad kUj;Jthpd; MAjk; Nghd;wit vd mwpayhk;. 
 
 Hence the diagnosis is made by using the following tools are important in Siddha 
system of Medicine. 
 1. Naadi (Pulse reading) 
 2. Sparisam (Tacfile sensation) 
 3. Naa (Tongue) 
 4. Niram (Colour) 
 5. Mozhi (Speech (or) Voice) 
 6. Vizhi  (Eye) 
 7. Malam (Stools) 
 8. Moothiram (Urine) 
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1.  Naadi 
“clypy; caph; jhpj;jpUg;gjw;F fhuzkhd rf;jp vJNth mJNt ehb” 
 Naadi is the vitiating elements of the body which is Vatham, Pitham, Kabam, 
Naadi is otherwise called a Uyirthathukkal. 
 Naadi can be felt by a Physician viz Vatham, Pitham and Kabam with the tips of 
Index, Middle and Ring fingers respectively at the anterior part of lower end of the radius 
bone of the patients.  It informs the physiological and pathological condition of the body. 
 The three Uyirthathukkal are formed by the combination of 
  Edakalai  +  Abanam  =  Vatham 
  Pinkalai  +  Piranan  =  Pitham 
  Suzhumunai  +  Samanan  =  Kabam  
 The ratio between Vatham, Pitham and Kabam is 1:1/2:1/4 respectively. 
 In Bala Karappan, Vatham naadi generally affected and then other naadi‟s are 
also deranged. 
 
2.  Sparisam 
 The following points are elicited through sparisam. Temparature of the skin on 
any abnormal grounds, Hypersensitiveness and thickness of the skin, swelling and 
dryness of the skin, ulcers, oedema, obesity, liver and spleen enlargement. 
 In Bala Karappan, the skin becomes well defined borders, hyperpigmented with 
central clearing nature. 
3.  Naa 
 This is the method of inspection of the tongue, gums, teeth, lips, palate etc., 
4.  Niram 
 Changes in the colour of the skin, teeth, eyes, nail and lips due to Mukkutra 
derangement are to be noticed Hypo (or) hyperpigmentation is also  be noted. 
 In Bala Karappan skin is hyperpigmented, erythemators, macular, slightly raised 
margenated with central clearing in nature. 
5.  Mozhi 
 Examination of Mozhi includes clarity of speech, crying, low and high piched 
voice, slurring speech. 
 No abnormalities were observed in Bala Karappan. 
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6.  Vizhi 
 Pallor of the conjunctiva, conjunctivitis, cataract (any redness and pterygium 
etc..) 
 No abnormality was seen in Bala Karappan. 
7.  Malam 
 Semisoild, colour, froth, abnormal consistency, frequency, constipation, foul 
smell etc.,  
In Bala Karappan constipation may be present. 
8.  Moothiram 
 Examination of urine for the determination of  Neerkuri and Neikuri.  It is one of 
the important diagnostic method. 
 
ePh;f;Fwp (Neerkuri) 
“te;j ePh; fhpnail kzk; Eiu vQ;rnyd; 
 iwe;jpaYsit aiwFJ KiwNa” 
- Neha; ehly; Kjy; ghfk;  
ePhpy; epwk;> kzk;> Eiu> vil> vQ;ry;> Mfpatw;iw Nehf;f Ntz;Lk;. 
Mbf;fyrj; jhtpNa fhJ nga;  
NjhUK$h;j;jf; fiyf;Fl;gL ePhpd;  
epwf;Fwp nea;Fwp epUkpj;jy; flNd” 
     - Njud; 
Prior to the day of urine Examination the patient should have good sleep and 
instructed to take a balanced diet.  After waking up in the morning, the first voiding urine 
is collected in a clear wide mouthed glass container and is subjected to analysis of 
“Neerkkuri” within 1½ hours. 
Urine has the following general features 
 Niram 
 Edai 
 Manam 
 Nurai 
 Enjal  
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nea;f;Fwp (Neikkuri): 
Foe;ijfspd; ehbeil rhpahf fzpg;gjpy; rpukk; cs;sjhy;> nea;f;Fwp 
ghpNrhjid %yk; Nehahsh; vf;Fw;wj;jhy; ghjpf;fg;gl;Ls;shh; vd;gjid 
fzpf;fyhk;. 
ghyf; fug;ghd; Nehahspapd; rpWePiu Nrhjid tl;bypy; Cw;wp xspkpFe;j 
,lj;jpy; ePhpd; miyapy;yhj NghJ ey;nyz;nzaj;;Jsp tp;l;L ghh;f;fg;gl;lJ 
rpyhpy; muntd ePz;Lk Mop Nghy; (Nkhjpuk;) gutpAk;> rpyhpy; Kj;J Nghy; 
epd;Wk; fhzg;gl;lJ. 
muntd ePz;bd; m/Nj thjk;  
MopNghw; gutpd; m/Nj gpj;jk;  
Kj;njhj;J epw;fpd; nkhoptnjd; fgNk 
- Neha; ehly; Kjy; ghfk; 
 
“vz;nza; tpl;L ghu;f;Fk; tpjp  
epwf;Fwp Fiuj;j epUkhz ePupw; 
rpwf;f ntz;nza;Nahh; rpWJsp eLtpLj;  
dpd;wjptiy Nghk; newptpopawpTk;  
nrd;wJ GfOQ; nra;jpia AzNu” 
The collected specimen (urine) is kept open in a glass dish or china clay 
container.  It is to be examined under direct sunlight, without any shaking of the vessel.  
Then add one drop of gingelly oil without disturbing the urinary specimen and the 
NeiKuri was noted in direct sunlight and conclude the diagnosis as follows 
 
Character of Vathaneer 
Muntd ePz;bd/Nj thjNk 
 When the oil drop lengthens like a snake, it is called “Vatha Neer” 
 
Character of Pithaneer 
Msp Nghw;gutpd; m/Nj gpj;jk; 
 When the oil drop spreads like a ring, it is called “Pitha Neer” 
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Character of Kabaneer 
Kj;njhj;J epw;fpd; nkhoptnjd; fgNk” 
 When the oil drop appears like a pearl, it is called “Kaba Neer” 
 
Character of Thonthaneer 
 Snake in the ring, ring in the snake, snake in the pearl and ring in the pearl are the 
characters of “Thontha Neer”. 
 
Types of land (Nilam) 
 Nilam is classified into 5 types depending on the surrounding vegetation, 
landscape and ecological state study of 5 places is very much necessary as some diseases 
are common in particular kand. 
 1.  Kurinji  –  Mountain and its surroundings liver diseases and fluorosis 
    are common. 
2.  Mullai  –  Forest and its surroundings pitha noi and liver diseases 
   are common. 
3.  Marutham  –  Field and its surroundings. 
    The ideal places for healthy living. 
4.  Neithal  –  Sea and sseashores.     
   Liver disease occurs in combination with other diseases. 
5.  Paalai   -   Desert and its surroundings.    
   Vatha, Pitha, Kabha, diseases occur. The disease Bala 
   Karappan was predominant in Neithal nilam. 
Paruvakalam 
 Siddhars have classified a year into six seasons each containing two tamil 
months. 
They are, 
1. Kaarkalam   -  Avani & Purattasi (Aug  15   to   Oct15) 
 
2. Koothirkalam  - Ippasi &Karthika (Oct  15 to Dec15) 
 
3. Munpanikalam -  Margazhi &Thai (Dec 15 to Feb15) 
 
4. Pinpanikalam  - Masi &Panguni (Feb 15 to Apr15) 
 
5. Elavanilkalam  -  Sithirai &Vaigasi (Apr15 to June15) 
 
6. Muthuvenilkalam - Aani &Aadi  (June15  to Aug15) 
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Udal Vanmai (Body Immunity) 
 
The   vanmai is classified into three kinds. 
They are, 
1. Iyarkai Vanmai 
2. Kaala Vanmai 
3. SeyarkaiVanmai 
 
1. IyarkaiVanmai 
Natural immunity of the body caused by Mukkutram right from birth onwards. 
2. KalaVanmai 
Development of immunity according to age and environment. 
3. SeyarkaiVanmai 
Improving the health by intake of nutritients, food materials, exposure to some 
disease, activities and medicines. 
 
Udal thathukkal (Seven udal kattugal) 
 
Udal thathukkal General definition of each type 
 
Saram 
 
Gives strength to body and mind 
 
Seneer 
 
Responsibl for knowledge, strength, boldness, healthy 
complextion. 
 
Oon 
 
Gives structure and shape to body and is responsible 
for movements of thebody 
 
Kozhuppu 
 
Lubricates the internal   organs   and   helpsthe   organs to 
worksmoothy. 
 
Enbu 
 
Protects the vital organs and   act asbasis for 
movements and maintains bodystructure. 
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Moolai 
 
Present   inside   the   bones   and   it givesstrength and 
maintains the normalcondition of the bone. 
 
Sukilam/Suronitham 
 
Responsible for reproductive function. 
 
Human  body  is  made  up  of  seven  udal kattugal  which   are  important   
for the structure   and  function   of   the   body. Among  theseven udal kattugal (seven 
physical  constituents)  saaram  and seneer are commonlyaffected in bala karappan. 
 
Management of  Bala Karappan in Siddha System  
kpfpDk;FiwapDk; Neha;nra;Ak; EhNyhh;  
tspKjyh ntz;zpa %d;W 
- jpUf;Fws; 941 
The learned books count three, with win as first; of these, As any one prevail, or fail; 
„twill cause disease. 
 
In   Siddha   system   the   main   aim   of   the   treatment    is    to    set    right   
the   derangement   of   mukkutram. Treatment   is    not    only    for    perfect    healing 
but also for   prevention   and   rejuvenation. It   is   also very much essential   to   know   
the   disease through   its   aetiology. The   nature and severity   of   the   illness,   the    
seasons    and    the    time   of    occurance must be observed clearly. 
 
Line of treatment 
Line of treatment is asfollows 
a. Kaappu (Prevention) 
b. Neekam (Treatment) 
c. Niraivu (Restoration/Rejuvenation of wellbeing) 
1. Kaappu (Prevention of BalaKarappan) 
 Use  warm water for bath 
 Take bath daily and avoid bathing in lake, pond. 
 Use green gram powder or “Nalangu Maa” instead of soap for 
bath. 
 Wash in dresses with disinfectant solution and dry in direct sunlight. 
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 Prevent from Mosquito bite. 
 Advised to wear fresh dry and cotton clothes. 
 Advised to trim the nails, 
 It is a good habit to wash hands after touching other people or animals. 
 
General instructions for Eczema patients 
1. The   patients  should   avoid  extremes  of   climate. If   it   is   not possible to 
change the place of   residence,   then   air   conditioning is  the answer. 
2. The patient should not scratch and keep his nails short. 
3. The diet should be light.  The exact composition  of the diet depends upon the 
History of the patients, the diet habits and the results of the allergy test. 
4. Allergic stuffs should be avoided. 
5. Healthy hobbies and playing should be encouraged. They  help  to divert 
attention and speed up recover. 
 
 Neekam (Treatment) 
The aim of Neekam is based on 
 To bring the deranged three humours to equilibrium state. 
 To treat the patient with 
 Internal Medicine 
 External Medicine 
 Dietrestictions 
 
3. Niraivu (Rejuvenation) 
Physical, psychological, social and economic rehabilitation and  reassurance of 
individuals is known asNiraivu. 
 
 Rest
 Positive mental attitude
 Life style modification
 Modification in daily activities
 
The patients are well   motivated.  The   nature   and   course   of   the   disease 
is explained tothem. 
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kUj;Jtk; 
 
1. Ntw;Wepiy tsh;r;rpaile;j thjj;jpid jd;dpiyg;gLj;jNtz;Lk; 
2. jd;dpiy tsh;r;rpaile;j Iaj;jpid rkg;gLj;jNtz;Lk; 
3. gpj;jFw;wj;jhy; ghjpg;gile;Js;s thjj;jpidAk; rhpg;gLj;jNtz;Lk;. 
4. td;ik ,oe;j clw ;fl;Lfis td;ik milar; nra;Ak ;tifapy; 
kUe;jspf;fNtz;Lk;. 
 
Keeping  in  mind  the  need  for  bringing   out   an   effective   therapy for  Bala 
Karappan from Siddha system  of  Medicine, the  author  has  undergone this dissertation  
work  with Karappan Nei  (Internal and Enternal Medicine). The dosage of Medicine all 
6 – 12 years (6 – 8 years – 5ml, 9-12 years – 10ml) (bd). 
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3. b. MODERN ASPECT 
Anatomy of the skin: 
 
 
Cross section of theskin 
 
The skin is  a  vital  organ  that  covers  the  entire  outside  of  the  body,  
forming  a  protective barrier   against   pathogens  and   injuries  from   the environment.  
The skin is the body‟s largest organ. The color, thickness and texture of skin vary over 
the body. There are two general types of skin.Thin and hairy, which is more prevalent on 
the body and thick and hairless, which is found on parts of the body that are used heavily 
and endure a large amount of friction, like the palms of the hands or the soles of the feet. 
 
              Basically, the skin is comprised of two layers that cover a third fatty layer. 
These three layers differ in function, thickness and strength. The outer layer is called the 
epidermis. It is a tough protective layer that contains the melanin–producing 
melanocytes. The second layer is called the dermis. It contains nerve endings, sweat 
glands, oil glands, and hair follicles. 
 
Under these two skin layers is a fatty layer of subcutaneous tissue, known as 
the subcutis or hypodermis. 
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Parts of the skin: 
 Theepidermis
 Dermis
 Hypodermis /subcutaneoustissue
 
Epidermis: 
The epidermis is the most superficial layer of the skin and provides the first 
barrier of production from the invasion of foreign substances into the body. The 
principal cell of the epidermis is called akeratinocyte. 
 
Layer of the epidermis: 
 Stratum corneum /corneal layer /horney layer
 Stratumlucidum
 Stratum granulosum/granular layer
 Stratum basalis /basal layer
 Malpighian layer

It is the viable part of the epidermis and contains nucleated keratinocytes. It 
consists of all layers of epidermis except corneal layer.Vitamin Dis synthesized in this 
layer. Thickness of the viable part is 100 µm. 
 
Stratum corneum/corneal layer / horney layer: 
It is the outer most layer and formed by a specialized process, known as 
keratinization. It is thinnest at eyelid (10-15 µm) and thickest at soles (100 µm). It is  
made up of piled –up layers of flattened anucleated keratinocytes, known as corneocytes. 
It appears as a brick wall where the corneocytes are the bricks, and a mixture of lipids 
and proteins is like that of cement andsands. 
 
Stratum lucidum: 
It is an electolucent layer lies between corneal and granular layers. It is most 
appreciable at palms and soles. 
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Stratum granulosum/granular layer: 
 
It consists of 1-3 layers of keratinocytes. These cells are having cytoplasmic 
granules and so name is implied Keratinocytes of this layer contain basophilic granules, 
known as keratohyaline granules. Keratohyaline granules contain various proteins 
including involucrin, loricrin and profilaggrin. 
 
Stratum spinosum/spinous layer: 
 
It consists of polygonal kerationcytes and they are interlocked with each other 
through cytoplasmic processes, appearing as spines and so the name is implied. Cells of 
upper of spinous layer contain odland bodies or lamellar granules, synthesized by their 
Golgi apparatous. Odland bodies contain baskets of lipids, polysaccharides and 
hydrolytic enzymes. These lipi contents contribute to form outer layer of the cornified 
envelope of corneyocytes. Lipid layer contains ceramids (50 %), cholesterol (35%), and 
free fatty acids (15%). 
 
Stratum basalis / basal layer: 
 
It consists of single layer of cuboidal or columnar cells which continuously 
proliferate to replenish the pool of epidermal cells. Basal layer is not straight like corneal 
layer, it is undulating, having upward and downward projections. 
 
Contents of theepidermis: 
 Keratinocyte
 Melanocyte
 Langerhanscell
 Merkelcell
 Epidermal parts of eccrine and apocrineducts
 Epidermal part of pilosebaceous unit.
 
Dermis: 
The dermis is located beneath the epidermis and is the thickest of the three layers 
of the skin (1.5 to 4 mm thick), making up approximately 90 percent of the thickness of 
the skin.  
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The main functions of the dermis are to regulate temperature and to supply the 
epidermis with nutrient-saturated blood. Much of the body's water supply is stored 
within the dermis. This layer contains most of the skin specialized cells and structures. 
 
Sweat Gland: 
Apocrine glands are specialized sweat glands that can be found only in the axilla, 
umbilicus, around the anus and genitalia. These glands secrete a milky sweat that 
encourages the growth of the bacteria responsible for body odor. 
 
Eccrine glands are the true sweat glands. Found over the entire body, these 
glands regulate body temperature by bringing water via the pores to the surface of the 
skin. 
 
Sebaceous Gland: 
 
Sebaceous or oil glands, are attached to hair follicles and can be found 
everywhere on the body except for the palms of the hands and the soles of the feet. 
These glands secrete oil thathelps keep the skin smooth, suppleand protects against an 
overgrowth of bacteria and fungi on the skin. 
 
Apocrine and Mammary Gland: 
 
Apocrine glands are similar in structure, but not identical to ecocrine glands. 
Theyare found in the axillae, anogenital region, as modified glands in the external ear 
canal, the eyelid, and the breast (mammary glands). They produce odour and do not 
functionprior to puberty. The mammary gland is considered a modified and highly 
specialized type of apocrine gland. 
 
Collagen and Elastin: 
The dermis is held together by a protein called collagen, made by fibroblasts. 
Fibroblasts are skin cells that give the skin its strength and resilience. Collagen is a 
tough, insoluble protein found throughout the body in the connective tissues that hold 
muscles and organs in place. Elastin a similar protein, is the substance that allows the 
skin to spring back into place when stretched and keeps the skin flexible. 
The dermis layer is made up of two sub layers. 
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Papillary layer: 
The upper papillary layer contains a thin arrangement of collagen fibers. The 
papillary layer supplies nutrients to the layers of the epidermis and regulates 
temperature. 
 
Reticular layer: 
The lower reticular layer is thicker and made of thick collagen fibers. It 
strengthens the skin, providing structure and elasticity. It also supports other components 
of the skin, such as hair follicles, sweat glands and sebaceousglands. 
 
Subcutis: 
The subcutis is the innermost layer of the skin, and consists of a network of fat 
and collagen cells. The functions of this layer is insulator, conserving the body's heat, 
and as a shock-absorber, protecting the inner organs. It also stores fat as an energy 
reserve for thebody. 
 
Hair: 
Hair is found on almost every part of the body except on the palms, soles. The 
dorsal surface of the terminal phalanges, inner surface of the labia, inner surface of the 
prepuse and glans penis. Hairs differ in length, thickness and colour in the differernt 
parts of the body. 
There are three types of hair: 
1. Long, medullated and pigmented hair seen on the scalp. 
2. Short, fine, non medullated and pigmented „lanugo‟ hair is seen in women,  
             children and on the faces and trunks of the adults. 
3. Thick bristles seen in the nose and theears. 
 
Cutaneous blood supply: 
Cutaneous vessels ultimately arise from underlying named source vessels. The 
cutaneous vessels originate either directly from the source arteries or as terminal 
branches of muscular vessels. Cutaneous vessels ultimately anastomose with other 
cutaneous vessels to form a continuous vascular network within the skin. 
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Lymphatics: 
Skin lymphatics parallel the blood supply and function to conserve plasma 
proteins and scavenge foreign material, antigenic substances, and bacteria. These 
unvalved superficial dermal vessels drain into valved deep dermal and subdermal 
plexuses, then coalesce to form larger lymphatic channels which ends in internal jugular 
vein junctionbilaterally. 
 
Functions: 
1. ProductiveFunction: 
In human beings, the tough, Horney, and keratinized waterproof epidermis, and 
appendages like hair and nails, provide a sufficently strong barrier against injury, 
epidermal penetration of harmful substances and bacterial invasions. The skin is to 
protect against sunlight by synthesis by synthesis of melanin pigment. 
 
2. Secretory Function: 
Skin secreats sweat through sweat glands and sebum through sebaceous glands. 
By secreting aweat, skin regulates body temperature and water balance. Sebum keeps the 
skin smooth andmoist. 
 
3. Sense Organ: 
The skin is richly supplied with nerves and various types of specialized sensory 
organs, which provide information regarding environmental changes. 
 
4. Storage Function ofskin: 
Fat is laid down in fact cells as a permanent store of subcutaneous adipose tissue 
this provides the reserve stores of body energy. 
 
5. Thermoregulation: 
Eccrine (sweat) glands and dilated blood vessels (increased superficial 
perfurtion) aid heat loss, while constricted vessels greatly reduce cutaneous blood flow 
and conserve heat. 
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6. Vitaminsynthesis: 
In exposure to sunlight skin synthesis 7dehydro cholesterol, the precursor of  
vit D. 
 
7. Production from UVrays: 
Skin protects the body aganits the damaging effects of UV rays of sunlight.  
Melanin pigment in the skin helps in the production. 
 
8. Immunity: 
Sebum secreated from sebaceous glands is acidic and contains microbial agent‟s 
clasmatocytes in the skin the cells of mononuclear phagocyte system that trap and kill 
the organism. Skin is the natural dressing of the body. 
 
9. Contributes to central bloodvolume: 
Cutaneous vascular bed accommodates a good quantity of blood volume. Hence 
Constrictions of blood vessels in the skin contribute to central blood reservoir, from 
where blood can be diverted to vital organs at the time need. 
 
Embriology: 
The whole of the skin-epidermis and dermis-is a unified integrated organ system, 
but it develops from two different primitive embryonic layers epidermis from the 
ectoderm and dermis from the mesoderm. 
The general ectoderm of the early human embryo, except for the part that 
specializes as the neural ectoderm, consists of a single layer of cuboidal cells. By the 
fifth week of intra-uterine life, this becomes double layered. During the third month of 
foetal life, three layers of cells recognizable, the periderm, the intermediate and the basal 
layer which is close to the derma. The basal cells multiply rapidly and keep pushing the 
older cells towards the periderm, and thus, by the fifth month a stratum of these cells 
(prickle cells) superficial to the basal cells, forms a definite stratum malpighii. 
The cells in the zone overlying the stratum malpighii show keratohyalin granules 
and form the stratum granulosum. As the cells keep moving outwards owing to new cells 
being added from the basal layer, the most superficial ones culminate in cornification 
forming the stratum corneum near the surface. Next to the stratum corneum, a thin, clear 
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zone containing homogeneous semi-fluid eleidin is evident, particularly on the palms 
and soles, giving rise to the stratum lucidum. The early intermediate layer of cells 
becomes a part of the stratum germinativum, and the periderm by the end of the fourth 
month of foetal life is cast off as a part of the vernix caseosa. 
The embryonic stratum germinativum, besides giving rise to the surface 
epidermis, forms the primary epithelial germ which later develops, by downward 
prolongations into the mesoderm, into the hair, sebaceous glands and apocrine glands 
and also forms the eccrine sweat glands. Soon after birth, the cells of the stratum 
germinativum acquire pigment granules from the melanoblasts which migrate from the 
primitive neural crest and specialize in melanin pigmentformation. 
The dermis is mostly derived from the mesenchyme. Untill the end of the second 
month of intra-uterine life, the dermis consists of closely packed, spindle-shaped 
mesenchymal cells, and by the third month of intra uterine life, fine reticulam fibres are 
demonstrable, which later increase in number and thickness and form the collagenous 
fibres (Maximow and Bloom). The subcutaneous fat is apparent by the end of the third 
month of the intra-uterine life, but it becomes abundant only during the later months of 
foetal life. 
The nail starts as an epidermal specialization on the dorsum of the tips of the 
digits by the third month of foetallife. 
The earliest hair appears on the eyebrows, upper lip and chin at the end of the 
second month of intra-uterine life. By the fourth month, hair appears over the general 
body surface. This hair is fine, silky, downy, tremed lanugo hair and is cast off before 
birth as a component of the vermixcaseosa. 
Most of the sebaceous glands in the body develop in connection with hair 
follicles during the fifth month of foetal life, as solid epidermal buds, which later 
become lobulated. In certain regions like the upper eyelids, hairless deeper portion of the 
vestibule of the nose, prepuce, vulva and the anal region. These glands arise from the 
general epidermis, independent of the hair follicles. 
Most of the eccrine sweat glands develop independently as solid down-growths 
from the epidermis. They first appear on the finger, lips, palms and the soles during the 
fourth month of intra-uterine life. By the sixth month of fetal life, they become simple 
cords, which later coil and acquire lumina. 
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Atopic Dermatitis 
The signs and symptoms of Bala karappan are closely related to signs and 
symptoms of Atopic Dermatitis (AD). Hence I correlated the Bala Karappan with  
Atopic Dermatitis occurring inchildren. 
Defenition: 
Dermatitis literally means inflammation of the skin. When simple dermatitis' 
boils over" with added oedema, exuadation and crusting, the condition is acute eczema 
and when dermatitis gets associated with hyperstasia and hyperkeralosis, the condition is 
chronic eczema. Such changes occur predominantly in the epidermis. Primary lesions 
inculdes macules, papules, vesicles, edematous patches or plaques. Secondary lesions 
with oozing, crusting, scaling fissuring and lichenification follow frequently. 
Dermatology use dermatitis and eczemainterchangeabily. 
History: 
The term "Atopic dermatitis" was coined in 1933 by Wise and Sulzberger 
Etiology: 
The causes of eczema are unknown but usually atopic dermatitis is associated 
with some trigger factors. Effective eczema management requires a combination of 
prevention and treatment. In addition to preventing eczema flare-ups by minimizing any 
known triggers, treatment is also an important part of eczema management. Basically, 
two factors cause dermatitis andeczema. 
 Allergic or sensitive skin. 
 Exposure to anirritant. 
 
Predisposing factors: 
 Genetic factors 
 Environment factors 
 Allergens 
 Age. 
Genetic factors: Allergic disorder, asthma, hay fever. 
Environment factors: Skin irritants (soap or detergent, cosmetics dust, chemical  
                        solvents), Climate. 
Allergens: Plant pollen, household dust, mites, molds animal dander, and certain foods. 
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Age: The risk is greatest for infants and children. 65% of patients develop first year of 
life, 90% develop symptoms before age 5. Improves in adulthood 50% of those affected 
in childhood are affected through out life. 
Genetic & familial predisposition: There is usually a personal or family history of 
allergy, like asthma, eczema and hay fever. 
General debility: Lowering of resistance of the individual in general debility 
predisposes to eczema. 
Climate: Climate extremes like heat and severe cold. 
 
Immunology: 
Immunology deals with the body‟s response to antigenic challenge. Sensitization 
develops when a different clone of T-lymphocytes is activated. The sensitized 
Tlymphocytes yield two sub populations of lymphocytes. Memory cells those are 
responsible for the persistence of contact allergy. Effector cells that initiate the allergic 
response when appropriately challenged. 
 
Pathophysiology: 
Allergy & hypersensitivity 
The body behaves in a particular way when it is exposed to a chemical substance 
known as, „Allergen‟ for the first time, but changes the nature of its reaction when it is 
exposed for the second and subsequent times. This change is due to proteins known as 
antibodies. The moment, the allergen IgE combination stimulates the mast cells which 
unload their chemical contents into the surrounding tissues. These chemical mediators of 
allergy cause the manifestations of allergy such as erythema, wheal and flare reaction. 
Flare is due to dilatation of arterioles by local axon reflex and the liberation of 
vasodilator substances like histamine and its by products like serotonin, bradykinin, 
acetylcholine from the injured cells like mast cells and basophils etc. The manifestation 
of hypersensitivity may be immediate (or) delayed type. 
 
Cutaneous Allergy 
In the skin two important but different allergic reactions occur. 
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Dermal reaction 
 Dermal reaction is commonly seen in urticaria. Allergic reaction takes place in 
the dermis. Intra dermal tests (scratch) show reactivity. 
 The causative antigen reaches the skin through ingestion, inhalation or injection 
of protein substances and the reacting antibodies circulate in the serum. 
 Epidermal reaction 
 It is seen in allergic dermatitis or eczema. 
 The causative substance reaches the skin by contact. Intra dermal allergic tests 
are negative, but patch test shows reactivity 
 Allergen + Epidermal protein – Antigen formation (probably in lymph glands) 
 Allergen + Antibodies – Eczematous reaction (In epidermis) 
 A severe local reaction may result in auto-intoxication & dissemination of 
eczematous reaction to distant parts. 
Status Eczematicus 
It is believed that in case of severe allergic states, a state may develop when the 
patient becomes hypersensitive to even unrelated substances resulting in status 
eczematicus comparable to status asthmaticus in practice of internal medicine. 
Reaction time 
It is the time taken by a sensitized individual to manifest a clinical reaction 
following contact with a known sensitizer. It is usually 12-24 hours but may vary from 
one hour to 120 hours. 
Dissemination reaction 
It is a fleeting erythematous macular reaction involving the face and flexures, 
caused by the escape of lymphokines in the circulation resulting in vasodilatation at 
distant site. 
Clinicalfeatures: 
Atopic dermatitis is characterized by superficial inflammatory oedema of the 
epidermis associated with vesicle formation. Itching varies from mild to severe 
paroxysms which may even interfere with work and sleep. It can differ in severity, 
frequency and duration amongindividuals. 
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Skin areas affected by atopic dermatitis can exhibit a variety of characteristics 
including: 
 Erythema 
 Darkening of the area of skin affected by eczema (hyperpigmentation) 
 Dryness 
 Papules 
 Scaling 
 Vesiles 
 Oozing 
 Thickening of the affected (Lichenification) skin due to requents 
cratching. 
 
Clinical Evaluvation: 
Atopic dermatitis passes in three different phases: 
1. Infantile eczema (Age: 2 months to 2 years). Affects the cheeks and may 
extend to the forehead. The lesions are an erythematous, edematous patch covered with 
vesicles. Eventually, it becomes exudative and crusted. Itching may interface sleep. 
There is nolichenifiction. 
2. Childhood phase (Besnier's prurigo- age: 5 to 12 years). The flexure 
surface of the limbs and neck are affected. The lesions consist of itchy papules and 
lichenifiedplaques. 
3. Adulthood phases (dissemination neurodermatitis in adults). The 
flexures are the most commonly involved sites; the front and side of the neck, and the 
eyelids may also be affected. Pruritus is severe. The lesions consist of chronic lichenified 
papules becoming confluent to form poorly defined reddish - brown plaques. There is no 
oozing (chronic). 
 
Atopic dermatitis in children 
Introduction 
 Most common chronic paediatric skin disorder, affecting 15% of children. 
 Cause unknown but seems to be result of a complex inflammatory process. 
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 Generally begins during infancy or childhood; Signs and symptoms AD is 
characterized by pruritus with resultant scratching that leads to excoriations and 
lichenification. 
 The appearance of lesions varies with the patiant‟s  age and background, 
 Infants and toddlers; involvement of the face, trunk and extensor 
extremities 
 Childhood; Lesions are concentrated in flexural areas, such as the 
anticubital and popliteal fossae; wrists and ankles. 
Children who have atopic dermatitis are susceptible to certain bacterial and viral 
infections. Increased adherence of Staphylococcus aureus to the skin and reduced 
production of anti- microbial peptides may explain the high rates of colonisation with 
and infection due to this bacterium. Altered T-cell function may expain the 
predisposition of children to develop Molluscum contagiosum, Eczema herpeticum and 
Eczema vaccinatum. 
 
Prognosis: 
The prognosis for children with atopic dermatitis is good; 80% to 90% of infants 
experience a spontaneous resolution or improvement in symptoms by adolescence. 
 
Other Common types of Dermatitis: 
1. Contact Dermatitis 
Contact dermatitis is localized to the site of extrinsic stimulation by foreign 
substance or allergic reaction. Eczema reactions such as reddening and blistering occur 
at the contact site. There are specific types of contact dermatitis, such as diaper 
dermatitis and housewive‟s hand eczema. The causative substances include certain 
plants, chemical agents, and nickel, mercury and other metals. 
 
Clinical features 
Erythema, serous papules, vesicles, erosions and crusts are localized at the 
contact site of the causative agent. The eczematous lesions are relatively sharply 
circumscribed and are intensely itchy. Although only localized areas are affected, 
erosive lesions may become widespread when the causative agent is spread by rubbing 
and scratching.  
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If the inflammation spreads over the entire body, systemic symptoms such as 
fever  may arise. When the causative agent is highly stimulative, it may cause necrosis of 
the skin and ulceration. 
 
Pathogenesis 
Allergic contact dermatitis basically occurs as a type IV allergic reaction. The 
causative agent invades the body percutaneously and is captured by Langerhans cells. It 
moves to the regional lymph nodes and transmits information about the antigen to 
thymus derived T cells, and they proliferate in the lymph nodes. If the causative agent 
reinvades the body after sensitization, the sensitized T cells become activated to release 
various cytokines, which leads to a prompt inflammatory reaction that causes dermatitis. 
This reaction is not produced by the first contact, but it is produced in previously 
sensitized persons even by contact with a minute amount of the antigen. 
 
2. Seborrheic Dermatitis 
Seborrheic dermatitis occurs on sites of skin where sebum is actively secreted. It 
is characterized by erythematous lesions accompanied by yellowish scales. This is one of 
the most common skin diseases, occurring in infants, adolescents and adults. 
Pityrosporum fungus resident in the skin is a factor in the occurrence. 
 
Clinical features 
Dermatitis appears as follicular eczema on seborrheic sites or intertriginous areas 
in the head, face, axillary fossa, neck and external genitals. The main features of the 
lesions are oleaginous scales and erythematous plaques that may be slightly itchy. In 
infants, yellowish crusts begin to form on the scalp, eyebrows and forehead. In infants, 
scaly erythematous plaques may also form 2 to 4 weeks after birth. In most cases they 
resolve 8 to 12 months after birth. In adolescents and adults, pityroid scales increase and 
scaly erythematous lesions form on the eyebrows and nasolabial groove. Seborrheic 
dermatitis is chronic and recurrent. 
 
Pathogenesis 
Triglycerides in sebum are decomposed by microbes resident in the skin to 
produce free acid. The free acid reacts to cause seborrheic dermatitis. 
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3. Nummulareczema 
Round, relatively large eczematous plaques are produced. Nummular eczema 
may occur at any site on the body, and it tends to progress to auto sensitization 
dermatitis. 
 
Clinical features 
Nummular eczema is frequently seen in the winter. Multiple round eczematous 
lesions occur, mostly on the extremities (particularly on the extensor surface of the lower 
extremities), trunk, hips and buttocks. At the periphery of the lesions, serous papules 
aggregate, in the center of which exudative erythema is produced with scales on the 
surface. Most cases are accompanied by intense itching and multiple scars from rubbing 
and scratching. As the lesions progress, they may produce dispersal eruption to progress 
into autosensitization dermatitis. 
 
Pathogenesis 
Scratched insect bites may develop urticarial lichens that, when rubbed, progress 
to nummular eczema, or nummular eczema may result from asteatotic eczema in the 
elderly, or it may appear as a symptom of atopic dermatitis. 
 
4. AutosensitizationDermatitis 
Multiple small papules and erythematous lesions accompanied by itching occur 
systemically. They are caused by sudden aggravation of a localized lesion. This 
dermatitis is caused by endogenous allergic reaction. 
 
 Clinical features 
Reddening, swelling and acute aggravation of exudation occur in the lower 
extremities as primary lesions of autosensitization dermatitis (in 50% to 60% of cases). 
Two weeks to several weeks after acute aggravation of reddening, swelling and 
exudation, dispersed eruptions appear. In most cases, the eruptions are erythema, 
papules, serous papules, or pustules of 2 to 5 mm in diameter dispersed symmetrically 
on the extremities, trunk, and face. These are often accompanied by intense itching. 
Systemic symptoms such as fever and fatigue may occur. 
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Pathogenesis 
Autosensitization dermatitis arises from endogenous allergic reaction. Decayed 
proteins, bacteria, fungal components, and toxins produced by injured tissues in a 
primary lesion are considered to be the antigens. These may spread through the entire 
body such in blood flow from the primary lesion, or they may spread by rubbing or by 
an accidental dose of the causative substance (orally or intravenously). Autosensitization 
dermatitis is caused by sensitization against the antigens. The primary lesions can be 
nummular eczema, stasis dermatitis, contact der-matitis, atopic dermatitis, tinea pedis, or 
eczematization of aburn. 
 
5. Stasis Dermatitis 
Edematous erythema or eczematous plaques form on the lower thighs as a result 
of varicose veins or congestion in the lower extremities. This disease tends to affect 
those who work standing, the elderly and obese women. It may progress to 
autosensitization dermatitis. 
 
Clinical features 
Edematous erythema occurs on the lower third of the leg, particularly at the 
upper ankles. The site gradually presents a dark red, scaly, eczematous plaque, 
pigmentation or whitish atrophie Blanche. Minor trauma may induce ulceration. 
Treatments for stasis dermatitis may induce allergic contact dermatitis as a complication, 
from the application of an antiseptic or a topical agent. Aggregated serous papules often 
progress to autosensitization dermatitis. 
 
Pathogenesis 
Congestion in the cutaneous blood vessels is caused by impairment of venous 
out flow, which leads to bleeding from the capillary vessel loop in the dermal upper 
layer. Hemosiderins deposit in tissues, and the skin takes on a blackish-brown 
appearance. The keratinocytes are injured by further impairment of blood flow. Atrophy 
and scaling occur in the epidermis and there is tendency of ulceration. The skin looses its 
function as a barrier and becomes more reactive to extrinsic irritation, leading to 
eczematous lesions in many cases. 
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Investigations for eczema 
Patch test 
Patch tests detect type IV (delayed or cell-mediated) hypersensitivity. It is 
common practice for a battery of around 20 common antigens, including common 
sensitizers such as nickel, rubber and fragrance mix to be applied to the skin of the back 
under aluminium discs for 48 hours. The sites are then examined for a positive reaction 
24 hours later and possibly again a further 24 hours later. The positive test is revealed by 
the development of an eczematous patch with erythema swelling and vesicles at the site 
of application. Patch test reaction is graded in the followingdegrees, 
+ - Only redness 
++ - Marked redness and swelling 
+++ - Marked redness, swelling and papules 
++++ - redness, oedema and vesicles 
Specific IgE levels to antigens can be measured in serum by a specific radio 
allergic sorbent test (RAST). These are occasionally performed to support diagnosis of 
atopic eczema and to determine specific environmental allergens, eg. Pet dander, horse 
hair, house dust mite, pollens and foods.  
 
Prick tests 
Prick tests are a way of detecting cutaneous type I (immediate) hypersensitivity 
to various antigens such as pollen, house dust, mite or dander. 
 
Assessment tools 
There are two assessment tools used in Morden aspect. These are EASI score 
An EASI score is a tool used to measure the severity and extent of atopic eczema 
(Eczema Area and Severity Index). 
There are four body regions: 
1. Head and neck 
2. Upper limbs 
3. Trunk 
4. Lower limbs 
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Intensity: The intensity of redness, thickness, scratching, lichenification of the 
eczema is assessed as none (0), mild (1), moderate (2) and severe (3). Half scores are 
allowed. The four intensity scores are added up for each of the four body regions to give 
subtotals A1, A2, A3, A4.  
Area: The percentage area affected by eczema is evaluated in the four regions of 
the body. In each region, the area is expressed as nil (0), 1-9% (1), 10-29% (2), 30-49% 
(3), 50-69% (4), 70-89% (5) or 90-100% (6). 
Caculation for area: Each of the body area scores is multiplied by the area 
affected (C1, C2, C3, C4) 
Total score: The EASI score is C1 + C2 + C3 + C4. 
The SCORAD index 
A = spread.../100  
B = intensity.../18 
C = subjective symptoms.../20  
SCORAD calculation: A/5 +7 B/2 + C 
1. Extentcriteria 
 Headand Neck  9% 
 Upper limb each  9% 
 Lower limb each 18% 
 Anterior Trunk 18% 
 Back   18% 
 Genitalia  1% 
2. Intensity criteria 
 Erythema : stage 1 / stage 2 / stage3 
 Edema / papulation : stage 1 / stage 2 / stage3 
 Oozing / crusting : stage 1 / stage 2 / stage3 
 Excoriation : stage 1 / stage 2 / stage3 
 Lichenification : stage 1 / stage 2 / stage3 
3. Subjective symptoms 
The two most representative items concerning the quality of life of patients are: 
 Pruritus 
 Insomnia 
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SCORAD index is a clinical tool for evaluating the severity of atopic dermatitis 
in order to provide better management of patient. So I have chosen SCORAD index 
method for the assessment of Atopic Dermatitis. 
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3. C. DRUG REVIEW 
 
Ingredients of Karappan Nei (Internal and Enternal Medicine) 
 
 Nilavembu   (Andrographis Paniculata) 
 Chensanthanam  (Pterocarpus Santalinus) 
 Kadukkai   (Terminalia chebula) 
 Muththakaasu  (Cuperus Rotundus) 
 Thippili   (Piper longum) 
 Devadharus   (Cedrus Deodara) 
 Kariveppilai   (Murreya Koenigii) 
 Thetran vithai   (Strychnos Potatorum) 
 Manjal   (Curcuma langa) 
 Pasumpaal   (Cow‟s Milk) 
 Pasu Nei   (Cow‟s Ghee) 
 
1. epyNtk;G –Andrographis Paniculata 
Scientific classification: 
  Kingdom         : Plantae 
  Division          : Tracheophyta 
  Order              : Lamiales 
  Family            : Acanthaceal 
  Genus  : Andrographis 
  Species : Paniculata 
 
NtWngah;;;;: 
 rpul;Fr;rp> fhz;lfk;> fpuhjk;> fphpahj;J> fpuhfjp> ehl;L epyNtk;G> 
mdhhpajpj;jk;> fhz;lk;> Nfhfzk; 
 
Organoleptic Characters 
Taste  : Kaippu  
Potency    :  Veppam  (Heat) 
Division :  Kaarpu    (Pungent) 
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Action 
Stomachine 
Tonic 
Alterative 
Stimulant 
 
nghJFzk; 
  thjRuk; ePNuw;wk; khw;WQ; RuNjhNl 
  fhjnkd Xlf; foAq;fhz; - khjuNr! 
  gpj;j kaf;fWf;Fk; gpd;Gnjsp itf;nfhLf;Fk; 
  Rj;jepy Ntk;gpd; njhopy;. 
 
Chemical constituents: 
 14 – deoxyandrographolide, 14 – deaxy – 12 – hydroxyan – drographolide, 
Andrographolide, β – sitosterol, slimasterd, chlorophyll a, 5,2‟ – dihydorxy – 7, 8 – 
dimethroxyflavone, β – sitosteryl fatty acid esters, lupeol, triacylglycerols 
 
Medicinal uses: 
  The whole plant has been used for several intermittent fevers, inflammation, 
pyrexia and External applications such as Anti-dote for snake-bite, poisonous stings for 
some insects. 
   The leaf extract is a remedy for the treatment of infectious disease, colicpain, 
loss of appetite irregular stools and diarshea. 
   Decoction of the aerial parts is used to treat hypertension, diabetes, cancer, 
malaria. 
2. nrQ;re;jdk; –Pterocarpus santatlinus 
Scientific classification 
  Kingdom : Plantae 
  Division : Tracheophyta 
  Order  : Fabales 
  Family  : Fabaceal 
  Genus  : Pterocarpus 
  Species : Santalinus 
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NtWngah; 
nrQ;re;jdk;> rptg;Gr;re;jdk; 
 
Organoleptic Characters 
Taste  :  Kaippu, Siru thuvarappu  
Potency    :  Thatppam (Cooling), Veppam (Heat) 
Division :  Inippu, Kaarppu 
Action 
Alternative; 
Diuretic 
Diaphoretic 
Stimulant 
Disinfectant 
Astringent 
                       Cooling 
nghJFzk;: 
  Nfhjpy; re;jdQ; rPNjh\;zq; nfhz;bUf;Fk; 
  thjgpj;jk; Iak; kdg;gpuzk; - XJRuk; 
  Nkfk; jdpj;jhfk; ntg;G nrhwp Ak;Nghf;Fk; 
  Mfe; jdf;FWjp ahk;. 
 
Chemical constituents: 
 Santalin A, Santalin B, Pterocarpol, Pterocarpin, eudesmal (α, β and γ-isomers), 
Pterocarpin. 
 
Medicinal uses 
 The wood used in the form of a powder (or) chips is anti inflammatory, astringent 
and tonic. 
 A paste of the wood is brewed as a tea in the treatment of chronic dysentery. 
 The wood paste is applied externally as a cooling application to boils, 
inflammatory disease of the skin, swollen limbs, ophthalmia, sore eyes and headache. 
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3.  கடுக்காய்– Terminaliachebula 
Scientific Classification 
Kingdom   :  Plantae 
Division  : Angiosperm 
Order  : Myrtales  
Family  :  Combretacea 
Genus  :  Terminalia  
Species  : Chebula 
NtWngah; 
 mf;Nfhlk;> mq;fzk;> me;jd;> mguzk;> migad;> mkhpjk;> mkiy> 
mKjk;> mk;ik> mk;Ujh> mugp> mhpjfp> miad;> mt;tpajh> ,Nurfp> uktjp> 
Iatp> i`ktjp> fL> fha]{j;jh> rpapUjk;> rpua`p> rpNuhl;lk;> rpth> Nrjfp> 
Nrjepfh> Nrah> jpt;ah> Njtp> ee;jphp> ner;rp> gpj;jpak;> ghhpak;> gp\f;thu> Gjdh> 
Gjd;> g;ugj;ah> g;uhzjh Nkfk;> [Pt;ah> n[ah> thpf;fha;> tdJh;f;fp> Nuhfpzp. 
 
Organoleptic Character 
Taste  : Kaippu 
Potency : Veppam (Heat) 
Division : Kaarpu   (Pungent) 
Action 
Stomach Carminative Expectorant Anthelmintic Anti dysentery 
 
nghJFzk; 
  jhil fKj;jf;fp jhY Fwpaptplg; 
  g{il rpypgjKw; NgjpKlk; - Milnal;lhj; 
  J}ykpb Gz;thj Nrhzpfh khiyapuz; 
  Lhykpb Nghk;thpf;fh ahy;. 
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Chemical Constituents: 
Chebulin from flowers. Palmitic, stearic, oleic, linoleic, arachidic and behenic 
acids from fruit kernels. Fruits contain about 30% of an astringent substance; 
astringency is due to the charectersitic principle chebulnic acid. Also contain tannic 
acid 20-40%, gallic acid, resin etc. and a purgative glycoside of anthraquinone 
derivative. Chebulin exhibited anti spanmodic action on smooth muscle similar to 
papaverine. 
 
Medicinal Uses: 
The fruits are astringent, sweet, acrid, bitter, sour, thermogenic, anodyne, 
anthelmintic, anti-inflammatory, vulnerary, alterant, stomachic, laxative, purgative, 
carminative, digestive, cardiotonic, aphrodisiac, antiseptic, diuretic, febrifuge, 
depurative and tonic. They are useful in vitiated conditions of tridosa, wounds ulcers, 
inflammations, gastropathy, anorexia, helminthiasis, flatulence, haemorrhoids, 
jaundice, hepatopathy, splenopathy, pharyngodynia, hiccough, cough, urophathy, 
versical and renal calculi, cephalalgia, epilepsy, ophthalmopathy, skin diseases, 
leprosy, intermittent fever, cardiac disorders, stomatitis, neuropathy and general 
debility. 
 
4. Kj;jf;fhR –  Cyperus Rotundus 
Scientific classification 
  Kingdom - Plantae 
  Division - Angiosperms 
  Order  - Poales 
  Family  - Cyoeraceal 
  Genus  - Cyperus 
  Species - Rotundus 
NtWngah; 
 Nfhiu 
 
Organoleptic Characters 
Taste  :  Kaippu  
Potency    :  Thatppam (Cooling) 
Division :  Kaarpu (Pungent) 
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Action 
Astringent 
Stimulant 
Tonic 
Diuretic 
Diaphoretic 
Demulunt 
Emmenagogue 
Vermifuge 
 
nghJFzk; 
  rPj Rue;jPh;f;FQ; nrk;Gdy;gpj; jk;NghFk; 
  thj Rue;jzpf;Fk; itafj;jpy; - Ntijnra;a 
  te;j gpzpianay;yhk; thl;LKj; jf;fhR 
  nfhe;JyTk; thh;FoNy! $W 
  mjprhuk; gpj;jk; mdw;whfk; Iaq; 
  FjpthjQ; Nrhgq; nfhba – Kjph;the;jp 
  Ahiuj; njhlh;e;jhYk; mt;tth;f;nf yhq;Fsj;Jf; 
  Nfhiuf; fpoq;iff; nfhL. 
 
Chemical Constituants 
 Cyperene , Cyoerenone, Alpha–Cyperone, Alpha–rotunol, Beta-cyperone, Bela-
pinene, Beta-rotunol, Beta-selinene, Calcium, Camphene, Copaene, Isocyperol, 
Kobusone, Isokobusone, D-gluoose, flavonoids, Linolenic-acid, Magnesium, 
Manganese, Sitosterol, Stearic-acid, Sugeonol, Oleanolic-acid-3-0-neohesperidoside, 
Myristic-acid 
 
Medicinal uses 
 Astringent, diaphoretic, diuretic, analgesic, Antihacterial, Carminative, 
antitussive, aromatic, litholytic, stimulant, stomachic, vermifuge, tonic, sedative. 
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5. jpg;gpyp –  Piper longum 
Scientific classification 
  Kingdom - Plantae 
  Division - Magnoliophyta 
  Order  - Piperales 
  Family  - Piperaceal 
  Genus  - Piper 
  Species - Longum 
 
NtWngah; 
 Mh;fjp> cz;ruk;> cyitehrp> fhkd;> Flhhp>Nfhyfk;> Nfhyp> 
NfhioaWf;fp> ruk;> rhb> Jstp> khfjp> fid> nrsz;b> jz;Lyp> fzk;> fypdp> 
ghzk;> gpg;gpyp> itNjfp> mk;G> MjpkUe;J. 
Organoleptic Characters 
Taste  :  Kaaruppu (Pungent)  
Potency    :  Thatppam (Cooling) 
Pirivu  :  Inippu (Sweet) 
Action 
Stimulant 
Carminative 
nghJFzk; 
  <is apUk ypiug;Gg; grg;gpzpfs; 
  khs nthopahky; thl;LNk – ahSKiw 
  ghq;fh awpe;Jnra;t{h; gz;ojj;ijg; gz;bjNu 
  Ntq;iftha;g; ghd;fiz nka;. 
 
Chemical Constituents 
 Alkaloids, Piperine, Pipelongumine, Piperlonguminine, n-hexadecane, n-heptade-
cane, n-octadecane, α-thiyene, terpinolene, zingiberene, p-cymene, didhydrocarveol, 
dihydrostigmastend, glycosider, Bracheyamide A, Brachyamide B, Brachystine. 
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Medicinal uses 
 Powdered long pepper administered with honey will relieve cough, cold, asthma, 
hoarsenless and hiccup. 
 Anti asthamatic, immune suppressant, piles, malcuial fever, romiting, sinusitis. 
6. NjtjhU –  Cedrus deodara 
Scientific classification 
  Kingdom - Plantae 
  Division - Pinophyta 
  Order  - Pinales 
  Family  - Pinaceal 
  Genus  - Cedrus 
  Species - Deodara 
 
NtWngah; 
 Njtjhuk;> J}z;> ,UjhU> jhU> jhuk;> Njtj Ruh;kuk;> gj;jpujhUfk; 
 
Organoleptic Characters 
Taste  : Siru kaippu  
Potency    :  Veppam (heat) 
Pirivu  :  Karuppu 
Action 
Carminative 
nghJFzk; 
  Njtjh uf;Fze;jhd; Nrh;e;Jtsh; gpdprj;ijf; 
  fhtfj;jp Nyhl;Lq; fug;gyNt – khtyth; 
  nrhyYk;G uhz RunkhLe; Nuw;wj;ij 
  nty;Y kdw;wzpf;F nka 
 
Chemical Constituents 
 Texifolin, Cedeodarin, ampelopsin, cedrin, cedrinoside, deodarin, himachalol, 
allohimachalol, himadarol, centdarol, dewardiol, isocentdarol, dihydromyricetin. 
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Medicinal uses 
 The leaves are bitter, acrid and thernigebic, and are useful in inflammation and 
tubercular glands. 
 The heartwood is bitter, acrid thermogenic, emollient, enodyne, anthelmintic, 
digestive, Carminative, Cardiotonic, galacto-purifier, anti-inflammatory, diuretic, 
antiseptic, laxative and it useful in inflammations skin diseases, insomnia, epilepsy, 
hiccough. 
 
7. fwpNtg;gpiy –  Murraya Koenigii 
Scientific classification 
  Kingdom - Plantae 
  Division - Magnoliapsida 
  Order  - Sapindales 
  Family  - Rutaceal 
  Genus  - Murraya 
  Species - Koenigii 
 
NtWngah; 
  fwpNtg;gpiy> fUNtg;gpiy> fwpagpiy 
 
Organoleptic Characters 
Taste  : Siru kaippu  
Potency    :  Veppam (heat) 
Pirivu  :  Karuppu  (Pungent) 
Action 
Tonic 
Stomachic 
 
nghJFzk; 
  thapdUrp tapw;Wisr;r dPLRuk; 
  ghAfpd;w gpj;jKykd; gz;Zq;fhd; - J}a 
  kUNtW fhe;jsq;if khNj! Cyfpw; 
  fUNtg; gpiyaUe;jpf; fhz; 
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Chemical Constituents 
 α-pinene, Sabinene, β-pinene, β-cary ophyllene, limonene, bornyl acetate, 
terpinen-4-01, γ-terpinene, α-humulene. 
 
Medicinal uses 
 Fresh leaves, dried leaf powder and essential oil are widely used for flavouring 
soups, curries, fish and meat dishes, eggs dishes, traditional curry powder blends, 
seasoning and ready to use other fool preparations. 
 Whole (or) inparts as antiemetics, antidiarrheal, antifangal, depressant, anti-
inflammatory, body aches for kidney  pain and vomiting. 
 
8. Njw;whd; tpij –  Strychnos Potatorum 
Scientific classification 
  Kingdom - Plantae 
  Division - Angiosperms 
  Order  - Gentianales 
  Family  - Loganiaceac 
  Genus  - Strychnos 
  Species - Potatorum 
NtWngah; 
  ,y;yk;> fjfk;> rpy;yk;> NjW 
 
Organoleptic Characters 
Taste  : Kaippu  
Potency    :  Veppam (heat) 
Division :  Karuppu  (Pungent) 
Action 
Alterative 
Tonic 
Stomachic 
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nghJFzk; 
  ,y;yk; kyf kpuz;L kapd;whNdh 
  apy;yh kyf kpUf;FNk - ,y;yhky; 
  thiof; fdpAk; tilA kpKJKz;ghd; 
  thiof; fdpAdlitj; jtd; 
 
Chemical constituents 
 Diaboline, Saponin glycoside having oleanolic acid and as aglycone and D-
galactose and D-mannose as sugar moieties, chlorogenic acid, oleanolic acid, 3 β-
autaxyoleanolic acid, β-Sitosterol, lupenediol, arachidic, lignoceric, palmitic, stearic, 
linoleic and oleis acid. 
 
Medicinal uses 
 The seeds are bitter and used as an astringent, demulcent, emetic, diuretic, 
stomachic and also used to purify water and anti-inflammatory. 
 They are used in vitiated conditions of vata and kabha, hepatopathy, nephropathy, 
gonorrhea, leucorrhea, gestropathy, bronchitis, chronic diorrbea, dysentery, ulcers, other 
eye diseases, scleritis 
 
9. kQ;rs; –  Curcuma longa 
Scientific classification 
  Kingdom - Plantae 
  Division - Angiosperms 
  Order  - Zingiberales 
  Family  - Zingiberaceal 
  Genus  - Curcuma 
  Species - Longa 
 
NtWngah; 
  Mhprdk;> fhd;rdp> eprp> g{jk; 
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Organoleptic Characters 
Taste  : Karuppu  (Pungent) Kaippu (Bitter)  
Potency    :  Veppam  (heat) 
Pirivu  :  Karuppu  (Pungent) 
Action 
Carminative 
Stimulant 
Hepatoprotective 
 
nghJFzk; 
  nghd;dpwkhk; Nkdp Gyhdhw;w Kk;NghFk; 
  kd;D GUl trpakhk; - gpd;dpnaKk; 
  the;jpagpj;j Njhlikak; thjk;Nghe; jPgdkhq; 
  $h;e;jkQ;r spd;fpoq;Ff;F. 
Chemical constituents 
 The rhizome contains he pigment curcumin an essential oil of Sesquiterpenes, 
Zingiberene, D-phellandrene, turmerone, dehydroturmerone, α-alantolactone, curcumene 
and cineal. 
Medical uses 
 Aromatic, Stimulant, tonic, Carminative and  antholmintic.  The rhizome is useful 
in gastric ulcer, Anti-inflammatory, Anti fungal, anti viral and cholegogic properties. 
 It is prescribed in the therapy of gastric and duodenal ulcer and also for skin 
oilments. 
 
10. gRk; ghy; –  Cow’s Milk – LACTUS 
NtWngah; 
  gak;> fPuk;> Rij> gaR> ghF> mKJ> Jj;jk;> rhW 
nghJFzk; 
  ghyh; fpoth; goQ;Ruj;Njhu; Gz;zhsp 
  #iyah; Nkfj;Njhh; Jh;gyj;Njhh; VYkpth; 
  vy;yhh;f;F khFk; ,isj;jtu;f;FQ; rhjfkha; 
  ey;yha; gRtpd;ghy; ehl;L 
- Gjhh;j;j Fz rpe;jhkzp 
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Composition of Milk 
 Milk is a translucent white liquid produced by the mammary glands of mammals, 
a PH ranging from 6.4 to 6.8 making it slightly acidic. 
 Cow‟s Milk contains on a average 3.4% protein, 3.6% fat and 4.6% lactose 0.7% 
minerals and supplies 66 k cal of energy per 100 gms.  The largest structure in the fluid 
protein of the milk is casein protein micelles. 
 Cow‟s Milk is a rich source of vitamins including riboflavin, Vitamin E, Vitamin 
A, folate, thiamin, niacin, vitamin B6, vitamin B12. 
 
Health benefits of cow’s Milk 
Strengthens bones and teethMilk has often been recommendedas a remedy for 
everything from goul and acthritis to respiratory distress and burns on the skin 
 Weight loss 
 Growth and development 
 Boosts immunity 
 
11. gRநெய் –  Cow’s Ghee 
nghJFzk; 
  jhfKb iyRl;fk; the;jp gpj;jk; thAgpu 
  Nkfk; tapw;nwhpT tpf;ffyoy; - khfhrq; 
  Fd;kk; twl;rp Flw;Gul;l y];jpRl;fQ; 
  nrhd;%yk; Nghf;Fepiwj; Jg;G 
- Fzg;ghlk; jhJ-rpt tFg;G 
 
It has been used in the treatment of Vomiting, Pitha disease, Stomach burning, 
hic-cough, peptic ulcer, dryness of sjin and irritable bowel syndrome. 
 
Compositions of Ghee 
 Cows ghee abundant in saturated fatty acids. It contains approximately 8% 
saturated fatty acids, triglycerides, diglycerides, monoglyverides, phospholipids, beta 
carotene 600 IV and vitamin E which are known anti oxidants. 
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4. MATERIALS AND METHODS 
Ingredients of Karappan Nei (Internal And External Medicine) 
 Nilavembu  (Andrographis Paniculata) 
 Chensanthanam  (Pterocarpus Santalinus) 
 Kadukkai  (Terminalia chebula) 
 Muththakaasu  (Cyperus Rotundus) 
 Thippili  (Piper longum) 
 Devadharus   (Cedrus Deodara) 
 Kariveppilai   (Murreya Koenigii) 
 Thetranvithai  (Strychnos Potatorum) 
 Manjal   (Curcuma langa) 
 Pasumpaal  (Cow‟s Milk) 
 PasuNei  (Cow‟s Ghee)  
 
Collection of Raw drugs: 
 The drugs were purchased from authorized country raw drug store in Chennai. 
 
Identification and Authentication of the drug: 
 All the plant materials were identified and authenticated by the Botanist National 
Institute of Siddha, Tambaram sanatorium, Chennai. 
 
Rj;jpKiwfs; 
 epyNtk;G> Nfhiuf;fpoq;F – fLutpapYyh;j;jp vLj;Jf; nfhs;f. 
 kQ;rs; - Nky; Njhypidrptp Jz;Lfshf eWf;fp ,utpapYyh;j;jp itj;Jf; 
nfhs;sTk;. 
 Njw;whd; tpij–gRk;ghypy; xUehopif Cwitj;J epupy; fOtp cyh;j;Jf. 
 NjtjhU> nrQ;re;jdk; - tapughfj;ij nghd;tWtyhf tWj;J vLj;Jf; 
nfhs;sTk;. 
 fLf;fha; - Nky; Njhypid vLj;Jf; nfhz;L nfhl;lapid epf;fpnfhs;sTk;. 
 fwpNthg;gpiy–Rj;j t];jpuj;jpdhy; Jilj;J gOg;G> mOfy; 
Kjypatw;iw epf;fp vLj;Jf; nfhs;sTk;. 
 jpg;gpyp– J}rpapid epf;fp ,stWg;ghf vLj;Jf; nfhs;sTk;. 
 gRnea; - mLg;Nghw;wp mjpYs;s ePh; Rz;l> neapid fhe;jhky; fha;r;rp 
tbfl;lTk;. 
 gRghy; - fha;r;rp vLj;Jf; nfhs;sTk;. 
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Preparation Method: 
All the ingredients mentioned above will be taken 10 grams each and crushed 
well. Then added 3.9 litter milk mixes well then add 2.6 litters ghee and boiled it till the 
mixture reaches Ghee form. 
 
DOSAGE  : 5-10 ml (bd) 
 
ADJUVANT  :  Honey 
 
INDICATIONS : Karappan 
 
DURATION  : 48 days 
DRUG STROAGE : Prepared medicine will be stored in clean  
    and dry glass container 
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INGREDIENTS OF KARAPPAN NEI 
 
    NILAVEMBU    CHENSANTHANAM 
 
 
  
  
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      KADUKKAI    MUTHTHAKAASU 
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INGREDIENTS OF KARAPPAN NEI 
 
 
       THIPPILI        MANJAL 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
DEVADARU     KARIVEPPILLAI 
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INGREDIENTS OF KARAPPAN NEI 
 
 
          THETTRAN VITHAI         PARU NEI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  PASUMPAAL 
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KARAPPAN NEI 
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A.  Pre-Clinical study 
i. Acute toxicity studies 
ii. Physico chemical analysis 
iii. Phyto chemical analysis   
iv. Bio chemical analysis 
v. In vitro Anti-inflammatory activity 
 
B.  Clinical Study 
 An open clinical study was carried out in 30 children affected by Bala Karappan 
aged  between 6 – 12 year. 
 
A.  PRE CLINICAL STUDY 
A i. Acute Toxicity Study 
Toxicological Evaluation of Karappan Nei (KN) 
The following in vivo toxicity studies were carried out on Karappan Nei (KN) by 
World Health Organization (WHO) guidelines.  
  Acute Oral Toxicity study (WHO)   
The toxicity study was carried out at National Institute of Siddha. The study was 
done after getting permission from the Institutional Animal Ethical Committee with  
IAEC Approval No:  NIS/IAEC-IV/03/05012017.  
 The test animals were obtained from Tamil Nadu Veterinary and Animal 
Sciences University, Madhavaram. Animals were kept in animal house, National 
Institute of Siddha, Chennai.  
 
DESCRIPTION OF THE METHOD  
 
Selection of the animals:  
Animals were selected as per guidelines. Healthy adult animals of Wistar albino 
rat, both male and female sex were used for acute oral toxicity study. The female animals 
used in the studies were nulliparous and non-pregnant.  
Housing and feeding conditions:  
The temperature in the experimental animal room: 22ºC (± 3ºC) 
Humidity: 60 ± 10 %  
  
70 
 
Lighting: Artificial, the sequence being 12 hours light, 12 hours dark. 
The animals were housed in polypropylene cages provided with bedding of husk. 
The animals had free access to distal water. For feeding, Standard pellet diet (bought 
from Sai Meera foods pvt. Ltd, Bangalore) was used.  
Preparation of animals:                      
 The animals are randomly selected, to permit individual identification by cage 
number and individual marking on the fur of each animal was made with picric acid. The 
animals were kept in their cages for 7 days prior to dosing to allow for acclimatization to 
the laboratory conditions. The principles of laboratory animal care were followed.  
Test Substance:         
Karappan Nei (KN) is dark yellowish in colour, free flowing- greasy liquid and 
Slightly pungent. 
Route of administration:     
 Oral route was selected, because it is the normal route of clinical administration.  
 
PROCEDURE:  
ACUTE ORAL TOXICITY STUDY  
Experimental Animals: 
Species and strain    : Wistar Albino rat 
 Sex      : Male and Female  
Age, Weight     : 6-8 weeks, 150-175 gm 
 Test guideline    : WHO guideline   
Groups/treatment    : Grouped by randomization  
Duration of exposure to the Single dose : Karappan Nei (KN)  
Study duration    : 14 days 
 Number of animals    : 10 male, 10 female 
 Route of administration   : Oral 
Number of animals and dose levels  :  1.8 ml 
 
Animals are divided into two groups, each group containing 5 male and 5 female 
rats. One group as control and the other as test group. Control group is treated with saline 
and other groups were treated with test drug Karappan Nei (KN) ten times the 
therapeutic dose (1.8ml). 
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Groups No. of Rats 
 
Group I  Vehicle control (saline ) 5 male, 5 female 
Group II  Test drug –Karappan Nei  (1.8ml) 5 male, 5 female 
 
Administration of doses:  
The test drug was administered in a single dose by using oral gavage. Animals 
were fasted prior to drug administration. Following the period of fasting, the animals 
were weighed and test drug was administered. The control groups received equal volume 
saline. The test drug was administered at 10 times the therapeutic dose (1.8ml). The food 
was with held for 3-4 hours after dosing the animal.  
 
Observations:  
Observations were made and recorded systematically and continuously observed 
after the substance administration as per the guidelines.  
 ½ hour, 1 hour, 2 hours, 4 hours and up to 24 hours observation 
 All rats were observed twice daily for 14 days  
 Body weight  were Calculated weekly once   
 Feed & water intake  were Calculated daily 
 
Cage side observation   
The animals were monitored for behavioral parameters like Alertness, 
Aggressiveness, piloerection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, Muscle relaxant, Hypnosis Analgesia, 
Lacrimation, Exophthalmos, Diarrhea, Writhing,  Respiration, Mortality.  
 
Gross necropsy:  
At the end of the 14th day, all the animals were sacrificed by using the injection 
of  Pentothal sodium Gross necropsy includes examinations of the external surface of the 
body, all orifices, cranial, thoracic and abdominal cavities and their contents. Brain, eye, 
lungs, heart, spleen, liver, kidneys, adrenals, uterus of all animals were examined. 
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A.ii)  Physicochemical analysis of Karappan Nei (KN) 
 The Physiochemical analysis of the drug Karppan Nei was done at Noble 
Research Solutions Tamilnadu Chennai. Since the form of drug is like ghee the 
parameter such as Description (State, Colour, Odor), Determination of weight/ml, 
Refractive Index, Viscosity value, Iodine value, Saponification value, Acid value, 
Peroxide value, TLC/HPTLC, Heavy metal analysis, Sterility test, Test for Specific 
Pathogen, Test for Pesticides and Aflatoxin assay was done using quality control 
methods for medicinal plants materials as described in AYUSH protocol. 
 
1. Sample Description 
 
 
State Liquid 
Appearance Dark Yellowish 
Nature Greasy Viscous 
Odor Pleasant Characteristic 
 
2.   Determination of Weight/MI 
 Weight per ml - 0.046 gm. /ml 
 
3.  Determination of Refractive Index 
Determination of RL was carried out using Refract meter. 
 
4. Determination of Weight per ml 
Weight per ml was determined using the comparative weight calibration method, 
in which the weight of 1ml of the base of the formulation was calculated and then weight 
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of 1 ml of finished formulation were been calculated. The difference between weight 
variations of the base with respect to finished formulation calculated as an index of 
weight per ml. 
 
5. Determination of pH 
Sample being liquid in nature the direct litmus evaluation method was adopted to 
check the pH of the sample.  
 
6.  Determination of Viscosity value 
Viscosity determination were been carried out using Ostwald viscometers. 
Measurement of viscosity involves the determination of the time required for a given 
volume of liquid to flow through a capillary. The liquid is added to the viscometer, 
pulled into the upper reservoir by suction, and then allowed to drain by gravity back into 
the lower reservoir. The time that it takes for the liquid to pass between two etched 
marks, one above and one bellow the upper reservoir, is measured. 
 
7.  Determination of Iodine value 
About 20 gm. of test sample was transferred into Iodine flask. To which 10 ml of 
chloroform was added and warmed slightly and cooled for 10 minutes. Followed by this 
about 25 ml of Wii‟s solution was added in the same flask and shaken well. The flask 
was allowed to stand for 30 mines and refrigerated for an hour About 10 ml of KI 
solution was added to this and titrated against 0.1 N Sodium thiosulphate solutions until 
the appearance of yellow colour. 1 ml of starch indicator was added and again titrated 
against the sodium thiosulphate solution from the burette. Disappearance of blue colour 
indicates end point. Repeat the above procedure without taking sample and note the 
corresponding reading for blank titration. 
 
8.  Determination of saponification value 
About 2 gm of test sample was transferred into the round  bottomed flask. To this 
about 20 ml of 0.5 N alcoholic KOH solutions was added to the round bottomed flask. 
Repeat the same procedure without taking the sample for blank titration. Reflux both 
sample and blank round bottomed flasks for 1 hour. After reflux, allow both the round 
bottomed flasks to cool. Titrate the samples using 0.5 N HCl with phenolphthalein 
indicator. The disappearance of pink indicates the end point.  
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9.  Acid Value 
Accurately 5 g of test sample was weighed and transferred into a 250 mL conical 
flask. To this, a 50 mL of neutralized alcohol solution was added. This mixture was 
heated for 10 min by heating mantle. Afterwards, the solution was taken out after 10 min 
and 1 or 2 drops of phenolphthalein indicator was added. This solution was titrated 
against KOH solution from the burette. The appearance of pink color indicated the end 
point. The volume of consumed KOH solution was determined and the titration of test 
sample was carried out in triplicate and the mean of the successive readings was used to 
calculate the acid-value of the respective sample by following expression. 
Acid value = Titter Value X 0.00561X 1000 / Wt of test sample (g) 
 
10.  Peroxide value 
5 g of the substance being examined, accurately weighed, into a 250-ml glass-
stoppered conical flask, add 30 ml of a mixture of 3 volumes of glacial acetic acid and 2 
volumes of chloroform, swirl until dissolved and add 0.5ml volumes of saturated 
potassium iodide solution. Allow to stand for exactly 1 minute, with occasional shaking, 
add 30 ml of water and titrate gradually, with continuous and vigorous shaking, with 
0.01M sodium thiosulphate until the yellow colour almost disappears. Add 0.5 ml of 
starch solution and continue the titration, shaking vigorously until the blue color just 
disappears (a ml). Repeat the operation omitting the substance being examined (b ml). 
The volume of 0.01M sodium thiosulphate in the blank determination must not exceed 
0.1 ml. 
Peroxide value = 10 (a-b)/w 
 
11.  TLC/HPTLC 
1. TLC Analysis 
Test sample was subjected to thin layer chromatography (TLC) as per 
conventional one dimensional ascending method using silica gel 60F254, 7X6 cm 
(Merck) were cut with ordinary household scissors. Plate markings were made with soft 
pencil. Micro pipette were used to spot the sample for TLC applied sample volume 10-
micro liter by using pipette at distance of 1 cm at 5 tracks. In the twin trough chamber 
with different solvent system Toulene: Ethyl Acetate: Acetic Acid (1.5:1:0.5) After the 
run plates are dried and was observed using visible light Short-wave UV light 254nm 
and light long-wave UV light 365 nm 
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Reference 
Lukasz Komsta, Monika Waksmundzka-Hajnos, Joseph Sherma. Thin Layer 
Chromatography in Drug Analysis. CRC Press, Taylor and Francis. 
 
2. High Performance Thin Layer Chromatography Analysis 
HPTLC method is a modern sophisticated and automated separation technique 
derived from TLC. Pre-coated HPTLC graded plates and auto sampler was used to 
achieve precision, sensitive, significant separation both qualitatively and quantitatively. 
High performance thin layer chromatography (HPTLC) is a valuable quality assessment 
tool for the evaluation of botanical materials efficiently and cost effectively. HPTLC 
method offers high degree of selectivity, sensitivity and rapidity combined with single-
step sample preparation. In addition it is a reliable method for the quantitation of nano 
grams level of samples. Thus this method can be conveniently adopted for routine quality 
control analysis. It provides chromatographic fingerprint of phytochemicals which is 
suitable for confirming the identity and purity of medicinal plant raw materials.  
 
Chromatogram Development 
It was carried out in CAMAG Twin Trough chambers. Sample elution was 
carried out according to the adsorption capability of the component to be analyzed. After 
elution, plates were taken out of the chamber and dried. 
 
Scanning 
Plates were scanned under UV at 366nm. The data obtained from scanning were 
brought into integration through CAMAG software. Chromatographic finger print was 
developed for the detection of phytoconstituents present in each extract and Rf values 
were tabulated.
 
 
Reference 
1. Wagner H. Plant Drug Analysis. A thin Layer chromatography Atlas.2nd ed. 
Heidelberg: Springer-Verlag Belgium; 2002:305, 227. 
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12.  Heavy metal analysis 
Standard: Hg, As, Pb and Cd – Sigma 
 
Methodology 
Atomic Absorption Spectrometry (AAS) is a very common and reliable technique 
for detecting metals and metalloids in environmental samples. The total heavy metal 
content of the sample KN was performed by Atomic Absorption Spectrometry (AAS) 
Model AA 240 Series. In order to determination the heavy metals such as mercury, 
arsenic, lead and cadmium concentrations in the test sample KN. 
 
Sample Digestion 
Test sample KN digested with 1mol/L HCl for determination of arsenic and 
mercury. Similarly for the determination of lead and cadmium the sample were digested 
with 1mol/L of HNO3. 
 
Standard reparation 
As & Hg- 100 ppm sample in 1mol/L HCl 
Cd &Pb- 100 ppm sample in 1mol/L HNO3 
 
13.  Sterility test by pour plate method 
Objective  
The pour plate techniques were adopted to determine the sterility of the product. 
Contaminated / un sterile sample (formulation) when come in contact with the nutrition 
rich medium it promotes the growth of the organism and after stipulated period of 
incubation the growth of the organism was identified by characteristic pattern of 
colonies. The colonies are referred to as Colony Forming Units (CFUs).   
 
Methodology 
About 1ml of the test sample was inoculated in sterile petri dish to which about 
15 ml of molten agar 45
o
C were added. Agar and sample were mixed thoroughly by 
tilting and swirling the dish. Agar was allowed to completely gel without disturbing it. 
(About 10 minutes). Plates were then inverted and incubated at 37
o
 C for 24-48 hours. 
Grown colonies of organism was then counted and calculated for CFU. 
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14.  Test for Specific Pathogen 
Methodology 
0.5 ml of the test sample was directly inoculated in to the specific pathogen 
medium (EMB, DCC, Mannitol, Cetrimide) by pour plate method. The plates were 
incubated at 37
o
C for 24 – 72 hrs for observation. Presence of specific pathogen 
identified by their characteristic color with respect to pattern of colony formation in each 
differential media. 
Abbreviation 
Organism Abbreviation 
E-coli EC 
Salmonella SA 
Staphylococcus Aureus ST 
Pseudomonas Aeruginosa PS 
 
15.  Test for Pesticides 
1.  Organochloorine Pesticides 
2.  Organophosphorus Pesticides 
3.  Phyrethroids 
 
Extraction 
About 10 g of test substance were extracted with 100 ml of acetone and followed 
byhomogenization for brief period. Further filtration was allowed and subsequent 
addition of acetone to the test mixture. Heating of test sample was performed using a 
rotary evaporator at a temperature not exceeding 40ºC until the solvent has almost 
completely evaporated. To the residue add a few milliliters of toluene R and heat again 
until the acetone is completely removed. Resultant residue will be dissolved using 
toluene and filtered through membrane filter. 
 
Reference 
1. WHO guideline for assessing the quality of herbal medicines with reference to 
contaminants and residues. WHO Geneva. 2007. 
2. Lohar. D.R.Protocol for testing of ASU medicines. Pharmacopoeial Laboratory 
for Indian  Medicines. Ministry of AYUSH. 2007. 
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16.  Aflatoxin Assay 
Standard 
Aflatoxin B1 
Aflatoxin B2 
Aflatoxin G1 
Aflatoxin G2  
 
Solvent 
Standard samples was dissolved in a mixture of chloroform and acetonitrile (9.8 : 
0.2) to obtain asolution having concentrations of  0.5 μg per ml each of aflatoxin B1 and 
aflatoxin G1 and 0.1 μg per mleach of aflatoxin B2 and aflatoxin G2. 
Test solution: Concentration 1 μg per ml 
 
Procedure 
Standard aflatoxin was applied on to the surface to pre coated TLC plate in the 
volume of 2.5 μL, 5μL, 7.5 μL and 10 μL. Similarly the test sample was placed and 
Allow the spots to dry and develop thechromatogram in an unsaturated chamber 
containing a solvent system consisting of a mixture ofchloroform, acetone and isopropyl 
alcohol (85 : 10 : 5) until the solvent front has moved not less than 15 cmfrom the origin. 
Remove the plate from the developing chamber, mark the solvent from and allow the 
plateto air-dry. Locate the spots on the plate by examination under UV light at 365 nm. 
 
Reference 
Luciana de CASTRO. Determining Aflatoxins B1, B2, G1 And G2 In Maize 
Using Florisil Clean Up WithThin Layer Chromatography And Visual And 
Densitometric Quantification. Ciênc. Tecnol. Aliment.vol.21no.1 Campinas. 2001. 
 
A.iii.   Phytochemical analysis of Karappan Nei 
     Preparation of Extract: 
Sample Extraction were carried out with Ethyl acetate solvent and the resulting 
extract was utilized for the phytochemical analysis. 
 
1. Test for alkaloids: 
Mayer's Test: To the test sample, 2ml of mayer's reagent was added. 
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2. Test for coumarins:  
To the test sample, 1 ml of 10% sodium hydroxide was added. 
 
3. Test for saponins:  
 To the test sample, 5 ml of water was added and the tube was shaken vigorously. 
 
4. Test for tannins:  
 To the test sample, ferric chloride was added.  
 
5. Test for glycosides- Borntrager’s Test 
 
Test drug is hydrolyzed with concentrated hydrochloric acid for 2 hours on a 
water bath, filtered and the hydrolyte is subjected to the following tests. To 2 ml of 
filtered hydrolyte, 3 ml of chloroform is added and shaken, chloroform layer is 
separated and 10% ammonia solution is added to it. 
 
6. Test for flavonoids: 
To the test sample about 5 ml of dilute ammonia solution were been added 
followed by addition of few drops of conc. Sulfuric acid.  
 
7. Test for phenols: 
Lead acetate test: To the test sample; 3 ml of 10% lead acetate solution was 
added. 
 
8. Test for steroids: 
To the test sample, 2ml of chloroform was added with few drops of conc. 
Sulphuric acid (3ml), and shaken well. The upper layer in the test tube was turns into red 
and sulphuric acid layer showed yellow with green fluorescence. 
 
9. Triterpenoids (Noller’s test)  
Liebermann–Burchard test: To the chloroform solution, few drops of acetic 
anhydride was added then mixed well. 1 ml concentratedsulphuric acid was added from 
the sides of the test tube. 
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10. Test for Cyanins 
        A. Aanthocyanin: 
 To the test sample, 1 ml of 2N sodiumhydroxide was added and heated for 5 min 
at 100
0
C.  
 
11. Test for Carbohydrates - Benedict’s test 
To the test sample about 0.5 ml of Benedic‟sreagent is added. The mixture is 
heated on a boiling water bath for 2 minutes. 
 
12. Proteins (Biuret Test) 
 To extracts 1% solution of copper sulphate was added followed by 5% solution of 
sodium hydroxide. 
 
Reference :  
Brain KR, Turner TD. The Practical Evaluation of  Phyto pharmaceuticals.  
Bristol: Wright Scientechnica; 1975:36-45 
 
A.iv.   Biochemical analysis of karappan Nei 
Biochemical Analysis of Karappan Nei was done at the Biochemistry lab at 
National Institute of Siddha, Chennai by the method of Kolkate.. 
 
Preparation of Extract: 
5ml of sample was taken in a 250ml clean beaker and added with 50ml of 
distilled water. Then it is boiled well for about 10 minutes. Then it is cooled and filtered 
in a 100ml volumetric flask and made up to 100ml with distilled water. This preparation 
is used for the qualitative analysis of acidic/basic radicals and biochemical constituents 
in it. 
 
Procedure: 
 
Test for Silicate 
A 2ml of the sample was shaken well with distilled water. 
 
Action of Heat: 
           A 2ml of the sample was taken in a dry test tube and heated gently at first and 
then strong. 
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Action of Heat: 
           A 2ml of the sample was taken in a dry test tube and heated gently at first and 
then strong. 
 
Ash Test: 
            A filter paper was soaked into a mixture of extract and dil. cobalt nitrate solution 
and introduced into the Bunsen flame and ignited. 
 
I. Test for Acid Radicals 
 
Test for Sulphate: 
2ml of the above prepared extract was taken in a test tube to this added 2ml of 
4% dil ammonium oxalate solution 
 
 Test for chloride: 
2ml of the above prepared extracts was added with 2ml of dil. HCl is added until 
the effervescence ceases off. 
 
Test for Phosphate: 
2ml of the extract were treated with 2ml of dil.ammonium molybdate solution 
and 2ml of con. HNo3. 
 
Test for carbonate: 
          2ml of the extract was treated with 2ml of dil. magnesium sulphate solution. 
 
Test for Nitrate: 
1gm of the extract was heated with copper turning and concentrated H2So4  and 
viewed the test tube vertically down. 
 
II.Test for Basic radicals 
 
Test for lead: 
2ml of the extract was added with 2ml of dil.potassium iodine solution. 
 
Test for copper: 
One pinch (25mg) of extract was made into paste with con. HClin a watch glass 
and introduced into the non-luminuous part of the flame. 
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Test for Aluminium: 
           To the 2ml of extract dil.sodium hydroxide was added in 5 drops to excess. 
 
Test for Iron:  
           a. To the 2ml of extract add 2ml of dil.ammonium solution  
           b. To the 2ml of extract 2ml of thiocyanate solution and 2ml of con HNo3 is 
added. 
 
Test for Zinc: 
To 2ml of the extract dil.sodium hydroxide solution was added in 5 drops to 
excess and dil.ammonium chloride was added.  
 
Test for Calcium: 
        To 2ml of the extract was added with 2ml of 4% dil.ammonium oxalate solution. 
 
Test for Magnesium: 
To 2ml of extract dil. sodium hydroxide solution was added in drops to excess. 
 
Test for Ammonium: 
To 2ml of extract 1 ml of Nessler's reagent and excess of dil. sodium hydroxide 
solution are added. 
 
Test for Potassium: 
         A pinch (25mg) of extract was treated of with 2ml of dil. sodium nitrite solution 
and then treated with 2ml of dil.cobalt nitrate in 30% dil.glacial acetic acid. 
 
Test for Sodium: 
         2 pinches (50mg) of the extract is made into paste by using HCl and introduced 
into the blue flame of Bunsen burner. 
 
Test for Mercury: 
         2ml of the extract was treated with 2ml of dil.sodium hydroxide solution. 
 
Test for Arsenic: 
          2ml of the extract was treated with 2ml of dil.sodium hydroxide solution 
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III. Miscellaneous 
Test for Starch: 
      2ml of extract was treated with weak dil. Iodine solution. 
 
Test For Reducing Sugar: 
       5ml of Benedict's qualitative solution was taken in a test tube and allowed to boil for 
2 minutes and added 8 to 10 drops of the extract and again boil it for 2 minutes. The 
colourchanges are noted. 
 
Test for the Alkaloids: 
      a) 2ml of the extract was treated with 2ml of dil.potassium Iodide solution. 
      b) 2ml of the extract was treated with 2ml of dil.picric acid. 
     c) 2ml of the extract was treated with 2ml of dil.phosphotungstic acid. 
 
Test for Tannic Acid: 
 2ml of extract was treated with 2ml of dil.ferric chloride solution. 
 
Test for Unsaturated Compound: 
      To the 2ml of extract 2ml of dil.Potassium permanganate solution was added. 
 
Test for Amino Acid: 
      2 drops of the extract was placed on a filter paper and dried well. 20ml of Burette 
reagent is added. 
 
Test for Type of Compound: 
      2ml of the extract was treated with 2 ml of dil.ferric chloride solution. 
 
A. v.In vitro Anti-inflammatoryactivity 
In-vitro Anti-Inflammatory Activity by Protein (Albumin) denaturation Assay 
Albumin Denaturation Assay Procedure 
In-vitro anti-inflammatory activity KN was studied using albumin denaturation 
technique. The reaction mixture consisted of bovine serum albumin (5% aqueous 
solution) and test sample KN at varying concentration ranges from 100 to 500 µg/ml and 
standard Diclofenac sodium at the concentration of100 µg /ml of final volume. pH was 
adjusted by using a small amount of 1N Hydrochloric acid.  
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The samples were incubated at 37°C for 20 min and then heated at 57°C for 3 
min. After cooling the sample, 2.5 ml of phosphate buffer solution was added into each 
test tube. Turbidity developed was measured spectrophotometrically at 660 nm, for 
control distilled water was used instead of test sample while product control tests lacked 
bovine serum albumin. The experiment was performed in triplicate. 
The Percentage protection from denaturation is calculated by using the formulae 
 
Statistical analysis 
Results are expressed as Mean ± SD. The difference between experimental 
groups was compared by One-Way Analysis Of Variance (ANOVA) followed by Dunnet 
Multiple comparison test. 
 
Reference 
1. G.Leelaprakash, S.MohanDass. In-vitro anti-inflammatory activity of methanol 
extract of enicostemmaaxillare. Int. J. Drug Dev. & Res., 2011, 3 (3): 189-196. 
2. M.V.Anoop, A.R.Bindu. In-vitro Anti-inflammatory Activity Studies on 
Syzygiumzeylanicum (L.) DC Leaves. International Journal of Pharma Research 
& Review, August 2015; 4(8):18-27. 
 
B.  CLINICAL STUDIES: 
Clinical studies CTRI/2017/05/008722.REF/2017/04/014108 
A Protocol was prepared andsubmittedforIEC of National Institute of 
Siddha.The IEC approval number is No:NIS/IEC/2016/11-18/14.10.2016. The trial 
registed in Clinical trial Registry of India with Reg.No.CTRI/2017/05/008722. After 
obtaining approval from the committee, the clinical study on bala karappan  (Eczema) in 
children with the drug of choice KARAPPAN NEI (INTERNAL AND EXTERNAL 
MEDICINE) was carried outas per the protocol. 
The trial drug KarappanNei 5-10 Ml (bd) is given for 48 days. For OP patients  
the clinical assessment was be done on 0 st ,16 th,32 th,48 th  day and prognosis was 
noted .  Laboratory investigations were done on   0
th
 day & 48
th
 day of the trial. After the 
end of the treatment, the patients were advised to visit the OPD for another 1 months for 
follow-up. 
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Study Enrollment 
In this study, patients reporting at the NIS OPD with the three or more clinical 
symptoms of papules, vesicles, pustules, fissures, oozing, ulceration, oozing or dryness 
with foul smell, Pain in lower extremities, hyperpigmentation, was be examined 
clinically for enrolling in this study based on the inclusion and exclusioncriteria. 
  The patients who were enrolled was  informed about the study, experimental 
medicine, possible outcomes and the objectives of the study in the language and 
terms understandable to them and to their informants. 
  After ascertaining the patient and informants willingness, informed consent was 
obtained in writing from them in the consent form. 
  All these patients were given unique registration card in which patients 
Registration number of the study, Address, Phone number and Doctors phone 
number etc. were given, so as to report easily communication for the sake of 
thepatient. 
  Complete clinical history, complaints and duration, examination findings-- all 
wererecorded in the prescribed Proforma in the history and clinical assessment 
forms separately. 
  Patients were advised to take the trial drug and appropriate dietary advice given 
according to the patient‟s perfectunderstanding. 
 
Population and Sample: 
 The population consists of pediatric patients attending the OPD of Ayothidoss 
Pandithar Hospital, National Institute of Siddha, Chennai-47. 
 The sample consists of 6-12 years age group fulfilling all the inclusion criteria and 
the exclusion ncriteria. 
Sample size: 30 Patients 
Study place:  Department of Kuzanthai Maruthuvam, 
Ayothidoss Pandithar hospital, 
National Institute of Siddha, Ch-47 
Inclusion criteria: 
Age 6 to 12 years 
Both sex- male & female children 
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Symptoms of, 
 Pain in lower extremities  
 Itching 
 Papules 
 Vesicles 
 Pustules 
 Ulcer formation with oozing 
 Hyper pigmentation 
 Sleep disturbances 
 
Exclusion criteria: 
H/o Scabies 
H/o Photo dermatitis 
H/o jaundice  
H/o Any other serious illness 
 
Withdrawal criteria: 
 Exacerbation of symptoms 
 Occurrence of any adverse effect 
 Patients turning unwilling to continue the study during the course of trial 
period. 
 
Studydesign : An Open clinicaltrial. 
Studyduration : 24Months 
Dosageof drugs : 6-12 years (5 -10 ml) (bd) 
             For 6 – 8 years 5 ml 
      For 9 – 12 years 10 ml 
Adjuvant                       : Honey 
Dose calculation for pediatric group is based on Age, formula mentioned in the 
GunapadamThathuvagupputext. 
 
Assessments: 
i. Clinical assessment by SCORAD index 
ii. Routine investigations 
iii. Siddha method of assessment 
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i. Clinical assesment 
The SCORAD index 
A = spread.../100 
B = intensity.../18 
C = subjective symptoms.../20 
SCORAD calculation: A/5 +7 B/2 + C 
 
ii. Routineinvestigation 
Blood - HB, Total WBC, Total RBC, DC, AEC 
 
iii. Siddha method of assessment 
• Nilam 
• Kaalam 
• Uyir thathukkal 
• Udal thaathukkal 
• Envagai thervugal 
Out Come 
Primary outcome 
Number and screening of clinical symptoms are slightly reduced such as Papules, 
Vesicles, Pustules, Oozing from lesion, Itching by using SCORAD index. 
 
Secondary outcome 
Clinical Efficacy of the trail drug and its side effects if any… 
The experimental drug may have good efficacy and safety in clinical study. 
 
Data Management: 
After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Whenever study patient visits OPD during 
the study period, the respective patient file will be taken and necessary recordings will 
be made at the assessment form or other suitable form. The screening forms will be filed 
separately. The Data recordings will be monitored for completion and adverse event by 
HOD and data logical recording and completeness will be monitored by statistician 
(Sr.Research Officer (Statistics). All forms will be further scrutinized in presence of 
Investigators by Sr.Research Officer (Statistics) for logical errors and incompleteness of 
data before entering onto computer to avoid any bias. 
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No modification in the results is permitted for unbiased report.Any missed data 
found in during the study, it will be collected from the patient, but the time related data 
will not be recorded retrospectively all collected data will be entered using MS access 
software onto computer. Investigators will be trained to enter the patient data and cross 
checked by SRO. 
 
Adverse Effect/Serious Effect Management: 
If the trial patient develops any adverse reaction, he/she would be immediately 
withdrawn from the trial and proper management will be given in OPD of National 
Institute of Siddha and the same will be reported to regional pharmacovigilance center. 
 
Ethical Issues 
 To prevent any infection, with proper sterilization of lab equipment were 
used. 
 No other external or internal medicines wereused. 
 The data collected from the patient‟s informant was recorded. The patient‟s 
informant was informed about the diagnosis, treatment andfollow-up. 
 After the consent of the patient‟s informant (through consent form), patient 
was enrolled in thestudy. 
 Informed consent was obtained from the patient‟s informant explaining in the 
understandable language to the patient‟sinformant. 
 Treatment was provided free ofcost. 
 In conditions of treatment failure, adverse reactions, patients were given 
alternative treatment at the National Institute of Siddha with fullcare. 
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Data Collection Forms 
 
Form I  Screening & Selection Performa  
Form II  Consent Form 
Form III  Assent Form  
FormIV  Case Report Form  
FormV  Drug compliance  
FormVI  Information sheet 
FormVII  Dietary advice form  
FormVIII  Adverse reaction form  
FormIX  Pharmaco vigilance  
FormX  Withdraw form 
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5.  RESULTS AND OBSERVATION 
 
A.  Pre Clinical studies 
i. Acute Toxicity Study 
ii. Physicochemical analysis 
iii. Phytochemical analysis 
iv. Bio chemical analysis 
v. In vitro Anti inflammatory activity 
 
A. i. Acute Toxicity Study 
 
Results  
Behavioral Signs of Acute Toxicity Study of  Karappan Nei 
 
Parameters 
30 mints 4 hrs 24 hrs 1
st
 week 2
nd
 week 
C E C E C E C E C E 
Skin & Fur N N N N N N N N N N 
Mucous Membrane N N N N N N N N N N 
Respiratory rate N N N N N N N N N N 
Heart rate N N N N N N N N N N 
Salivation & 
Lacrimation 
N N N N N N N N N N 
Lethargy NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
Piloerection N N N N N N N N N N 
Urinary 
incontinence 
NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
Defecation N N N N N N N N N N 
Sleep & Gait N N N N N N N N N N 
Tremors 
&Convulsion 
NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
Mortality NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
 
N – Normal, C – control, E – Experimental 
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All the data were summarized in the form of (table-7) revealed that there was no 
abnormal signs and behavioral changes in all animals at the dose level of 1.8ml is 
administered orally, during the study period.   
There was no mortality observed after dosing of Karappan Nei upto 1.8ml during 
the study period of 14 days. This indicates that the LD50 of Karappan Nei is more than 
1.8ml  
There were no changes in skin and fur, eyes and mucous membranes of all 
animals. The eating, drinking habit, sleep pattern, locomotion were normal in all animals 
and no changes in body weight as compared to control group.  
At the end of the 14 the day, necropsy was performed and there was no 
abnormality seen in test groups as compared to control group during the examination. 
 
A. ii.  Physicochemical analysis of Karappan Nei 
Analytical Report 
S.No Parameter Karappan Nei 
1 Specific Gravity 
1.0190 
2 Viscosity at 50
o
C (Pa s) 
28.28 
3 Refractive index  
1.38 
4 Weight per ml (gm/ml) 
 
5 Iodoine value (mg I2/g) 
142.24 
6 
Saponification Value                                  
(mg of KOH to saponify 1gm of fat) 
287.82 
7  Ph 
5 
8 Weight per ml 
0.046 gm/ml 
9 Acid Value mg KOH/g 0.617 
10 Peroxidase Value mEq/kg 7.429 
 
  
92 
 
Interpretation 
Since specific gravity of Karappan Nei is 1.0190 an viscosity at 50 c (Pa s) is 
28.28. High value of saponification is 287.82. This value indicate to bio active molecules 
may present in karappan Nei. Its having ph 5. 
A. iii. Phytochemical analysis of Karappan Nei 
 
Interpretation 
 Phytochemical analysis shows the presence of Alkaloids, Coumarins, Tannis, 
Glycosides, Flavonoids, Phenols, Steroids, Triterpenoids, and absence of Cyanins, 
Carbohydrates, Protenis, Saponin. 
 
 
S.No Parameter Observation Result 
1. Test for alkaloids Dull white precipitate revealed Present 
2. Test for Coumarins Formation of Yellow color Present 
3. Test for Saponins Copious lather formation Absent 
4. Test for tannis Dark blue or greenish black color Present 
5. Test for glycoside Pink color Present 
6. Test for flavonoids Yellow color Present 
7. Test for Phenols Bulky white precipitate Present 
8. Test for steroids 
The layer showed yellow with green 
flurorescence 
Present 
9. Triterpenoids Appearance of red ring Present 
10. Test for Cyanins Formation of bluish green colour Absent 
11. Test for Carbonhydrates Characteristic colour precipitate Absent 
12. Proteins Violet purple colour Absent 
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RESULTS 
  
Test for Alkaloids          Test for Flavonoids 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test for Steroids      Test for Glycoside 
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   Test for Triterpenoids       Test for Phenols 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test for Tanins          Test for Proteins 
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     Test for Saponins      Test for Carbohydrates 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Test for Beta cyanins 
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A. iv. Biochemical Analysis of  Karappan Nei 
  Results of Acid radicals studies 
 
S.No Parameter Observation Result 
1 Test for Sulphate Cloudy appearance present Absent 
2 Test for Chloride No Cloudy appearance present Absent 
3 Test For Phosphate Cloudy  yellow appearance present Absent 
4 Test For Carbonate Cloudy appearance present Present 
5 Test For Nitrate - Absent 
6 Test for  Sulphide - Absent 
7 
Test For Fluoride 
& oxalate 
- Absent 
8 Test For Nitrite - Absent 
9 Test For Borax - Absent 
 
 
Interpretation 
 
The acidic radicals test shows the presence of Carbonate. 
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Results of basic radicals studies 
 
S.NO Parameter Observation Result 
1 Test for Lead - Absent 
2 Test for Copper - Absent 
3 Test For Aluminium. - Absent 
4 Test For Iron. 
Blood  red colour 
Appeared 
Present 
5 Test For Zinc - Absent 
6 Test for Calcium 
Cloudy appearance and 
white precipitate present 
Absent 
7 Test For Magnesium 
White precipitate 
Obtained 
Absent 
8 Test For Ammonium 
Mild brown colour 
appears 
Absent 
9 Test For Potassium - Absent 
10 Test For Sodium - Absent 
11 Test For Mercury - Absent 
12 Test For Arsenic - Absent 
 
Interpretation 
 
The basic radical test shows the presence of Iron, and absence of heavy metals 
such as lead, arsenic and mercury etc .
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Miscellaneous 
 
S.No Parameter Observation Result 
1 Test for Starch - Present 
2 Test for Reducing sugars - Absent 
3 Test For Alkaloids. Yellow colour developed Present 
4 Test For Tannic acid 
Blue-black precipitate 
obtained 
Absent 
5 
Test for unsaturated 
compounds 
- Absent 
6 
Test for Type of 
compounds 
Green and Red colour 
present 
Absent 
 
Interpretation 
 
The Miscellaneous test shows presence of Starch, Alkaloids, absence of 
Reducing sugar, Tannic acid, Unsaturated Compounds and types of component. 
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A. v. In-Vitro anti – inflammatory activity of Karappan Nei was studied using 
albumin denaturation technique. 
The results obtained was tabulated below 
FINAL RESULT 
Concentration in µg/ml Absorbance 
Control 
0.92  ± 0.07 
KN 100 0.76  ± 0.02 
KN 200 0.63  ± 0.064 
KN 300 0.52  ± 0.02 
KN 400 0.43  ± 0.51 
KN 500 0.34  ± 0.6 
Diclofenac sodium                
(100 µg) 
0.010  ± 0.08 
 
Each value represents the mean ± SD. N=3 
Concentration in 
µg/ml 
Percentage Inhibition of Protein 
Denaturation 
KN 100 10.46  ± 3.36 
KN 200 
24.5  ± 3.30 
KN 300 
35.65  ± 3.91 
KN 400 45.4  ± 2.20 
KN 500 55.83  ± 3.26 
Diclofenac sodium                
(100 µg) 
91.45  ± 1.41 
 
Each value represents the mean ± SD. N=3 
Result Analysis 
The result obtained from the present clearly indicates that the test drug KN was 
effective in inhibiting heat induced albumin denaturation. Maximum percentage 
inhibition of about 55.83 % was observed at 500 μg/ml when compare to that of the 
Diclofenac sodium, a standard anti-inflammatory agent with the maximum inhibition 
91.45 % at the concentration of 100 μg/ml. 
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Conclusion 
From the result of the study it was concluded that the test drug KN possess 
promising anti-inflammatory property in protein denaturation assay. 
Absorbance Range of test and standard at Trial 1 
 
 
 
 
 
 
Absorbance Range of test and standard at Trial 2 
 
 
 
 
 
 
Absorbance Range of test and standard at Trial 3 
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Preparation of Test and control 
 
 
 
 
 
 
 
 
Absorbance of reaction mixture – Test Sample 
 
 
 
 
 
 
 
 
 
 
 
 
Absorbance of reaction mixture – Control and Standard 
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B. Clinical Studies 
30 Children aged 6 -12 Years with confirmed diagnosis of BALA KARAPPAN 
with satisfying the inclusion criteria were enrolled in this study after obtaining written 
informed consent and were to receive KARAPPAN NEI (Internal And External 
Medicine) with dosage of 5-10 ml BD for 48 days. 
 
Results were observed with respect to the following criteria 
 
1. Age 
2. Sex 
3. Religion 
4. Parent’s Socio Economic Status 
5. Diet habits 
6. Allergic history 
7. Family history 
8. Duration of illness 
9. Site of lesion  
10. Nilam 
11. Paruva kaalam 
12. Uyir thathukkal 
Vatham 
Pithan 
Kabham 
13. Pori / pulangal 
14. Kanmenthiriyangal 
15. Ezhu udalkattugal 
16. Envagai thervugal 
17. Clinical symptoms 
18. Haemotological Profile 
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TABLE 1: Distributions of Children with Bala karappan according to Age 
 
SL.NO AGE IN YEARS NO OF CASES PERCENTAGE 
1 6-8 11 36.7% 
2 9-12 19 63.3% 
TOTAL 30 100.0% 
 
 
 
Inference     
             Among the 30 patients selected for this study, maximum  numbers  of patients 
63.3% were  in  the  age  group  of  9 to 12 years,  36.7% were  in  the  age group of 6 to 8 
years. 
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TABLE 2: Distributions of Children with Bala karappan according to Sex 
SL.NO SEX NO OF CASES PERCENTAGE 
1 Male Child 15 50.0% 
2 Female Child 15 50.0% 
TOTAL 30 100.0% 
 
 
 
 
  
Inference: 
Among the 30 children included in this study, 50.0% were male and female 50%. 
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TABLE 3: Distributions of Children with Bala karappan according to Religion 
 
SL.NO RELIGION NO OF CASES PERCENTAGE 
1 Hindu 28 93.3% 
2 Christian 2 6.7% 
3 Muslim 0 0.0% 
 
TOTAL 30 100.0% 
 
 
 
 
Inference 
High   incidence of  karappan was noted 93.3% in Hindus, And 6.7%  in Christian 
people. No cases were reported from Muslim community in this study period. 
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TABLE 4: Distribution of children  with  Bala Karappan according to parent’s Socio 
economic status: 
 
SL.NO SOCIOECONOMIC STATUS NO OF CASES PERCENTAGE 
1 Upper 6 20.0% 
2 Upper Middle 11 36.7% 
3 Upper lower 8 26.7% 
4 Lower middle 5 16.7% 
TOTAL 30 100.0% 
 
 
 
 
Inference 
Out of 30 patients, 20.0% of the patients were from Upper income group, 36.7% 
patients were from Upper middle income group, 26.7% patients were from Upper 
Lower and the remaining 16.7% patients were under Lower Middle income group. 
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TABLE 5: Distribution of children with Bala Karappan according to Diet: 
 
SL.NO FOOD HABITS NO OF CASES PERCENTAGE 
1 Vegetarian 0 0.0% 
2 Non-vegetarian 30 100.0% 
TOTAL 30 100.0% 
 
 
 
 
Inference 
All the cases involved in this study were non-vegetarians 100%. 
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TABLE 6: Distribution of children with Bala Karappan according to Allergic 
history: 
 
SL.NO ALLERGY H/O NO OF CASES PERCENTAGE 
1 H/O similar complaints 3 30.0% 
2 Bronchial asthma 2 20.0% 
3 Hospitalization 0 0.0% 
4 
Any other (Mosquito bite, 
Food allergy and Dust 
allergy) 
5 50.0% 
TOTAL 10 100.0% 
 
 
 
 
Inference 
Out of 30 patients, 30% of the patients showed past H/O similar complaints, 20% 
had Bronchial Asthma, and 50% had history like Mosquito bite, Food Allergy, Dust 
Allergy. No patients having history of hospitalization.  
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TABLE 7: Distribution of children with Bala Karappan according to Family history: 
 
SL.NO FAMILY HISTORY NO OF CASES PERCENTAGE 
1 Positive 3 10.0% 
2 Negative 27 90.0% 
TOTAL 30 100.0% 
 
 
 
  
Inference 
Among 30 patients, 90% of the patients showed no family history related with 
this disease 10%  showed positive family history. 
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TABLE 8: Distribution of children with Bala Karappan according to Duration of  
Illness 
 
SL.NO DURATION NO OF CASES PERCENTAGE 
1 < 2 months 2 6.7% 
2 3 - 11 months 7 23.3% 
3 1 - 3 years 16 53.3% 
4 4 - 7 years 4 13.3% 
5 8 - 10 years 1 3.3% 
TOTAL 30 100.0% 
 
 
 
 
Inference 
Among the 30 patients the maximum number of patients (53.3%) had the duration 
of illness between 1 to 3 years, (23.3%) of them had between 3 to 11 months, (13.3%) 
were below 4 to 7 years, (6.7%) were between < 2 months and (3.3%) were 8-10 years. 
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TABLE 9: Distribution of children with Bala Karappan according to Site of 
involvement 
 
SL.NO SITE NO OF CASES PERCENTAGE 
1 Upper limb 0 0.0% 
2 Lower limb 7 23.3% 
3 Upper limb and Lower limb 21 70.0% 
4 
Upper limb, lower limb and 
trunk, gluteal religion 
2 6.7% 
 
 
 
 
Inference 
Among 30 patients 70.0% had the lesion in both upper and lower limbs, 23.3% 
had lesion only in the lower limbs, and 6.7% had lesion only in upper limbs and lower 
limb, trunk. gluteal region. 
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TABLE 10: Distribution of children with Bala Karappan according to Nilam 
Habitat 
 
SL.NO NILAM NO OF CASES PERCENTAGE 
1 Kurinji 0 0.0% 
2 Mullai 0 0.0% 
3 Maruthum 7 23.3% 
4 Neithal 23 76.7% 
5 Paallai 0 0.0% 
 
 
 
 
  
Inference 
Among  the   30   patients 77%   of   the   patients   were   from   Neithal  (Coastal  
Area),  23% are  from  Marutham  (Fertile  Land), 0 %  were reported  from Kurinji  (Hill   
area), Paalai (Dessert area) and Mullai (Forest Land). 
  
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
Kurinji Mullai Maruthum Neithal Paallai
0.0% 0.0%
23.3%
76.7%
0.0%
NILAM HABITAT
113 
 
TABLE 11: Distribution of children with Bala Karappan according to Paruvakaalam: 
 
SL.NO PARUVA KAALAM NO OF CASES PERCENTAGE 
1 Kaarkaalam 0 0.0% 
2 Koodirkaalam 18 60.0% 
3 Munpani 7 23.3% 
4 Pinpani 5 16.7% 
5 Elavenil 0 0.0% 
6 Muthuvenil 0 0.0% 
 
 
 
 
Inference 
 Among the 30 patients admitted for this study, the highest number of patients 
(60.0%) reported in Koothir Kaalam and 23.3% were reported in Muthuvenil Kaalam, 
16.7% were reported in pinpani kalam. 
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Table 12: Distribution of children with Bala Karappan according to Uyir thathugal: 
 
12. a: VAATHAM 
SL.NO VAATHAM CLASSIFICAION NO OF CASES PERCENTAGE 
1 Piranan 0 0.0% 
2 Abanam 0 0.0% 
3 Viyanan 0 0.0% 
4 Uthanan 30 100.0% 
5 Samanam 30 100.0% 
6 Nagan 0 0.0% 
7 Koorman 0 0.0% 
8 Kirukaran 5 16.7% 
9 Devathathan 7 23.3% 
10 Thenajeyan 0 0.0% 
 
 
 
Inference 
 Samanan and Uthanan  (Papules , Pustules, Vesicles) was found to be affected in 
all the 30 patients and devathathan (sleep disturbances) was affected in 23.3% of patients, 
Kirukaran was affected in 16.7%  of  patients  (Cold, Cough). 
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TABLE 12.b:  PITHAM 
 
SL.NO PITHAM CLASSIFICAION NO OF CASES PERCENTAGE 
1 Analapitham 0 0.0% 
2 Renjagam 4 13.3% 
3 Saathagam 0 0.0% 
4 Pirasagam 30 100.0% 
5 Alosagam 0 0.0% 
 
 
 
Inference 
 
Prasakam (skin) was affected in all the cases 100% and Ranjagam (anaemia) 
was affected in 13.3% of patients. 
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TABLE 12 (C): KABAM 
 
SL.NO KABAM CLASSIFICAION NO OF CASES PERCENTAGE 
1 Avalambagam 1 3.3% 
2 Kilethegam 0 0.0% 
3 Tharpagam 0 0.0% 
4 Pothagam 0 0.0% 
5 Santhigam 0 0.0% 
 
 
 
  
Inference 
In 3.3% of the patients avalambagam (indigestion) was found to be affected.  
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TABLE 13: Distribution of children with Bala Karappan according to Pori / 
pulangal: 
 
SL.NO PORI NO OF CASES PERCENTAGE 
1 Mei 30 100.0% 
2 Vai 0 0.0% 
3 Kan 0 0.0% 
4 Mooku 0 0.0% 
5 Sevi 0 0.0% 
 
 
 
Inference 
Mei was affected in 30 patients (100%) of cases. 
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TABLE 14: Distribution of children with Bala Karappan according to 
Kanmenthiriyangal: 
SL.NO KANMENTHIRIYANGAL NO OF CASES PERCENTAGE 
1 Kai 18 60.0% 
2 Kal 27 90.0% 
3 Vaai 0 0.0% 
4 Eruvai 0 0.0% 
5 Karuvai 0 0.0% 
 
 
 
Inference 
Among 30 patients, Kai was affected in 60.0 %, Kaal was affected in 90 %. 
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TABLE 15: Distribution of children with Bala Karappan according to Ezhu udal 
katugal: 
 
SL.NO EZHU UDAL KATTUGAL NO OF CASES PERCENTAGE 
1 Saaram 30 100.0% 
2 Seneer 4 13.3% 
3 Oon 0 0.0% 
4 Koluppu 0 0.0% 
5 Enbu 0 0.0% 
6 Moolai 0 0.0% 
7 Sukkilam/suronitham 0 0.0% 
 
 
 
Inference: 
In Bala karappan Saram was affected 100 %, Senneer was affected 13.3%. 
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TABLE 16: Distribution of children with Bala Karappan according to Envagai 
thervu: 
 
SL.NO EN VAGAI THERVUGAL NO OF CASES PERCENTAGE 
1 Na 0 0.0% 
2 Niram 30 100.0% 
3 Mozhi 0 0.0% 
4 Vizhi 0 0.0% 
5 Sparisam 30 100.0% 
6 Malam 0 0.0% 
7 Moothiram 0 0.0% 
8 Naadi 
VathaPitham 25 83.3% 
PithaVatham 5 16.7% 
PithaKabam 0 0.0% 
 
 
Inference: 
In bala karappan Niram affected 100%, Sparisam affected 100%,  
And Nadi, vatha pitham affected 83.3%, pitha vatham 16.7%  affected. 
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Table 17: Results of Clinical Symptoms 
SL.
NO 
SYMTOMS 
NO OF 
CASES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
IMPRO
VEMEN
T 
PERCE
NTAGE 
NO OF 
CASES 
PERCE
NTAG
E 
NO OF 
CASES 
PERCE
NTAG
E 
1 Itcing 30 30 100.0% 6 20.0% 80.0% 
2 
Presence of blislers, 
papules, pustules, 
vesicles 
30 30 100.0% 1 3.3% 96.7% 
3 
Pain in lower 
extrimitis 
30 14 46.7% 0 0.0% 46.7% 
4 
Ulcer formation with 
oozing 
30 25 83.3% 6 20.0% 63.3% 
5 Sleep disturbance 30 30 100.0% 2 6.7% 93.3% 
6 Hyperpigmentation 30 30 100.0% 21 70.0% 30.0% 
 
CLINICAL FEATURES-BEFORE TREATMENT AND AFTER TREATMENT 
1. Itching  –  before And after  treatment: 
 
 
Inference 
        Among 30 cases (100%) only 6 cases (20.0%) reporting with itching symptoms. 
 
  
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
Before Treatment After Treatment
100.0%
20.0%
Itcing
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2. Presence of Blisters, Papules, Pustules, Vesicles  -  before And after treatment 
 
Inference 
        Among 30 cases (100%) only 1 cases (3.3%) reporting with presence of Blisters, 
Papules. 
3. Pain in lower extremities  -  before And after treatment 
 
 
Inference 
        Among 30 cases (100%) No cases reporting with symptom of pain in lower 
extremities. 
  
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
Before Treatment After Treatment
100.0%
3.3%
Presence of 
blislers, papules, pustules, vesicles
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
Before Treatment After Treatment
46.7%
0.0%
Pain in lower extrimitis
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4. Ulcer formation with oozing  -  before and after treatment 
 
Inference 
        Among 30 cases (100%) Only 6 cases (20.0%) reporting with ulcer formation with 
oozing. 
 
5. Sleep disturbance -  Before And After treatment 
 
 
Inference 
        Among 30 cases (100%) Only 2 cases (6.7%) reporting with sleep disturbance. 
 
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
Before Treatment After Treatment
83.3%
20.0%
Ulcer formation with oozing
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
Before Treatment After Treatment
100.0%
6.7%
Sleep disturbance
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6. Hyperpigmentation  -  Before And After treatment 
 
Inference 
        Among 30 cases (100%) only 21 cases (70.0%) reporting with hyperpigmentation. 
 
CLINICAL IMPROVEMENT IN PERCENTAGE 
 
 
Inference 
In this study among 30 children’s, 80.0%  Itching, 96.7% Papules, Vesicles, 
Blisters, Pustules,  46.7% had Pain in lower extremities, 63.3% had Ulcer formation with 
oozing, 93.3% sleep disturbances, 30.0% hyper pigmentation were cured. 
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
Before Treatment After Treatment
100.0%
70.0%
Hyperpigmentation
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0% 80.0%
96.7%
46.7%
63.3%
93.3%
30.0%
Improvement Percentage
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18)  RESULTS OF SCORADCALCULATION 
 
S.No Op No Name 
Age 
/Sex 
Before 
treatment 
After 
treatment 
Difference Percentage 
1. J76040 Baby.S. Keerthi 
11 / 
FCH 
50.9 5.9 45 88.40 
2. J80924 
Baby. 
Vishalisharmitha 
9 / 
FCH 
55.5 1.4 54.1 97.47 
3. J69345 Mast. E. Sathish 
Kumar 
10 / 
MCH 
53.9 5.5 48.4 89.79 
4. J81265 
Mast. S. P. Tamil 
Selvan 
6 / 
MCH 
49.9 0.8 49.1 98.39 
5. D65176 Baby. N. Varshini 
7 / 
FCH 
49.1 7.4 41.7 84.92 
6. I49712 
Mast. N. Naveen 
Kumar 
10 / 
MCH 
56.6 5.7 50.9 89.92 
7. J13039 Mast. G. HariPrabu 
9 / 
MCH 
41.6 4.1 37.5 90.14 
8. J53646 
Mast. G. 
Vijay 
10 / 
MCH 
74.5 9.6 64.9 87.11 
9. J81699 
Mast. P. 
Thirukumaran 
11 / 
MCH 
55.1 4.3 50.8 92.19 
10. J50305 Baby. N. Vishnupriya 
11 / 
FCH 
50.8 1.2 49.6 90.63 
11. J83239 
Baby. S. 
Bakkiyashree 
12 / 
FCH 
57.7 5.7 52 90.12 
12. H89794 Baby. M. Panimalar 
9 / 
FCH 
46.1 5.5 40.6 88.06 
13. J84052 Baby. M. Sujitha 
10 / 
FCH 
50.8 4.5 46.3 91.14 
14. J29851 Baby. S. Saiharini 
6 / 
FCH 
55.3 11.5 43.8 79.20 
15. J85012 Baby. A. Preethi 
9 / 
FCH 
39.6 4.1 35.5 89.64 
16. J75070 Mast. T. Yokesh 
8 / 
MCH 
38 4.3 33.7 88.68 
17. H43096 Baby. S. Monika 
7 / 
FCH 
64.5 10 54.5 84.49 
18. J84247 Mast. T. Varun 
9 / 
MCH 
35.1 0.2 34.9 99.43 
19. J82049 Baby. T. Meera 
12 / 
FCH 
34.6 0.2 34.4 99.42 
126 
 
20. G27954 Mast. S. Logeshwaran 
11 / 
MCH 
55.6 7.6 48 86.33 
21. I71990 
Mast. S. 
LigneshKarthick 
8 / 
MCH 
38.6 4.5 34.1 88.34 
22. J39198 Mast. B. Monish 
7 / 
MCH 
46.4 4.3 42.1 90.73 
23. J88484 
Baby. I. K. 
Durgashree 
6 / 
FCH 
40.9 4.1 36.8 89.97 
24. J84638 Baby. R. Elakkiya 
12 / 
FCH 
43.5 4.1 39.4 90.57 
25. I83253 
Mast. P. Vishnu 
Vardhan 
7 / 
MCH 
64.2 10.8 53.4 83.17 
26. J86891 
Mast. M. 
Depak 
12 / 
MCH 
41.9 0 41.9 100 
27. J90700 Baby. M. Nisha 
10 / 
MCH 
39.8 1 38.8 97.48 
28. I17135 
Mast. M. Nithish 
Kumar 
8 / 
MCH 
54.9 7 47.9 87.24 
29. J42189 Baby. S. Pravishika 
12 / 
FCH 
55.5 0 55.0 99.09 
30. J86724 Baby. S. Sri Ishwarya 
7 / 
FCH 
67.9 11 56.9 83.79 
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19)  HAEMATOLOGICALPROFILE: 
 
Haematological values were plotted before and after treatment 
 
S.No Op No Hbgms% TC 
cells/cu.mm 
RBC 10
6
 
cells/cu.mm 
ESR ½ 
hr/1hr 
AEC 
BT AT BT AT BT AT BT AT BT AT 
1 J76040 11.5 11.5 8600 9200 4 4.2 2/4 2/4 346 252 
2 J80924 
12.4 12.4 5000 5500 4.3 4.3 2/4 2/4 165 152 
3 J69345 12.4 12.4 10000 11200 4.5 4.6 4/10 2/4 286 352 
4 J81265 
12.8 12.8 8800 9600 5.4 5.5 4/10 2/8 502 364 
5 D65176 13.1 13.1 11200 11400 5.2 5.1 2/4 2/8 176 256 
6 I49712 
11.8 11.8 8900 9100 5 4.8 2/4 2/8 348 278 
7 J13039 11.6 11.8 18100 10100 4.5 4.5 4/10 2/6 682 381 
8 J53646 
12.9 12.9 7100 9100 4.5 4.4 2/4 2/4 251 202 
9 J81699 
11.9 12.1 5500 7200 4.3 4.4 4/10 2/8 165 252 
10 J50305 
12.2 12.3 7100 9100 4.3 4.6 4/12 12/8 193 278 
11 J83239 
13.7 13.8 7100 8900 5.2 5.2 2/4 2/8 369 252 
12 H89794 
11.5 11.6 9200 6100 4.2 4.1 4/12 2/4 489 208 
13 J84052 
12.4 12.4 9500 11100 4.3 4.2 2/6 2/8 546 442 
14 J29851 
12.7 12.7 9200 8900 4.6 4.8 2/4 2/4 411 366 
15 J85012 
11.5 11.6 5900 7200 4.2 4.4 2/10 2/4 212 308 
16 J75070 
11 11.2 8200 9100 4.3 4.4 4/10 2/10 223 312 
17 H43096 
13.4 13.2 11400 10900 4.5 4.4 4/16 2/10 282 151 
18 J84247 
11.9 11.9 6700 5800 4.2 4.3 4/12 2/10 362 312 
19 J82049 
12.6 12.6 8100 6300 4.2 4.2 4/10 2/8 556 308 
20 G27954 12.1 12 11500 12300 4.5 4.2 2/10 2/6 428 367 
21 I71990 
11.6 12 8500 7200 4.3 4.5 2/6 2/4 109 145 
22 J39198 
12.7 14.2 7300 5400 5 4.9 2/4 10/14 167 239 
23 J88484 
12.5 14.1 7500 5200 4.8 4.7 2/4 2/6 142 168 
24 J84638 
12.3 12.4 6200 6500 4.3 4.3 4/16 6/8 191 258 
25 I83253 
12.4 16.1 5400 9000 4.3 5.4 2/8 2/4 210 161 
26 J86891 13.6 14.2 9100 6200 5.1 5 2/4 12/8 252 252 
27 J90700 
13.2 12,4 6400 6800 4.9 4.5 2/6 2/4 105 254 
28 I17135 
12.3 12.7 5400 11000 4.2 4.3 4/10 4/10 153 220 
29 J42189 
12.3 12.7 11300 11400 4.4 4.1 10/24 10/20 502 380 
30 J86724 
13 13.6 9900 11900 5.6 6 10/26 18/38 454 366 
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Differential Count Profile of WBC 
 
S.no Op.no Polymorphs Lymphocytes Monocytes Eosiniphils Basophils 
BT AT BT AT BT AT BT AT BT AT 
1 J76040 52 54 40 48 7 3 6 2 - - 
2 
J80924 
42 42 52 52 7 5 6 3 - - 
3 J69345 55 56 39 44 6 2 4 1 - - 
4 
J81265 
32 44 60 58 8 6 5 2 - - 
5 D65176 64 62 32 48 4 4 6 3 - - 
6 
I49712 
38 42 56 54 6 4 4 0 - - 
7 J13039 62 56 30 44 8 6 7 0 - - 
8 
J53646 
53 52 42 48 5 8 0 0 - - 
9 
J81699 
46 52 48 50 6 4 6 2 - - 
10 
J50305 
38 43 56 52 6 4 0 0 - - 
11 
J83239 
51 56 39 44 10 6 0 0 - - 
12 
H89794 
50 49 43 36 2 2 7 0 - - 
13 
J84052 
50 52 48 52 8 6 0 0 - - 
14 
J29851 
45 48 48 52 7 6 2 0 - - 
15 
J85012 
45 48 48 52 7 6 4 0 - - 
16 
J75070 
48 52 57 56 5 2 0 0 - - 
17 
H43096 
59 54 36 42 5 2 3 2 - - 
18 
J84247 
38 52 56 52 2 2 4 4 - - 
19 
J82049 
53 49 38 46 22 7 1 0 - - 
20 G27954 43 47 51 53 22 4 4 0 - - 
21 
I71990 
62 65 34 28 4 1 0 0 - - 
22 
J39198 
58 53 37 39 5 1 0 0 - - 
23 
J88484 
44 63 52 31 4 6 0 0 - - 
24 
J84638 
55 51 42 42 7 - 3 0 - - 
25 
I83253 
40 65 57 30 9 5 1 0 - - 
26 J86891 54 56 40 40 6 5 3 2 - - 
27 
J90700 
36 56 59 40 5 5 0 0 - - 
28 
I17135 
57 75 38 20 5 5 0 0 - - 
29 
J42189 
53 60 37 32 10 8 6 1 - - 
30 
J86724 
58 54 34 39 8 7 6 2 - - 
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Distribution of Children’s with Bala Karappan according treatment 
results obtained: 
 
      S.No SCORAD % No. of Cases Percentage 
1 SCORAD 0% 0 0 
2 SCORAD>25% 0 0 
3 SCORAD 25% -50% 0 0 
4 SCORAD 50% - 75% 0 0 
5 SCORAD 75% - 100% 30 100% 
 
 
Inference: 
Out of the 30 cases, the signs and symptoms were reduced markedly in 30 cases 
were reduced the clinical symptoms by SCORAD value is 75% -100%, No cases had 
SCORAD 0%, >25, 25% - 50%, 50% -75%. These results were based on the clinical 
improvements observed by author. 
 
For clinical studies 
All collected data were entered into MS Excel software using different columns 
as variables and rows as patients. STATA software was used to perform statistical 
analysis. Basic descriptive statistics include frequency distributions and cross- 
tabulations were performed. Bar diagram, Pie charts were used to describe the value of 
different variables for pictorial representation. The quantity variables were expressed as 
Mean and standard deviation and qualitative data as percentage. A probability value of 
less than 0.05 was considered to indicate as statistical significance. Paired ‘t’ test was 
performed for determining the significance between before and after treatment. 
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Statistical Analysis 
 
A. Summary of statistics at SCORAD scale 
 
 
Treatment 
No of 
Cases 
Mean ± 
Std. Dev 
Minimum Maximum 
Before 
Treatment 
30 50.29+9.92 34.6 74.5 
After 
Treatment 
30  
4.87+3.41 
0 11.5 
 
Observation: 
The mean + S.D before and after treatment on SCORAD reveals that there is reduction 
after treatment i.e 90% reduction.  
B. Statistical significance of treatment 
 
 
SCORAD Mean ± Std. Dev ‘t’ value ‘P’ value 
Before 
Treatment 
 
50.2933+9.9232 
31.0072 
 
P<0.001 
 
 
After 
Treatment 
 
4.8766+3.4176 
 
Observation: 
 
There is statistically highly significant reduction of eczema from–SCORAD 
scoring after the treatment. 
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1. J 83239  
BEFORE      AFTER 
 
 
 
 
 
 
 
 
 
 
2.  J 42189  
 
     BEFORE       AFTER 
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3. J 53646 
 
BEFORE                                                       AFTER 
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7. DISCUSSION 
 
Bala Karappan is a skin disease characterized by blisters, papules, vesicles, 
pustules, itching, pain present in lower extremities, ulcer formation with oozing, sleep 
disturbance, hyperpigmentation. The clinical signs and symptoms of  Bala karappan is 
nearly correlated with Atopic Dermatitis in modern science. In this present study, 30 
cases were treated in the outpatient department of Kuzhanthai Maruthuvam, according 
to clinical features mentioned in textbook of Bala vagadam. The diagnosis was made 
based on clinical symptoms. The chosen drug Karappan Nei (External and 
External) indicated for Bala karappan has been given to all the participants with the 
dosage of 5-10 ml/ bd. This clinical study was conducted after the proposal was 
screened by the Screening committee of National Institute of Siddha. The Clinical 
study has been approved by IEC of NIS, approval No: NIS/IEC/2016/11-
18/14.10.2016. The trial registered in Clinical trial Registry of India (CTRI) with 
Reg.No.CTRI/2017/05/008722. The Authentication of ingredients of the trial drug 
was obtained from Medicinal Botanist, National Institute of Siddha, Chennai. 
The trial drugs were prepared by the author in the Gunapadam practical 
laboratory of National Institute of Siddha with supervision of lab in charge and the 
Guide. The trial drug was prepared as per the standard operating procedure as 
mentioned in the protocol. 
There is statistically highly significant reduction of eczema from–SCORAD 
scoring after the treatment. 
The Physicochemical analysis and phytochemical analysis of the trial drug 
Karappan Nei was done at Noble Research Solutions, Chennai. Since the form of the 
drug was like ghee the parameters such as Determination of Weight/ml, Refractive 
Index, Ph, Viscosity value, Iodine value, Saponification value, Acid value, Peroxide 
value was done using Quality control methods as per the AYUSH protocol for 
medicinal plants materials. 
 
The Bio chemical analysis revealed the presence of Iron. 
 
In clinical studies, the patients were recruited for the trial based on inclusion and 
exclusion criteria and after getting the informed consent from the patient. 30 patients 
were included in this study. All 30 patients were treated in Kuzhandhai  Maruthuvam 
OPD of Ayothidoss Pandithar Hospital of National Institute of Siddha. Separate 
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proforma was maintained for every patient. Progress chart was also maintained by 
using SCORAD index to monitor the clinical signs and symptoms of the disease. The 
treatment was aimed at normalizing the deranged thodams and providing relief from 
symptoms. Before treatment, the patients were advised to adapt lifestyle modifications 
such as oil bath weekly once and to follow good dietary regimen. 
The patients were treated with trial drug Karappan Nei for 48 days. Patients 
were instructed to take the medicines regularly and advised to follow pathiyam and to 
avoid exposure to allergic substances if any. Patients were asked to visit the hospital 
on 8
th
 day and 16
th
 day, 32
th
 day and 48
th
 day. After completion of the study; the 
patients were advised to visit the OPD for one month for further follow-up. The 
results observed during the study period were discussed as below. 
Age 
Among the 30 patients selected for this study, maximum  numbers  of patients 
63.3% were  in  the  age  group  of  9 to 12 years,  36.7% were  in  the  age group of 6 
to 8 years. 
Sex 
By the results of the clinical study, Among the 30 children included in this study 
50% were male children and 50% female children. 
Religion 
           High incidence of karappan was noted 93.3% in Hindus, And 6.7 % in Christian 
people. No cases were reported from Muslim community in this study   period. 
 
Socio-economic status 
Out of 30 patients, 20.0% of the patients were from Upper income group, 36.7% 
patients were from Upper middle income group, 26.7% patients were from Upper Lower 
and the remaining 16.7% patients were under Lower Middle income group. 
 
Diet 
In this study all the cases involved in this study were non-vegetarians 100%. 
Allergic history 
Out of 30 patients, 30% of the patients showed past H/O similar complaints, 20% 
had Bronchial Asthma and 50% had history like Mosquito bite, Food Allergy, Dust 
Allergy. No patients having history of hospitalization.  
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Family history 
Among 30 patients, 90%of the patients showed no family history related with this 
disease 10% showed positive family history. 
Duration of illness 
Among the 30 patients the maximum number of patients (53.3%) had the 
duration of illness between 1 to 3 years, (23.3%) of them had between 3 to 11 months, 
(13.3%) were below 4 to 7 years, (6.7%) were between < 2 months and (3.3%) were 8-
10 years. 
Site of involvement 
Among 30 patients 70.0% had the lesion in both upper and lower limbs, 23.3% 
had lesion only in the lower limbs, and 6.7% had lesion only in upper limbs and lower 
limb, trunk. gluteal region. 
Nilam Habitat 
Among the 30 patients 77%  of the  patients were  from  Neithal (Coastal  Area),  
23% are  from Marutham  (Fertile  Land),  0 %  were reported  from Kurinji (Hill   area), 
Paalai (Desert area) and Mullai (Forest Land). 
Paruvakaalam 
Among the 30 patients admitted for this study, the highest number of patients 
(60.0%) reported in Koothir Kaalam and 23.3% were reported in Muthuvenil Kaalam, 
16.7% were reported in pinpani kalam.  
 
Mukkutram 
Vali (Vatham) 
Due to the derangement of different vatha the following symptoms occur. 
Samanan and Uthanan (Papules , Pustules, Vesicles) were found to be affected in all the 
30 patients and devathathan (sleep disturbances) was affected in 23.3% of patients, 
Kirukaran was affected in 16.7%  of  patients  (Cold, Cough). 
Azhal (Pitham) 
Prasakam (skin) was affected in all the cases 100% and Ranjagam (anaemia) 
was affected in 13.3% of patients. 
Iyyam (Kabam) 
In 3.3% of the patients avalambagam  (indigestion) was found to be affected. 
Pori 
Mei was affected in 30 patients (100%) of cases. 
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Kanmenthiriyam 
Among 30 patients Kai, was affected in 60.0 %, Kaal was affected in 90 %. 
 
Ezhu UdalKattukal 
In Bala karappan Saram was affected 100 %, Senneer was affected 13.3%. 
Envagai Thervukal 
         In bala karappan Niram affected 100%, Sparisam affected 100%. 
And the Nadi, vathapitham observed in 83.3%, pithavatham observed in 16.7%. 
Lab Investigation: 
 Laboratory investigation of blood was done for all 30 cases in before and after 
treatment. 
 
Clinical Features of Bala Karappan 
The clinical feature was recorded in this study among 30 children’s. Among them 
100% of patients had Itching, 100% had Papules, Blisters, Pustules, Vesicles, 46.7% 
had Pain in lower extremities, 83.3% had Ulcer formation with oozing, 100% had 
sleep disturbances, 100% had Hyperpigmentation before treatment . The patients 
showed a good prognosis after treatment with reduced percentage of clinical features 
as said above (20.0%), (3.3%), (0%), (20.0%), (6.7%) and (70.0%) respectively. Out 
of the 30 cases, the signs and symptoms were reduced markedly in 30 cases by 
SCORAD value of 75% -100%,No cases had SCORAD 0%, >25, 25% - 50%,50% -
75%. These results were based on the clinical improvements observed by SCORAD 
scoring. 
The trial medicine chosen for treatment of Bala Karappan is Karappan Nei. The 
ingredients of this drug have the properties (Anti inflammatory, Anti Oxidant, Wound 
Healing) of controlling the symptoms Bala Karappan. The pharmacological studies 
already reported on the individual drugs also favour of its effect in this disease of 
inflammatory condition.  
The mean and standard deviation of clinical symptoms of SCORAD index value 
for all the 30 patients before and after treatment is 50.293 ±9.923 and 4.876 ±3.417 
respectively. The mean + S.D before and after treatment on SCORAD reveals that there 
is reduction of symptoms in after treatment i.e 90% reduction. It is statistically highly 
significant in reduction of eczema. 
The results of the study suggest that the treatment with KARAPPAN NEI 
(Internal And External) has given significant improvement in patients of Bala 
Karappan. 
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7. SUMMARY 
 
The disease Bala Karappan was taken for the clinical study with the trial drug 
Karappan Nei (Internal And External Medicine) after scrutinizing by the Screening 
committee of National Institute of Siddha. 
 
Clinical studies were carried out after obtaining proper approval from IEC of 
National Institute of Siddha and the trial was registered in Clinical trial registry of India. 
The medicines were prepared after obtaining proper authentication of ingredients from 
Medicinal Botanist of National Institute of Siddha. Acute toxicity study, Physiochemical 
analysis, Phytochemical analysis and Pharmacological activity (anti – inflammatory) for 
the trial medicine was performed. 
 
All the 30 patients were treated in OPD of Kuzhandhai  Maruthuvam  department 
at Ayothidoss Pandithar Hospital of National Institute of Siddha. The patients with Bala 
Karappan were recruited for this study based on Inclusion and Exclusion criteria and a 
detailed clinical study was done. Separate proforma was maintained for each patient 
along with SCORAD index chart on 0, 16
th
, 32
th
, 48
th  
day  to monitor the prognosis. 
 
From the clinical study, it was inferred that Bala Karappan was affecting in the 
school going children (6-12 years) and the incidence was chronic in maximum number 
of patients. The trial drug was given two times in a day for 48 days. All the patients were 
advised to follow the strict diet regimen during the treatment. 
 
The Bio chemical analysis of drug showed presence of Carbonate, Iron, Starch. 
The physicochemical analysis showed that the trial drug was in appropriate in 
consistency for this study. The phytochemical analysis of drug showed presence of 
Alkaloids, Flavonoids, Glycosides, Steroids, Triterpenoids, Coumarins, Phenol, Tannins. 
The patients have not complained of any adverse effects or difficulties during the course 
of treatment. Thus the drug compliance was good with the patients of  Bala Karappan. 
The clinical efficacy of the trial drugs in children was analyzed statistically with all the 
symptoms mentioned in  the  assessment criteria and also through SCROAD index value.  
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The result were observed as follows,                        
  Among 30 children, the symptoms of  Bala karappan like 80.0% Itching, 96.7% 
Papules, Vesicles, Blisters, Pustules, 46.7% Pain in lower extremities, 63.3% Ulcer 
formation with oozing, 93.3% sleep disturbances, 30.0% hyper pigmentation were 
improved clinically. 
 
The signs and symptoms were reduced markedly in 30 cases by SCORAD value 
range of 75% -100%, and  No cases  have been identified the by SCORAD value range 
of 0%, <25% and 25% -50%, 50%-75%. 
 
The mean and standard deviation of clinical symptoms of SCORAD index value 
for all the 30 patients before and after treatment is 50.293 ±9.923 and 4.876 ±3.417 
respectively. The mean + S.D before and after treatment on SCORAD reveals that there 
is reduction of symptoms in after treatment i.e 90% reduction. It is statistically highly 
significant in reduction of eczema. 
 
The observation made during the study both clinically and statistically explores that 
the trail drug Karappan Nei was effective in the management of Bala Karappan in 
children. 
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8. CONCLUSION 
 
All the 30 patients clinically diagnosed as Bala Karappan were treated with 
Karappan Nei with the of dose for 5-10 ml Internally and also used as External 
medicine for two times a day for 48 days. 
 
The efficacy of the trial drug for the management of Bala Karappan was 
significantly effective by means of SCORAD value. The reduction of clinical 
symptoms was highly significant (p <0.001). The reduction in the clinical symptoms 
was 90% after treatment. 
 
Pharmacological activity of Karappan Nei was showed that, the drug was 
having potent anti-inflammatory activity by In-vitro studies. 
 
Hence the author strongly recommends that this trial drug Karappan Nei may 
be given to children without any hesitations for the management of Bala Karappan.  
The ingredients of the trial drug also cost effective. Further research works may be 
carried out in the large group of patients to explore this novel drug more scientifically. 
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                                         NATIONAL INSTITUTE OF SIDDHA 
       AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Preclinical and Clinical Evaluation of KARAPPAN NEI (Internal and External 
medicine) in the treatment of  BALA KARAPPAN(Eczema) in children. 
Form I- SCREENING AND SELECTION FORM    
1.  S.I. No:    2. OP/ IP No:                          3. Name:          
4. Age:                5. Gender:          6. Date of Enrollment:       
7. Informant:    8. Reliability:    
INCLUSION CRETERIA                                           YES        NO 
Age: between 6-12 years 
Itching                                         
Presence of Blisters/Papules/ Vesicles/                                                                 
Pustules 
Pain in lower extremities               
  
Ulcer formation with oozing       
Sleep disturbances       
 Hyper pigmentation 
Patients willing to give biological samples  
 Willing to attend OPD once in 7 days                                            
EXCLUSION CRITERIA: 
 Scabies   
Photo dermatitis   
  Jaundice 
             Patients with any other serious illness  
 
             Admitted to the trial                                    Yes                           No 
                        
                             If   yes                                        OP  No:                      IP No:   
                            
          
   Place:                                                                                                    Signature of Investigator 
 
   Date:                                                                                                      Signature of Guide            
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600047 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Pre Clinical and Clinical Evaluation of KARAPPAN NEI (Internal and External 
medicine) a Siddha drug for BALA KARAPPAN (Eczema) in children. 
 
II CONSENT FORM 
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent/guardian 
Signature  _________________ 
Name  _________________ 
Date  _________________ 
CONSENT BY PARENT 
 I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my son/daughter body functions. 
 I am aware of my right to opt my son/daughter out of the trail at any time during the 
course of the trail without having to give the reasons for doing so.  
 I, exercising my free power of choice, hereby give my consent to include my 
son/daughter as a subject in the clinical trial of ‘KARAPPAN NEI’ for the treatment of ‘ BALA 
KARAPPAN’.  
 
Date :       Signature  __________________ 
Place:      Name   __________________ 
                          Signature of witness  __________________ 
      Name   __________________ 
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தேசி஬ சித்ே ஫ருத்துவ நிறுவனம் 
அத஬ோத்ேிேோச பண்டிேர் ஫ருத்துவ஫னன சசன்னன-47 
குழந்னே ஫ருத்துவத்துனை 
 
       க஭ப்பான் நெய் ஧ரிகரிப்புத் தி஫ன஦க் கண்ட஫ியும் நருத்துய ஆய்வு  
 
ஒப்புேல் படிவம் II-A 
ஆய்யா஭பால் சான்஫஭ிக்கப்஧ட்டது. 
஥ான் இந்த நருத்துய ஆய்னய கு஫ித்த அன஦த்து யி஧பங்கன஭யும்  
ந஥ானா஭ினின் ப஧ற்ந஫ாருக்கு புரியும் யனகனில் எடுத்துனபத்நதன் எ஦ உறுதி 
அ஭ிக்கிந஫ன். 
நததி:                              னகபனாப்஧ம்: 
இடம்:                             ப஧னர்  
தநோ஬ோளி஬ின்  சபற்தைோர் ஒப்புேல் படிவம் 
என்஦ிடம் இந்த நருத்துய ஆய்யின் காபணத்னதயும், நருந்தின் தன்னந 
நற்றும் நருத்துய யமிமுன஫ப் ஧ற்஫ியும், இந்த நருத்துயத்னத பதாடர்ந்து எ஦து 
குமந்னதனின் உடல் இனக்கத்னதக் கண்காணிக்கவும், அதன஦ ஧ாதுகாக்க ஧னன்஧டும் 
நருத்துய ஆய்வுக்கூடப் ஧ரிநசாதன஦கள் ஧ற்஫ியும் திருப்தி அ஭ிக்கும் யனகனில் 
ஆய்வு நருத்துயபால் யி஭க்கிக் கூ஫ப்஧ட்டது. ஥ான் இந்த நருத்துய ஆய்யின் ந஧ாது 
காபணம் எதுவும் கூ஫ாநல் எப்ந஧ாது நயண்டுநா஦ாலும் என் குமந்னதனன 
யிடுயித்துக் பகாள்ளும் உரினநனன பதரிந்திருக்கிந஫ன். 
஥ான் என்னுனடன சுதந்திபநாக நதர்வு பசய்யும் உரினநனனக் பகாண்டு 
பாயகபப்஧ான் ந஥ாய்க்கா஦ க஭ப்பான் நெய் (உள் ஫ருந்து ஫ற்றும் நலரி ஫ருந்து) 
சித்த ஫ருந்திற்கான ஧ரிகரிப்புத் தி஫ன஦ கண்ட஫ியும் நருத்துய ஆய்வுக்கு எ஦து 
குமந்னதனன உட்஧டுத்த ஒப்புதல் அ஭ிக்கிந஫ன். 
 
நததி:                                           னகபனாப்஧ம்: 
இடம்:                                         ப஧ற்ந஫ார் ப஧னர்: 
                                                னகபனாப்஧ம்: 
                                              சாட்சிக்காபர் ப஧னர்:                                
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AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600047 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
 
Preclinical and Clinical Evaluation of  KARAPPAN  NEI (Internal and External 
medicine) in the treatment of  BALA KARAPPAN (Eczema) in children. 
 
FORM III CASE REPORT FORM 
 Sl.No : OP/IP No. Visit Date : (__/__/____) 
Name :  
Age    :  
Gender                Male             Female  
Father/ Mother /Guardian Name : 
 
 
Fathers Occupation : 
 
 
Fathers Monthly  Income : 
 
 
Religion : 
 
 
 
Socioeconomic Status : 
 
 
Informant : 
 
 
 
Postal Address & Contact No: 
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COMPLAINTS AND DURATION: 
 
          
H/O PRESENT ILLNESS: 
  
           
 Past History /Symptoms/Signs            Yes        No  If, Yes Details 
 Any Similar Complains           
 Bronchial Asthma 
 Dust Allergy 
  Hospitalization 
 Any other 
                    _____________ 
Family History 
Any Hereditary/ Familial Disease                      Yes                      No 
If Yes, Details-------- 
Immunisation History 
     Proper Immunization give     Yes                       No            
Food habits: 
                                                 1. Veg            2. Non-Veg    
General assessment   
                                                                 YES                  NO 
1. Picca  
2. Nail biting 
3. Bowel movements 
General Examination: 
1. Pallor    YES  NO 
2. Jaundice   YES  NO 
3. Cyanosis   YES  NO 
4. Clubbing   YES  NO 
5. Pedal oedema   YES  NO 
6. Lymph adenopathy  YES  NO 
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Vital signs:- 
1. Pulse rate / mint 
2. Heart rate / mint 
3. Respiratory Rate / mint 
4. Temperature-F 
Anthropometry:- 
          Height 
          Weight 
SYSTEMIC EXAMINATION: 
     EXAMINATION OF THE SKIN: 
1. Affected site:      
2. Colour:       Normal         Reddish  Black                  Greyish 
3. Itching:  No            Mild                 Moderate              Severe 
      4. Scaling:  No                          Mild                     Moderate              Severe 
                                                       YES                          NO 
5. Oozing: 
6.  Ulcération : 
7.  Macule : 
8. Papule: 
9. Pustule: 
10. Blister: 
11. Vésicles : 
12. Sleep disturbances 
13.  Erythema:         
14. Pigmentation: Normal    Hypo                  Hyper 
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CLINICAL   ASSESSMENT: 
S.NO CLINICAL 
SYMPTOMS 
 0 th DAY  16 th 
DAY 
32 th 
DAY 
48 th 
DAY 
1. Itching     
2. Presence of 
Blisters/Papules/ 
Vesicles/Pustules 
    
3. Pain in lower 
extremities 
    
4. Ulcer formation 
with oozing 
    
5. Sleep 
disturbances 
    
6. Hyper 
pigmentation 
    
7.  SCORAD    
SCALE           
    
 
EXAMINATION OF OTHER SYSTEMS:           
                                                         Normal           Affected 
Cardio vascular system: 
Gastro intestinal system: 
Musculo skeletal system:  
Central nervous system: 
Endocrine system: 
Respiratory systems: 
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Nilam:-  
Kurinji  Mullai  Marutham     Neithal    Paalai 
Kaala Iyalbu:-  
 Kaarkalam             Koothirkaalam          Munpanikaalam  
 Pinpanikaalam            Illavenirkaalam          Muthuvenirkaalam 
Yaakai 
 Vatham          Vatha Pitham           Vatha Kabam 
 Pitham           Pitha vatham           Pitha Kabam 
 Kabam           Kaba Vatham           Kaba Pitham 
Gunam  
 Sathuvam   Rasatham   Thamasam 
Pori / Pulangal 
  Normal Affected  Normal Affected     Remarks 
Mei / unarvu 
Vaai / suvai  
Kan / parvai  
Mooku / natram 
Sevi / olli 
150 
 
Kanmendhirium / Kanmavidayam 
       Normal     Affected       Normal            Affected 
 Remarks 
Kai / dhanam 
Kaal / ghamanam 
Vaai / vaku 
Eruvai / visarkam 
Karuvai / anantham 
Uyir Thathukkal: 
Vatham:            Normal            Affected Remarks 
Pranan  
Abanan 
Viyanan  
Uthanan 
Samanan 
Nagan  
Koorman 
Kirukaran  
Devathathan   
Dhanajeyan      
 
Pitham            Normal           Affected Remarks 
Analam  
Ranjagam    
Saathagam   
Alosagam  
Prasagam 
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Kabam             Normal             Affected  Remarks 
Avalambagam    
Kilethagam   
Pothagam  
Tharpagam   
Samthigam  
Udalthathukkal       Normal            Affected  Remarks 
Saaram 
Senneer  
Oon  
Kozhuppu 
Enbu 
Moolai 
Sukilam / Suronitham   
Envagai Thervugal Normal         Affected  Remarks 
Naa  
 Niram 
 Thanmai 
 Suvai 
Niram   
Mozhi   
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Vizhi  
 Niram 
 Thanmai 
 Parvai 
Sparisam  
Malam 
 Niram   Normal Affected 
 Nurai   Normal Affected 
 Elagal   Normal Affected 
 Erugal   Normal Affected 
Moothiram 
   Neerkuri:       Niram          Normal  Affected 
  Edai   Normal Affected  
  Nurai             Normal  Affected 
  Manam            Normal  Affected  
  Enjal Neikuri  Normal Affected   
Neikuri: 
            Vatham 
            Pitham 
            Kabam 
           Others 
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LABORATORY  INVESTIGATIONS  
 
 
 
 
 
 
 
   
 
Naadi: 
   ThaniNadi 
 Vadham  Pitham  Kabam 
ThonthaNadi 
Vathapitham            Pitha vatham         Pitha kabam       Kabapitham 
ROUTINE BLOOD 
INVESTIGATIONS 
NORMAL 
VALUES 
 
BEFORE 
TMT 
Date: 
 
AFTER TMT 
Date: 
Hb ( gms%)  11.5 – 14.5    
T.RBC (milli /cu.mm)        4-4.9   
 
ESR (mm) 
½ hr. 0- 4   
1 hr.        0-13   
T.WBC (milli /cu.mm) 5000-14500   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 28-48   
Monocytes 3-6   
Eosinophils 0-3   
Basophils 0-1   
ABSOLUTE 
EOSINOPHIL 
COUNT 
440 cells/cu m.m   
Urine Investigation 
Before TMT 
Date: 
After TMT  
Date: 
Albumin   
Sugar   
Deposits   
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ThodaNadi 
 Vatha kabam          Kaba vatham   
Admitted to trial: Yes     No 
 If yes, S. No:  IP   OP 
Diagnosis: 
DRUGS ISSUED: _____________ 
Date  : ___________________     
Station: ___________________  
Date: ___________________     Signature of investigator: 
Signature of Guide:                                                      Date: 
                                                                                      Place: 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Preclinical and Clinical Evaluation of KARAPPAN NEI (Internal and External 
medicine)in the treatment of BALA KARAPPAN(Eczema) in children. 
 
FORM IV DRUG COMPLIANCE    
 
1.  S.I. No:    2. OP/ IP No:                          3. Name:          
4. Age:    5. Gender:   6. Date of Enrollment:      
7. Informant:    8. Reliability:  
 NAME OF THE DRUG           :  KARAPPAN NEI 
FORM OF THE DRUG             : LIQUID 
ADMINISTRATION                :  PER ORAL  
DOSE AND DURATION         :  5 ml (BD) FOR 48 DAYS 
ADJUVANT                              : Honey 
Days 
Date of  
Drug Intake 
Morning Evening 
1.    
2.    
3.    
4.    
5.    
6.    
7.    
8.    
9.    
10.    
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11.    
12.    
13.    
14.    
15.    
16.    
17.    
18.    
19.    
20.    
21.    
22.    
23.    
24.    
25.    
26.    
27.    
28.    
29.    
30.    
31.    
32.    
33.    
34.    
35.    
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36.    
37.    
38.    
39.    
40.    
41.    
42.    
43.    
44.    
45.    
46.    
47.    
48.    
  
 
 
Date: 
 
Station:                                                       Signature of principal Investigator: 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Preclinical and Clinical Evaluation of KARAPPAN NEI (Internal and External 
medicine)in the treatment of BALA KARAPPAN (Eczema) in children. 
FORM IV DRUG COMPLIANCE 
 
1.  S.I. No:    2. OP/ IP No:                          3. Name:          
4. Age:    5. Gender:   6. Date of Enrollment:      
7. Informant:    8. Reliability:  
 NAME OF THE DRUG           :  KARAPPAN NEI 
FORM OF THE DRUG             : LIQUID 
ADMINISTRATION                :  PER ORAL  
DOSE AND DURATION         :  10 ml  (BD ) FOR 48 DAYS  
ADJUVANT                              : Honey 
Days 
Date of  
Drug Intake 
Morning Evening 
1.    
2.    
3.    
4.    
5.    
6.    
7.    
8.    
9.    
10.    
11.    
12.    
13.    
14.    
15.    
16.    
17.    
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18.    
19.    
20.    
21.    
22.    
23.    
24.    
25.    
26.    
27.    
28.    
29.    
30.    
31.    
32.    
33.    
34.    
35.    
36.    
37.    
38.    
39.    
40.    
41.    
42.    
43.    
44.    
45.    
46.    
47.    
48.    
  
Date: 
 
Station:                                               Signature of Principal Investigator: 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Pre Clinical and Clinical Evaluation of KARAPPAN NEI (Internal and External 
medicine) Siddha drug for BALA KARAPPAN (Eczema) in children. 
 
                                        FORM  V – ADVERSE REACTION   
 
1.  S.I. No:    2. OP/ IP No:                           3. Name:                                                          
4. Age:              5. Gender:   6. Date of Enrollment:      
7.  Date of completion:           8. Informant:    9. Reliablity:  
          
 
Registration No    : 
Date of trial commencement  : 
Date of withdrawal from trial   : 
Description of adverse reaction  : 
 
        
Signature of Guide: 
Date:        Signature of Investigator: 
Place:   
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AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047 
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Pre Clinical and Clinical Evaluation of KARAPPAN NEI (Internal and External 
medicine) Siddha drug for BALA KARAPPAN (Eczema) in children. 
 
 1.  S.I. No:         2. OP/ IP No:                     3. Name:                                                      
4.   Age:            5. Gender:   6. Date of Enrollment:      
7.  Date of completion:     8. Informant:             9. Reliablity:   
 
FORM VI  WITHDRAWAL  
Date of trial commencement    : 
Date of withdrawal from trial   : 
Reason(s) for withdrawal:     
       Long absence at reporting   : Yes/ No 
       Irregular treatment     : Yes/ No 
       Shift of locality                : Yes/ No 
       Complication adverse reactions if any            : Yes/ No 
       Exacerbation of symptoms   : Yes/ No 
       Patient not willing to continue              : Yes/ No 
 
Signature of Guide: 
Date:                                     Signature of Investigator: 
Palace:                                                               
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ததசி஬ சித்த ஫ருத்துல ெிறுலனம் 
அத஬ாத்திதாச பண்டிதர் ஫ருத்துல஫னன, நசன்னன-47 
பட்டத஫ற்படிப்பு குறந்னத ஫ருத்துலத்துனம 
க஭ப்பான் தொய்க்கு க஭ப்பான் நெய் பரிக஭ப்புத் திமனனக் கண்டமியும் 
஫ருத்துல ஆய்வு 
ஒப்புதல் படிலம் II-B குறந்னதக்கானது 
 
-----------------------------------------ஆகி஬ ொன் ததசி஬ சித்த ஫ருத்துல 
ெிறுலனத்தில் பட்டத஫ற்படிப்பு குறந்னத ஫ருத்துலத்துனம஬ில் ப஬ிலும் 
஫ரு.மு.பாக்கி஬ததலி அலர்கரால் ெடத்தப்படும் க஭ப்பான் தொய்க்கு 
க஭ப்பான் நெ஬ின் பரிக஭ப்பு  திமனனக் கண்டமியும் ஫ருத்துல ஆய்லில் 
பங்தகற்பதற்கு எனது நபற்தமார்/காப்பாரர்  திரு/திரு஫தி ----------------------------- 
சம்஫தம் நதரிலித்திருப்பனத ென்கு அமிதலன். 
எனக்கு இந்த ஆ஭ாய்ச்சி பற்மி புரியும் லனக஬ில் 
எடுத்துன஭க்கப்பட்டுள்ரது. எவ்லா஭ாய்ச்சில் இருந்து எப்தபாது 
தலண்டு஫ானாலும் லியக எனக்கு உரின஫  இருக்கின்மது என்பனத 
பற்மியும் ென்கு நதரிந்து நகாண்டு எந்த ஆ஭ாய்ச்சி஬ில் பங்தகற்க்க 
சம்஫திக்கிதமன்.  
 
தததி:                                  குறந்னத஬ின் னகந஬ப்பம்: 
இடம்:                                 நப஬ர்: 
                                       நபற்தமார் னகந஬ப்பம்: 
                                      நப஬ர்: 
                                       சாட்சிக்கா஭ர் னகந஬ப்பம்: 
                                       நப஬ர்: 
                                       சாட்சிக்கா஭ர் உமவு முனம: 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI-47 
FORM VII – PATIENT INFORMATION SHEET 
 
Name of investigator:  Dr. M. Bakkiyadevi 
I Dr. M. Bakkiyadevi Studying as PG Scholar in kuzhandhai maruthuvam 
department at National Institute of Siddha, Tambaram Sanatorium is doing a open 
clinical study on “BALA KARAPPAN” (Eczema).  Eczema is a most common disease. 
The symptoms are pain in lower extremities, itching, blisters, papules, vesicles, pustules, 
ulcer formation with oozing, hyper pigmentation. In this regard, I am in a need to ask 
you few questions. I will maintain confidentiality of your comments and data obtained. 
There will be no risk of disclosing your identity and no physical, psychological or 
professional risk is involved by taking part in this study. Taking part in this study is 
voluntary. No compensation will be paid to you for taking part in this study.  
               You have the liberty in choosing to take part in the study or not to take part. 
You can choose not to answer a specific question. You may be benefited if you take part 
in this study. Moreover, taking part in the study may be of benefit to the community, as it 
may help us to understand the disease elaborately and its potential solution problem of 
defaulters and potential solutions. All the medicine and other relevant investigation 
procedures will be provide with free of cost.  
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the medicine 
“KARAPPAN NEI INTERNAL AND EXTERNAL MEDICINE. The information I am 
collecting in this study will remain between you and the investigator (myself). I will ask 
you few questions through a questionnaire. The questionnaire will take approximately 20 
minutes of your time. 
        If you wish to find out more about this study before taking part, you can ask 
me all the questions for study related contact me (Dr. M. Bakkiyadevi) through my 
mobile number  9994627411. You can also contact the Member-secretary of Ethics 
committee, National Institute Siddha, Chennai 600047, Tel no: 91-44-22380789, for 
rights and participation in the study.  
 
Name:        Date: 
            Signature: 
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                                                                   தகயல் ஧டியம் 
பாயகபப்஧ான் ந஥ாய்க்கா஦ சித்த நருந்துக஭ின் க஭ப்பான் நெய் (உள் ஫ருந்து 
஫ற்றும் நலரி ஫ருந்து) சித்த ஫ருந்திற்கான ஧ரிகரிப்பு தி஫ன஦க் கண்ட஫ியும் 
நருத்துய ஆய்யிற்கா஦ தகயல் ஧டியம். 
ஆபாய்ச்சினா஭ர் ப஧னர் Dr. மு.பாக்கி஬ததலி  
஥ிறுய஦த்தின் ப஧னர்   அத஬ாத்திதாச பண்டிதர் ஫ருத்துல஫னன 
                                                      நதசின சித்த நருத்துய ஥ிறுய஦ம்  
                                     தாம்஧பம் ச஦ட்நடாரினம் பசன்ன஦-47. 
நதசின சித்த நருத்துய ஥ிறுய஦த்தி ன் குறந்னத ஫ருத்துல துனம஬ில்   ஧ட்ட 
நநற்஧டிப்பு ஧னின்று யரும் ஥ான் பாயகபப்஧ான் என்னும்  ந஥ானில் நருத்துய 
ஆபாய்ச்சினில் ஈடு஧ட்டுந஭ன் . பாயகபப்஧ான் என்னும்  சித்த நருத்துயத்தில் 
பசால்஬ப்஧டும் ந஥ானா஦து தி஫ிர், தினவு, நசாமி, புண், தடிப்பு, நலடிப்பு, ெீர் கசிதல் ,உடல் 
இனரத்து அறகிறந்து தபாதல் முத஬ின கு஫ிகுணங்கள் காணப்஧டும் தன்னநயுனடனது. 
              இந்த ஆபாய்ச்சி  சம்நந்தநாக சி஬ நகள்யிகள்  நகட்கவும், நதனயனா஦ ஆய்யக  
஧ரிநசாதன஦க்கு தங்க஭து குமந்னதனன உட்஧டுத்தவும் உள்ந஭ன். 
              இது சம்நந்தநா஦  தங்க஭து குமந்னதனின்  அன஦த்து யியபங்களும் பகசினநாக 
னயக்கப்஧டும் எ஦ உறுதி அ஭ிக்கிந஫ன்.  இதில் ஧னணப்஧டி முத஬ின எந்த உதயி 
பதானகயும் யமங்கப்஧ட நாட்டாது. 
              இந்த ஆபாய்ச்சினின் ந஧ாது தங்க஭து குமந்னதனின் உடலுக்கு நயறு ஧ாதிப்பு 
ஏற்஧டும் ஧ட்சத்தில் நதசின சித்த நருத்துயநன஦னில் தக்க சிசிச்னச அ஭ிக்கப்஧டும். 
              இந்த ஆபாய்ச்சிக்கு  தங்கள் யிருப்஧த்தின் ந஧ரில்  குமந்னதனன உட்஧டுத்தும் 
஧ட்சத்தில் உள் ஫ருந்து ஫ற்றும் நலரி ஫ருந்தாக க஭ப்பான் நெய் 48 ஥ாட்கள் எடுக்க 
நயண்டும்.இந்த ஆபாய்ச்சினில்  ந஥ானி஦஭ாக நசர்ந்த ஧ி஫கு உங்களுக்கு யிருப்஧ம் 
இல்ன஬பன஦ில் எப்ந஧ாது நயண்டுநா஦ாலும்  தங்க஭து குமந்னதனன யி஬க்கிக் 
பகாள்஭஬ாம். 
              இந்த ஆபாய்ச்சி சம்நந்தநாக நற்஫ யி஧பங்களுக்கும் ந஥ானின் தன்னந ஧ற்஫ியும் 
அ஫ியதற்கும் ஆபாய்ச்சினா஭பா஦ Dr. மு.பாக்கி஬ததலி (஧ட்ட நநற்஧டிப்஧ா஭ர் குமந்னத 
நருத்துய ஧ிரிவு) னகந஧சி எண். 99946 27411 எப்ந஧ாதும் பதாடர்பு பகாள்஭஬ாம். 
               நநலும் இந்த ஆபாய்ச்சிக்கு IEC (஥ிறுய஦ ஥ீதிப஥஫ிகுழு) சான்று ப஧஫ப்஧ட்டுள்஭து. 
              இந்த ஫ருந்து சி஫ப்஧ாக பாயகபப்஧ான் ந஥ாய்க்காக அங்கீகரிக்கப்஧ட்ட  சித்த 
நருத்துய  நூ஬ில் கூ஫ப்஧ட்டுள்஭து . ஏற்க஦நய உ஧நனாகத்தில் உள்஭து . இதுயனப 
ந஥ானா஭ிக஭ிடம் எந்த யித ஧க்க யின஭வுகன஭ ஏற்஧டுத்தயில்ன஬.  நநலும் உணவு 
முன஫னில் உங்களுக்கு கூமப்பட்டுள்ரமுனமகனர ஧த்தின முனமகனர காக்குநாறு 
அ஫ிவுறுத்த ஧டுகி஫து.  
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1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
NATIONAL PHARMACOVIGILANCE PROGRAMME 
FOR  SIDDHA DRUGS 
 
Please note:  i.  All consumers / patients and reporters information will remain  
    confidential. 
   ii. It is requested to report all suspected reactions to the concerned, even if it     
     does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
Name 
Father name 
 Patient / Record No. 
Ethnicity Occupation 
Address  
Village / Town 
Post / Via 
District / State 
Date of Birth / Age: 
 
Sex:     Male / Female 
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
Date and time  of initial 
observation 
 Season: 
Description of reaction   
 
 Geographical area: 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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3. List of all medicines / Formulations including drugs of other systems used by the patient 
during the reporting period: 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle – 
Adjuvant 
Date  Diagnosis for which 
medicine taken  
Starting Stopped 
Siddha 
 
 
 
     
Any other system 
of medicines 
 
 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
Details Drug – 1 Drug – 2 Drug – 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained from    
e) Composition of the 
formulation / Part of the drug 
used 
   
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or used as 
self medication.  
d) Any other relevant information. 
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5. Treatment provided for adverse reaction: 
6. The result of the adverse reaction / side effect / untoward effects (please complete the 
boxes below) 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If yes, 
give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities? If Yes specify:  
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
Any Others  
9. H/O previous allergies / Drug reactions:  
10. Other illness (please describe): 
11. Identification of the reporter: 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
Address: 
Telephone / E – mail if any : 
 
 
Signature of the reporter:       Date: 
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Please send the completed form to:  
           The Director 
             National Institute of Siddha, 
                                                            (Pharmacovigilance Regional Centre For Siddha Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                             (O) 044-22381314    Fax : 044 – 22381314 
         Website : www.nischennai.org  
         Email: nischennaisiddha@yahoo.co.in   
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
This filled-in ADR report may be sent within one month of observation /occurrence of ADR   
 
 
 
Date:                                                                              
Station:  
 
Date :      
Station : 
Signature of the Investigator: 
Signature of the Lecturer:                                                  Signature of the HOD 
   
                                        
 
 
 
 
 
Who Can Report?     
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence and protected to the 
fullest extent.  
 Submission of report will be taken up for remedial measures only not for legal 
claim  
Name & address of the 
RRC-ASU / PPC-ASU 
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        NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
 Pre Clinical and Clinical Evaluation of KARAPPAN NEI (Internal and External 
medicine) Siddha drug for BALA KARAPPAN (Eczema) in children. 
                                        
                                        FORM IX – DIET FORM   
1.  S.I. No:    2. OP/ IP No:                           3. Name:                                                          
4. Age:              5. Gender:   6. Date of Enrollment:      
7.  Date of completion:           8. Informant:    9. Reliablity:           
 
jtpu;f;f Ntz;a czfs;  
 fj;jpupf;fha;> fUthL> Nrhsk;> fk;G> jpid> tuF> rhik> fhuuprp> 
ythiof;fha;> ghfw;fha;> nfspw;W kPd;> fpoF Mfpa fug;ghd; gz;lfis 
jtpu;f;fTk;. 
 Gz;fis fOt rpiff;fha; Jhs; gad;gLj;jf;lhJ. 
 nfhRf;fb ,y;yhky; ghu;j;Jf;nfhs;s Ntz;Lk;. 
 effis tsu tplhkYk;> Rj;jkhfTk; itj;Jf ;nfhs;sTk;. 
 Njhiy cWj;Jk; Milfis mzptij jtpu;f;fTk;. 
 kyf;fl;L ,y;yhky; ghu;j;Jf; nfhs;s Ntz;Lk;. 
 Fspg;gjw;f;F Nrhg;G cgNahfpg;gij jtpu;f;fTk;. 
 eyFkhT gad;gLj;jTk;. 
Nru;f;f Ntz;ba czTfs; : 
 fha;fwpfs;> fPiufs;> ghYk; ghy; nghUl;fSk; Mfpa rj;Js;s nghUl;fs;. 
 jz;zPu; mjpf msT Fbf;fTk;. 
 ey;;y fw;Nwhl;lKs;s ,lj;jpy; trpf;fTk; 
 Rj;jkhd Milfis mzpaTk;. 
 iffis Rj;jkhf itj;Jf; nfhs;sTk;. 
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CTRI Number CTRI/2017/05/008722 [Registered on: 31/05/2017] - Trial Registered Prospectively
Last Modified On 29/05/2017
Post Graduate Thesis Yes
Type of Trial Interventional
Type of Study Siddha
Study Design Single Arm Trial
Public Title of Study Pre clinical and Clinical evaluation of karappan nei (internal and external medicine) in the treatment
of Eczema in children
Scientific Title of
Study
Preclinical and Clinical evaluation of karappan nei (internal and external medicine) in the treatment
of Bala karappan (Eczema) in children on open clinical study
Secondary IDs if Any Secondary ID Identifier
Nil NIL
Details of Principal
Investigator or overall
Trial Coordinator
(multi-center study)
Details of Principal Investigator
Name Dr Bakkiyadevi M
Designation PG Scholar
Affiliation Ayothidoss pandithar hospital
Address Department of Kuzhandhai Maruthuvam, National institute of Siddha,
Tambaram sanatorium, Chennai 47 Department of Kuzhandhai
Maruthuvam, National institute of Siddha, Tambaram sanatorium,
Chennai 47
Kancheepuram
TAMIL NADU
600047
India
Phone 9994627411
Fax
Email bakkiyadevim@gmail.com
Details Contact
Person (Scientific
Query)
Details Contact Person (Scientific Query)
Name Dr K Suresh
Designation Lecturer
Affiliation Ayothidoss pandithar hospital
Address Department of Kuzhandhai Maruthuvam, National institute of Siddha,
Tambaram sanatorium, Chennai 47 Department of Kuzhandhai
Maruthuvam, National institute of Siddha, Tambaram sanatorium,
Chennai 47
Kancheepuram
TAMIL NADU
600047
India
Phone 9962571137
Fax
Email drsureshherbal@gmail.com
Details Contact
Person (Public Query)
Details Contact Person (Public Query)
Name Dr K Suresh
Designation Lecturer
Affiliation National institute of siddha
Address Department of Kuzhandhai Maruthuvam, National institute of Siddha,
Tambaram sanatorium, Chennai 47 Department of Kuzhandhai
Maruthuvam, National institute of Siddha, Tambaram sanatorium,
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CTRI Website URL - http://ctri.nic.in
Chennai 47
TAMIL NADU
600047
India
Phone 9962571137
Fax
Email drsureshherbal@gmail.com
Source of Monetary or
Material Support
Source of Monetary or Material Support
> Ayothidoss pandithar hospital National institute of siddha,Tambaram sanatorium, Chennai-47.
Primary Sponsor Primary Sponsor Details
Name Ayothidoss pandithar hospital
Address National Institute of siddha,Tambaram sanatorium, Cheenai-47
Type of Sponsor Research institution and hospital
Details of Secondary
Sponsor
Name Address
Nil Nil
Countries of
Recruitment
List of Countries
India
Sites of Study Name of Principal
Investigator 
Name of Site Site Address Phone/Fax/Email
Dr Bakkiyadevi M Ayothidoss pandithar
hospital
OPD NO 9, Department
of Kuzhanthai
maruthuvam, National
Institute of Siddha,
Tambaram Sanatorium
Kancheepuram
TAMIL NADU
9994627411
bakkiyadevim@gmail.c
om
Details of Ethics
Committee
Name of Committee Approval Status Date of Approval Is Independent Ethics
Committee?
Institutional ethics
committee
Approved 14/10/2016 No
Regulatory Clearance
Status from DCGI
Status Date
Not Applicable No Date Specified
Health Condition /
Problems Studied
Health Type Condition
Patients Bala karappan
Intervention /
Comparator Agent
Type Name Details
Comparator Agent Nil Nil
Intervention Karappan nei(internal) 5-10 ml twice a day with honey
for a period of 48 days
Inclusion Criteria Inclusion Criteria
Age From 6.00 Year(s)
Age To 12.00 Year(s)
Gender Both
Details 1. Children with symptoms of pain in lower extremities, Itching,
Papules, Vesicles, Pustules, Ulcer, Oozing, Hyper pigmentation,
Sleep disturbances
2.Patients willing to Blood investigation when required
3. Patient willing to be admitted in the hospital or willing to attend
OPD once in 7 days for 48 days.
Exclusion Criteria Exclusion Criteria
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Details 1.Scabies
2. Photo dermatitis
3. Jaundice
4. patients with any other serious illness
Method of Generating
Random Sequence
Not Applicable
Method of
Concealment
Case Record Numbers
Blinding/Masking Open Label
Primary Outcome Outcome Timepoints
It is mainly assessed by reduction of Clinical
symptoms by using SCORAD scale
48 datys
Secondary Outcome Outcome Timepoints
It is mainly assessed by therapeutic efficacy of
the trial drugs
48 days
Target Sample Size Total Sample Size=30
Sample Size from India=30
Phase of Trial Phase 3
Date of First
Enrollment (India)
01/08/2017
Date of First
Enrollment (Global)
No Date Specified
Estimated Duration of
Trial
Years=0
Months=6
Days=0
Recruitment Status of
Trial (Global)
Not Applicable
Recruitment Status of
Trial (India)
Not Yet Recruiting
Publication Details None yet
Brief Summary It is the single non-randomized,open label trial to determine the efficacy of Karppan nei (internal and external medicine) prepared from herbal constitutents in the patients with Balakarappan (Eczema). In this trial 30 patients will be recruitedand the trial drug will be administered 5-10 ml Twice a day with honey for a period of 48 days. During the trial period if any AE/SAE/SUSAR will be noticed and refered to pharmacovigilance department in NIS and further management will
also be given in NIS OPD/IPD. The entire trial will be monitored by the research monitoring committee of NIS.  During this trial all the safety efficacy parameters will be recorded in the CRF.  After completion of the trial all the study related
data will be analysed statistically. The outcome of this trial will be published in India Journal of Medical research. 
Powered by TCPDF (www.tcpdf.org)
page 3 / 3
